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Abstract 
Engineered proteins have strongly benefited the effectiveness and variety of 
precision drugs, molecular diagnostic agents, and fundamental research reagents. A 
growing demand for new therapeutics motivates the innovative use of natural proteins – 
improving upon their native properties – as well as discovering proteins with entirely new 
functionality. Importantly, these are fundamentally separate goals. While evolving 
improved function can result from making a few carefully chosen mutations, discovering 
novel function often requires giant leaps to be taken in protein sequence space. Discovering 
novel function is a notoriously challenging task. The immensity of sequence space (e.g. 
proteins of length n have 20n unique options) makes it essentially impossible to 
experimentally or computationally test all possible protein sequences. Within this space, 
the landscape is incredibly barren and rugged (i.e. most sequences lack function entirely 
and making small changes to a protein often damage the activity). Rather than randomly 
mutating a protein, combinatorial protein libraries provide a systematic and efficient 
approach for searching sequence space. This method offers precise control over which 
protein sites are mutated and which amino acids are allowed at the diversified sites. To 
improve the likelihood of sampling useful sequences, numerous techniques can elucidate 
the structure-function relationships in proteins.  Generally, these techniques have not been 
applied to combinatorial library design; however, we propose that some, or all, could be 
greatly beneficial in this area. In this thesis work, protein libraries are designed for the 
purpose of discovering high affinity, specific binders to a collection of interesting targets. 
High-throughput sequencing of evolved binders, natural protein-protein interface 
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composition, structural assessment, and computational analysis of stability upon mutation 
collectively informed sitewise library designs – residues predicted to support function were 
allowed but destabilizing residues or those not likely to benefit function were avoided. We 
use multiple small protein scaffolds (affibody and fibronectin) as model systems to test the 
hypothesis that constrained sitewise diversity will improve the efficiency of novel protein 
discovery. This hypothesis was experimentally supported by a direct comparison of high-
affinity ligand discovery between the sitewise constrained library and a uniformly 
diversified library (i.e. allowing all 20 residues at each diversified site).  The constrained 
library showed a 13-fold improved likelihood of binder discovery. Moreover, the 
constrained library variants demonstrated superior thermal stability (Tm 15 °C higher than 
unbiased variants). This work provides further evidence that sitewise diversification of 
protein scaffolds can improve the overall quality of combinatorial libraries by offering 
broad coverage of sequence space without sacrificing stability.  
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Chapter 1 – Introduction 
1.1. Discovering and evolving novel protein function is important for clinical utility, 
fundamental research, and industrial applications.  
The proper administration of effective medicines can broadly improve the 
efficiency of our health care system as well as improve the quality of life for individual 
patients battling cancer, diabetes, immune diseases, and more. Molecularly ‘targeted’ 
therapies and diagnostics are playing an increasingly beneficial role in this endeavor.1,2 
There are >100 protein-based molecular therapeutics approved by the United States Food 
and Drug Administration including monoclonal antibodies, insulin, human growth 
hormone, and granulocyte-colony stimulating factor.2–4 These molecular medicines enable 
precision therapy to modulate disease biochemistry in a focused manner.5 Similarly, 
molecular diagnostics empower scientists and clinicians to detect biomarkers and 
problematic cell types with high spatiotemporal resolution. Molecular imaging with 
engineered proteins enables detection and quantitative characterization of disease via 
molecular ultrasound, positron emission tomography (PET), and single-photon-emission 
computed tomography (SPECT).6 Even individual cells can be studied using intravital 
microscopy techniques.7,8 Outside of the clinic, a nearly endless variety of engineered 
proteins can be found. Industrial and research scientists rely on the binding and enzymatic 
functionality found within core techniques such as immunoaffinity bioseparation, Western 
blots, and flow cytometry.9  
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1.2. The path to novel protein function is wrought with challenges and pitfalls.  
Nature provides many proteins with an array of functionality (e.g. immune system 
antibodies, photosynthetic enzymes, etc.). However, the scientific community has 
repeatedly found that natural proteins rarely exist with optimal functionality and 
biophysical characteristics (thermal stability, chemical stability, solubility, etc.), leaving 
room for improvement.10–12 Moreover, to go beyond what nature offers, new applications 
could be established by taking an existing natural protein, then modifying the protein such 
that it takes on functionality distinctly different than its native role. Alternatively, one can 
imagine designing or developing proteins that are not found in nature to achieve new 
functions. Scenarios such as these demonstrate the utility of either improving protein 
function or discovering entirely new function. Importantly, the process of evolving 
improved function with an existing protein is fundamentally separate from discovering 
entirely new function. While evolving improved function can result from making a few 
strategically chosen mutations, discovering novel function typically requires huge leaps to 
be taken in protein sequence space. Thus, protein engineering is a worthy goal, yet a 
challenging goal because of the complexity of protein interactions both inter- and intra-
molecularly.  
Such complexity is echoed by our tenuous grasp of protein sequence-function 
relationships. Unfortunately, sequence space (i.e. all possible polypeptides of the 20 natural 
amino acids in a protein of length n, which is 20n sequences) is far too large to either 
experimentally or computationally test each unique amino acid sequence. The inaccuracy 
by which we predict mutations that will render a functional protein and which may improve 
biophysical characteristics is not a minor inconvenience.13–16 The majority of sequence 
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space lacks function entirely, making it exceedingly unlikely to find a useful protein simply 
by chance.17 Also, even if you have a stable and functional starting point, an average 
mutation imposed on it will both destabilize and reduce the functional activity of the 
protein.18–21 Owning to nature’s preferential selection of superior function rather than 
thermal stability, most natural proteins are only marginally stable (ΔGFolding = -5 – -10 
kcal/mol) to begin with.22–25 However, proteins, with the exception of intrinsically 
disordered proteins, require sufficient stability to fold properly and carry out a particular 
function.26 Thus, unwisely chosen mutations can yield variants that are unable to fold, thus 
preventing any potential functionality from being realized. De novo engineering of protein 
function, therefore, requires careful balancing of the requisite high number of mutations 
and their propensity for detriment. 
1.3. Protein evolution benefits from a more stable starting point as well as less 
destabilized variants 
Indeed, the likelihood of destabilizing mutations portrays naïve protein design as 
an arduous and inefficient task to the point of ineffectiveness. Discovering distinctly unique 
function from some protein starting point requires changing amino acids at several sites27, 
yet identifying a suitable combination of mutations is hindered by destabilization. To 
increase the fraction of stable variants that result from mutation, multiple approaches 
should be considered. One field of thought asserts that proteins offering a more 
thermodynamically stable fold are able to accept a higher fraction of random mutations 
while still maintaining their native fold.28,29 Bloom, et al. leveraged this approach to 
engineer new enzymatic functionality in P450. In their study, novel function was achieved 
through several functionally beneficial, but destabilizing, mutations. The critical mutations 
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were supported within a hyperstable P450 variant, but not the less stable parent.30 In this 
thesis, we pursue a related, but distinct approach in which strongly destabilizing mutations 
are avoided in favor of those that tend to be less destabilizing. Even in the absence of a 
hyperstable starting point, by improving the quality of mutations, an increased fraction of 
stable variants will follow.  
1.4. Navigating sequence space benefits from efficient search methods 
In the ideal case of protein engineering, it would be possible to precisely predict 
which positions within a protein should be modified to particular amino acids in order to 
elicit the function or biophysical property of interest. This type of rational design requires 
very low throughput and is well suited for scenarios where there exists rich structural and 
phylogenetic datasets related to both the protein and function of interest.31 This is not a 
common situation. When limited data exists for a target protein or function, it is likely to 
require screening a much greater variety of mutations to identify the desired properties. 
The vast and rugged nature of sequence space motivates that we probe the functional 
landscape (i.e. search for new function in the context of a given protein) in a systematic 
and efficient manner. This can be accomplished using a wide variety of techniques 
employed by the protein engineering community using protein libraries.32  
Protein libraries are composed of numerous unique members (variants) based on a 
common starting point (parent). The composition of the library (i.e. which sites are 
diversified and which amino acids are allowed at diverse sites) will significantly impact 
the ability to discover or evolve protein function. When very little is known about a parent 
protein, a scouting library can be generated that consists of point mutations scattered 
randomly throughout the entire protein. This approach, error-prone PCR33, has the benefit 
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of broadly searching while allowing for synergistic or epistatic mutations between distant 
sites; however, only shallow diversity is reached at any particular site and the likelihood of 
a specific site receiving a point mutation is largely stochastic. Alternatively, synthesized 
combinatorial libraries allow for much greater control over which sites are diversified and 
which amino acids are implemented at each site. One approach involves fully sampling all 
possible amino acids at a select number of protein sites (saturation mutagenesis).34 This 
results in a much greater depth of information, but at fewer sites and fails to broadly inform 
epistatic relationships. Consensus designs take advantage of available phylogenetic or 
homology information, implementing amino acid diversity that mimics the most frequently 
observed natural mutations.35 This approach is primarily limited by the quality and extent 
of phylogenetic data available and is restricted to functions previously observed in nature.  
Building combinatorial protein libraries is straightforward. The amino acid 
sequences are designed on the DNA level. Standard codons are used for specifying 
particular amino acids at each position, while degenerate codons allow for combinations 
of amino acids to be incorporated at a position of choice. Synthetically designed DNA 
oligos encoding for the protein libraries are amplified using PCR, then shuttled into a high-
throughput display system of choice – bacterial, mRNA, phage, ribosome, yeast, etc. In 
vitro and cell surface display systems provide a link between individual protein variants 
and the DNA which encodes for the variant. Thus, library member proteins can be easily 
identified by their DNA sequence after undergoing high-throughput selection methods 
such as magnetic bead sorting, fluorescence activated cell sorting, or cell panning.36,37 
Display technologies, while limited by transformation efficiency (bacterial, phage, 
and yeast) or volume throughput (mRNA and ribosome), allow for libraries that contain 
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109 – 1015 unique members.38,39 These library sizes (i.e. the actual number of unique 
members being experimentally tested) are significantly smaller than that of sequence space, 
even for small peptides.   
1.5. Experimental data and computational models inform protein library design. 
This disparity in searchable sequence space motivates protein libraries to 
incorporate only the most important variants, those that have the highest likelihood of 
demonstrating the function or biophysical parameter of interest. Efficient combinatorial 
libraries should avoid amino acid diversity that evokes extensive destabilization or detracts 
from functionality. Importantly, numerous techniques can provide insight into sequence-
structure-function relationships in proteins. While these methods have generally not been 
applied to combinatorial library design, we propose that some, or all, could provide utility 
in this area. Consensus design with natural protein homologs uses the identification of 
conserved sites to predict stabilizing mutations. Structural data inform computer 
simulations (e.g. Rosetta40) modelling the interface of protein binding events to predict 
mutations that promote strong affinity interactions.41 Estimating changes in stability upon 
mutation have also been successful.42–45 Even in the absence of computational tools, 
structural information can be probed to inform library design of a specific protein46 as well 
as highlighting the natural prevalence of amino acids within different secondary structures 
(e.g. glycine is common within loops, but is underrepresented in helices).  
Naturally observed sequences can guide protein library design. The amino acids 
most often observed in protein-protein interfaces suggest the most beneficial sidechains 
that facilitate binding events. For instance, tyrosine is particularly impactful at driving 
binding affinity and specificity, whereas serine can be a neutral interactor to offer an option 
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when tyrosine is not optimal for the particular site.47–51 Glycine contributes to 
conformational flexibility.52–54 Arginine content drives non-specific interactions at binding 
interfaces.54,55 Thus, for designing protein libraries where binding affinity is the property 
of interest, these amino acid preferences should be considered.56 
Beyond the prevalence of amino acids generally found at binding interfaces, nature 
can also provide insight to the arrangement of amino acid diversity from site-to-site. 
Analysis of the natural antibody repertoire shows that amino acid diversity varies at each 
site. Even within the complementarity determining regions (CDRs) of antibodies, amino 
acid composition is not uniformly distributed.57 Allowing variable levels of amino acid 
diversity has been successfully used in the context of natural58 and synthetic53 antibody 
repertoires as well as, to a limited extent, designed ankyrin repeat proteins46,59,60 and 
synthetic fibronectin domain libraries51,61. In the body of work presented here, high-
throughput evolution, deep sequencing, and sitewise diversification are used to guide 
efficient library design.61,62 
 
  
8 
 
Chapter 2 – High-Throughput Ligand Discovery Reveals a 
Sitewise Gradient of Diversity in Broadly Evolved Hydrophilic 
Fibronectin Domains 
Adapted from “Daniel R. Woldring, Patrick V. Holec, Hong Zhou, and Benjamin J. Hackel. 
‘High-Throughput Ligand Discovery Reveals a Sitewise Gradient of Diversity in Broadly 
Evolved Hydrophilic Fibronectin Domains.’ PLoS One 2015, 10 (9), e0138956.”   
2.1. Synopsis 
Discovering new binding function via a combinatorial library in small protein 
scaffolds requires balance between appropriate mutations to introduce favorable 
intermolecular interactions while maintaining intramolecular integrity. Sitewise constraints 
exist in a non-spatial gradient from diverse to conserved in evolved antibody repertoires; 
yet non-antibody scaffolds generally do not implement this strategy in combinatorial 
libraries. Despite the fact that biased amino acid distributions, typically elevated in 
tyrosine, serine, and glycine, have gained wider use in synthetic scaffolds, these 
distributions are still predominantly applied uniformly to diversified sites. While select 
sites in fibronectin domains and DARPins have shown benefit from sitewise designs, they 
have not been deeply evaluated. Inspired by this disparity between diversity distributions 
in natural libraries and synthetic scaffold libraries, we hypothesized that binders resulting 
from discovery and evolution would exhibit a non-spatial, sitewise gradient of amino acid 
diversity. To identify sitewise diversities consistent with efficient evolution in the context 
of a hydrophilic fibronectin domain, >105 binders to six targets were evolved and 
sequenced. Evolutionarily favorable amino acid distributions at 25 sites reveal Shannon 
entropies (range: 0.3-3.9; median: 2.1; standard deviation: 1.1) supporting the diversity 
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gradient hypothesis. Sitewise constraints in evolved sequences are consistent with 
complementarity, stability, and consensus biases. Implementation of sitewise constrained 
diversity enables direct selection of nanomolar affinity binders validating an efficient 
strategy to balance inter- and intra-molecular interaction demands at each site. 
2.2. Introduction 
Protein sequence space is immense, and the protein/function landscape is rugged 
and barren: very similar sequences often have greatly different function with the majority 
of sequences lacking any utility17. Protein complexity and our naivety of 
sequence/structure/function interplay63 hinder robust de novo design, although several 
designs have been successfully realized64–66. Thus, naïve identification of protein 
sequences with novel functions, or even mutants with improved function, benefits from 
combinatorial analysis of many proteins. The efficacy of this approach is directly 
dependent on combinatorial library quality and the phenotype selection process. The 
essence of discovery and evolutionary efficiency is to intelligently search sequence space 
by identifying the effective extent and amino acid distribution of diversity (if any) at each 
site. Protein discovery and evolution must balance 67 variance sufficient for generation of 
novel function (dominated by intermolecular interactions) versus conservation sufficient 
to maintain a high probability of foldable stability (intramolecular interactions)21. This 
challenge is heightened in small domains68 that have limited area for a binder interface and 
require mutation of a larger fraction of the molecule69. 
Antibody repertoires have evolved sitewise amino acid distributions across a range 
of diversities (Fig. 1A), which are used in natural and synthetic antibody libraries70–74. Yet 
most synthetic scaffold libraries – including affibodies75, affitins76,77, knottins78,79, 
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anticalins80, Fynomers81, Sso7d82, and OBodies83 – are binary with a fully conserved 
framework and uniformly diversified paratope (Fig. 1B). Note that different scaffolds use 
different uniform distributions including NNK codons84 or complementarity biases47,55 but 
generally lack sitewise variation. DARPin domain libraries have six sites with a uniform 
broad distribution and one site with N/H/Y diversity59. A hydrophilic DARPin library 
includes two additional sitewise diversities46. The most sitewise design in non-antibody 
scaffolds has been introduced in the type III fibronectin domain. Diversification of one, 
two, or three loops,85,86 or the sheet surface,87,88 of this 10 kDa beta sandwich has enabled 
evolution of binding to a host of molecular targets 86. Antibody-inspired amino acid bias in 
putative hot spots has proven effective within fibronectin libraries87,89–91. Diversification 
of two loops is evolutionarily superior to one-loop mutation92, and although diversification 
of the third loop (DE loop: G52-T56) is not requisite for high-affinity binding, 86,92–95 it can 
aid stability 93. Current library designs randomize G52 with G/S/Y, S53-S55 with Y/S, and 
12-22 sites in two other loops with a consistent distribution (30% Y, 15% S, 10% G, 5% 
each F and W, and 2.5% others except C). Sitewise design was extended beyond the DE 
loop using accessibility, stability, and homology data yielding nine different 
diversifications at 11 sites in addition to 12 sites with consistent complementarity-biased 
diversity 91. Also, in an alternative paratope approach to engineering fibronectin domains, 
five sites were identified for three different varieties of constrained diversities (4-8 amino 
acids) in addition to 12-19 sites with the complementarity biased diversity 87. While a 
variety of sitewise diversities have been implemented in the fibronectin domain, the 
evolved repertoires resulting from these libraries have not been broadly and deeply 
analyzed. 
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Figure 2-1. Diversity gradients in binding molecules. (A) The amino acid diversity, 
measured as Shannon entropy of antibody sequences (from the abysis database at 
http://www.bioinf.org.uk/abysis/) in the framework (open circles, white background) 
and CDRs (solid circles, gray background). (B) The Shannon entropy of 
combinatorial library designs for antibody (data from A), fibronectin (Fn) 96, 
designed ankyrin repeat (DARPin) 97, affibody 98, and anticalin 99, domains. (C) The 
relative impact of alanine mutation on binding is shown for several protein interfaces: 
TEM1-β–lactamase (TEM1) and β-lactamase inhibitor protein (BLIP) (PDB: 1JTG) 
100; extracellular RNase (barnase) and its intracellular inhibitory binding partner 
(barstar) (PDB: 1BRS) 101; light and heavy chain variable regions of anti-hen egg 
white lysozyme antibody D1.3 in the context of binding anti-D1.3 antibody E5.2 (not 
shown) (PDB: 1DVF) 102; human growth hormone (hGH) and extracellular domain 
binding partner (hGHpb) (PDB: 1A22) 103,104; heregulinβ (HRG) egf domain in the 
context of binding ErbB3 receptor-IgG fusion (not shown) (PDB: 1HAE) 105.  
The current study aims to quantitatively evaluate the broad extents of 
diversification and sitewise amino acid distributions that evolve in hydrophilic fibronectin 
domains (Fn3HP) developed as binding ligands. The Fn3HP mutant was previously 
evolved for hydrophilicity to improve processing and in vivo biodistribution 106. We posit 
that a broad repertoire evolved from combinatorial libraries for de novo discovery will 
exhibit sitewise complementarity-biased amino acid diversity in the binding hot spot 
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104,107,108, conserved wild-type sequence in the distal framework, and a gradient of 
diversification at intermediate sites including bias for conservation or interactive neutrality 
in proximal regions. This gradient is not purely spatial as protein structure and protein-
protein interfaces are complex (Fig. 1C). Moreover, for novel ligand discovery, the exact 
paratope is not known ahead of time, which blurs designed localization of a hot spot 107. 
The approach used was high-throughput discovery and directed evolution of 
thousands of binding ligands to various targets from a diverse combinatorial library 
followed by thorough sequencing of the library and binder populations to identify 
diversities and amino acids consistent with functional hydrophilic fibronectin domains (S1 
Fig.). Deep sequencing of evolved protein populations has proven effective for analysis of 
functionality landscapes for maturation of single protein clones 109, protein families 110,111, 
and antibody 112 repertoires. Here we apply deep sequencing to several high-throughput 
discovery and evolutionary campaigns to identify repertoires of evolved hydrophilic 
fibronectin domains. The results demonstrate a range of diversities and sitewise amino acid 
preferences consistent with a benefit of a gradient of sitewise constraint. A constrained 
library based on the observed evolutionary repertoire provides stable, high affinity binders 
directly without maturation, and the sequence analysis provides a metric to evaluate the 
balance of inter- and intra-molecular considerations in library design, which are 
quantitatively assessed. 
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2.3. Materials and Methods 
2.3.1 Library Construction 
Oligonucleotides, including amino acid diversity and loop length variation, were 
synthesized by IDT DNA Technologies (Tables 1-2 and S1-S2 Tables). Full-length Fn3HP 
amplicons were assembled by overlap extension PCR. The library of pooled diversified 
DNA was homologously recombined into a pCT yeast surface display vector 92 within yeast 
strain EBY100 113 during electroporation transformation. The protocol was similar to that 
described by Benatuil et al. 114. Yeast at an optical density at 600 nM of 1.3-1.5 were 
washed twice with cold water and once with buffer E (1 M sorbitol, 1 mM CaCl2) and 
resuspended in 0.1 M lithium acetate, 10 mM Tris, 1 mM ethylenediaminetetraacetic acid, 
pH 7.5. Fresh dithiothreitol was added to 10 mM. Cells were incubated at 30º, 250 rpm for 
30 minutes. Cells were washed thrice with cold buffer E and resuspended to 1.4 billion 
cells per 0.3 mL buffer E. Six µg of linearized pCT vector and 200 pmol of ethanol 
precipitated gene insert were added and transferred to a 2 mm cuvette. Cells were 
electroporated at 1.2 kV and 25 µF, diluted in YPD (10 g/L yeast extract, 20 g/L peptone, 
20 g/L dextrose), and incubated at 30º for 1 hour. Cells were pelleted and resuspended in 
100 mL SD-CAA (16.8 g/L sodium citrate dihydrate, 3.9 g/L citric acid, 20.0 g/L dextrose, 
6.7 g/L yeast nitrogen base, 5.0 g/L casamino acids). Plasmid-containing yeast were 
quantified by dilution plating on SD-CAA agar plates. 
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Table 2-1. Amino acid diversity encoded in first generation library.  Each row was constructed as a separate sublibrary. 
CDR’ refers to a degenerate codon with the following nucleotide frequencies: 20% A, 15% C, 25% G, and 40% T at site 
1, 50% A, 25% C, 15% G, and 10% T at site 2, and 0% A, 45% C, 10% G, and 45% T at site 3. Loop length diversity 
was afforded at mid-loop positions by inserting CDR’ diversity sites between sites P25-V29 and G79-S85 of the BC and 
FG loop, respectively, as denoted by subscripts within table. Length diversity at the DE loop occurred between S53-S55, 
consisting of diversity matching that of K54 as shown below. Note that throughout the manuscript, a series of unseparated 
capital amino acid abbreviations refer to equally possible amino acids; for example, SYNT indicates 25% each of serine, 
tyrosine, asparagine, and threonine at that site.  
 
Table 2-2. Amino acid diversity encoded in second generation library. CDR’ refers to a degenerate codon with the 
following nucleotide frequencies : 20% A, 15% C, 25% G, and 40% T at site 1, 50% A, 25% C, 15% G, and 10% T at 
site 2, and 0% A, 45% C, 10% G, and 45% T at site 3. Loop length diversity was afforded at mid-loop positions by 
inserting CDR’ diversity sites between sites P25-V29 and G79-S85 of the BC and FG loop, respectively, as denoted by 
subscripts within table. Length diversity at the DE loop occurred between S53-S55, consisting of either wild-type length 
or the exclusion of K54. 
 BC Loop DE Loop FG Loop 
Site D23 A24 P25 AVT 26-28 V29 R30 Y31 G52 S53 K54 S55 T56 T76 G77 R78 G79 DSPAS 80-84 S85 K86 
Generation 2 D A/ASYDNT P/PSYH CDR‘2-4 AST CDR' GY G SYNT (NSYT) 0-1 SYNT TSYN TSGA GSYADCNT CDR' GSDN CDR’1-5 S N 
 
 BC Loop DE Loop FG Loop 
Site D23 A24 P25 AVT 26-28 V29 R30 Y31 G52 S53 K54 S55 T56 T76 
GR 
77-78 G79 
DSPAS 
80-84 S85 K86 
Sublib. 
1 D A P CDR'1-4 AST CDR' G G S N0-2 S T T CDR‘ GDNSYC CDR’1-5 S N 
Sublib. 
2  DSYA AS PS CDR'1-4 AST CDR' GS GS S (NS) 0-2 S TS TS CDR‘ GDNSYC CDR‘1-5 S NS 
Sublib. 
3  DSYA ASYD PSYH CDR'1-4 AST CDR' GSYCDN GSYCDN SYNT (NSYT) 0-2 SYNT TSYN TSYN CDR‘ GDNSYC CDR‘1-5 SYNT NSYT 
Sublib. 
4 ACDGNSTY ACDGNSTY ACDGNSTY CDR'1-4 AST CDR' ACDGNSTY ACDGNSTY ACDGNSTY 
(ACDGNSTY) 0-
2 ACDGNSTY ACDGNSTY ACDGNSTY CDR‘ GDNSYC CDR‘1-5 ACDGNSTY ACDGNSTY 
Sublib. 
5 CDR' CDR' CDR' CDR'1-4 AST CDR' CDR' CDR' CDR' CDR' 0-2 CDR' CDR' CDR' CDR‘ GDNSYC CDR‘1-5 CDR' CDR' 
15 
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Each resulting Fn3HP naïve yeast library was evaluated for proper library 
construction by Sanger sequencing clonal plasmids harvested from the transformed yeast 
(57 clones from generation one and 15 from generation two naïve libraries) and later via 
Illumina sequencing. The yeast libraries were also labeled with biotinylated anti-HA 
antibody (goat pAb, Genscript) and anti-c-MYC antibody (9E10, Covance Antibody 
Products;) to detect the presence of N- and C-terminal epitopes present on either side of 
the Fn3HP clones, respectively, via flow cytometry. The fractional detection of cells 
displaying both HA and c-MYC, compared to those displaying HA alone, is indicative of 
full-length, stop codon-free clones. 
 
2.3.2 Binder Maturation and Evolution 
The Fn3HP yeast library was grown in SD-CAA selection media for several 
doublings (about 20 h) in an incubator shaker at 30°C until an optical density value of 6.0 
was reached, at which time the yeast were centrifuged and resuspended in SG-CAA 
induction media (10.2 g/L sodium phosphate dibasic heptahydrate, 8.6 g/L sodium 
phosphate monobasic monohydrate, 19.0 g/L galactose, 1.0 g/L dextrose, 6.7 g/L yeast 
nitrogen base, 5.0 g/L casamino acids) and grown overnight. The induced library was 
sorted twice via multivalent magnetic bead selections 115 via depletion of non-specific 
binders on avidin-coated beads and control protein-coated beads followed by enrichment 
of specific binders on target-coated beads. The pair of magnetic sorts was followed by a 
flow cytometry selection for full-length clones using the 9E10 antibody against the C-
terminal c-MYC epitope tag. Genes were mutated via error-prone PCR with loop shuffling 
93, then electroporated into yeast (EBY100) as previously described. Target binding 
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populations were isolated at two levels of stringency, mid- and high-affinity, for each of 
the four campaigns. A mid-affinity population included all clones that demonstrated either 
(i) magnetic bead sorting enrichment at least ten-fold greater for target protein than both 
avidin binding and non-specific control binding or (ii) binding to 50 nM multivalent target 
(3:1 stoichiometry of target preloaded on streptavidin-fluorophore) assayed via flow 
cytometry (S2 Fig.). A high-affinity population included all clones exhibiting binding to 
50 nM monovalent target assayed via flow cytometry. Herein, clones meeting these criteria 
are referred to as mid- and high- affinity binders, respectively. Flow cytometry was 
performed as previously described 116. 
 
2.3.3 Illumina MiSeq Sample Preparation and Sequence Analysis 
Plasmid DNA was isolated from yeast using Zymoprep Yeast Plasmid Miniprep II. 
DNA samples were divided into separate groups based on library generation of origin and 
binding affinity. Three categories were included for each generation: naïve clones from the 
initial libraries, mid-affinity binders collected via magnetic bead sorting, and high-affinity 
binders collected using FACS.  In total, six pools of DNA were isolated and uniquely 
analyzed in association with generations one and two. Following plasmid DNA extraction, 
two rounds of PCR were completed to assemble the Fn3HP gene fragment with Illumina 
primers, index tags, multiplexing bar codes, and TruSeq universal adapter (S4 Table). For 
all PCR conducted during amplicon library preparation, KAPA HiFi polymerase was used 
as it has been shown to reduce clonal amplification bias due to GC content 117 as well as 
fragment length bias 118. Compatible multiplexing and adapter primers were designed 
according to TruSeq sample preparation guidelines. Amplicons were pooled and 
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supplemented with 25% PhiX control library to increase MiSeq read accuracy. Illumina 
MiSeq paired-end sequencing with 2 x 250 read length was conducted (University of 
Minnesota Genomics Center) to obtain 7.2x106 pass filter (PF) reads from the populations 
of interest, of which 90% of all pass filter bases were above Q30 quality metric (99.9% 
read accuracy). 
 
2.3.4 Sequence Analysis 
Raw data generated through MiSeq consisted of forward and reverse read files 
(FASTQ) for each of the six multiplexed sublibraries. Assembly of paired end reads was 
done using PANDAseq 119. Assembled reads were analyzed using in-house Python 120 
code. Analysis work flow for each of the six subgroups (e.g. naïve, mid-affinity, high-
affinity populations originating from first and second generation libraries) consisted of first 
identifying full-length fibronectin DNA sequences, isolating each of the three diversified 
loop regions, and, lastly, calculating the amino acid frequency at each site. Additional 
calculations were necessary for the mid-affinity and high-affinity populations to both 
remove statistically rare events and avoid overcounting dominant clones. The removal of 
background (i.e. the rarest 2% of sequences, as determined by the rarity of nonspecific 
binders) was a precaution taken when analyzing the mid-affinity populations to account for 
the rare non-binding clones inherently collected via magnetic bead sorting 115. To address 
the potential detriment of overcounting within all binding populations, the sequences for 
each loop region were clustered based on 80% or greater sequence homology. For each 
cluster of similar sequences, the summation of the amino acids at each site were weighted 
by a power of one-half, then aggregated across all clusters. The resulting weighted sitewise 
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amino acid values were used for frequency calculations. Statistical analysis was performed 
using two sample Student’s t-test. Statistical significance was assessed while adjusting for 
familywise error rate using Bonferroni method, denoted at level α = 0.005. 
 
2.3.5 Stability Assessment 
High-affinity clones from three separate target binding campaigns of the current 
study were individually evaluated for stability using thermal denaturation midpoint, Tm, in 
the context of yeast surface display, as previously described 93. Wild-type Fn3HP and seven 
random clones from the second generation initial library were produced with a C-terminal 
six-histidine tag in BL21(DE3) and purified by immobilized metal affinity chromatography 
and reverse phase high performance liquid chromatography. Purified proteins (1 mg/mL in 
2 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, 50 mM NaCl, 2 mM 
ethylenediaminetetraacetic acid, 1 mM dithiothreitol) were analyzed via circular dichroism 
121 using a JASCO J815 instrument. Measurements of molar ellipticity were taken at 218 
nm while heating from 20-98°C at a rate of 1 °C per minute. Stability measurements of 15 
engineered fibronectin clones were retrieved from previously published studies wherein 
library design was implemented through a binary approach: broadly diversifying the 
anticipated paratope, using NNS 122 and NNB 93 codons, and fully conserving all other 
positions. 
 
2.3.6 Correlative Parametric Analysis of Amino Acid Distributions 
To evaluate the correlation of evolved sitewise amino acid frequencies with several 
computed parameter matrices (sitewise computational stability, sitewise amino acid 
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frequency in natural homologs, complementarity, and exposure), a sitewise amino acid 
frequency matrix (F) is calculated from Equation 1: 
 
𝐹𝐹 = ∑ (𝛼𝛼𝑘𝑘 + 𝛽𝛽𝑘𝑘 ∙ 𝜀𝜀) ∙ 𝑓𝑓𝑘𝑘𝑎𝑎,𝑏𝑏,𝑐𝑐𝑘𝑘     (Eq. 1) 
 
where αk  and βk are tunable weights to scale the primary parameter data (fk) as a function 
of exposure score, ε (see below). Parameter weights that are most consistent with 
experimental data were calculated using a least-square method to minimize error between 
the calculated matrix, F, and objective matrix, defined as the sitewise amino acid 
frequencies observed in binder sequences evolved from the second generation library. 
Constraints are placed such that each set of α values sum to 1.0 and each set of β values 
sum to zero. 
  
2.3.7 Amino Acid Frequencies in Natural Homologs 
The Pfam database offers an extensive collection of protein families compiled 
through hidden Markov models 123. The Fn3 protein family homologs (PF00041) were 
aligned to the 101 amino acids in Fn3HP. To reduce the impact of dominant replicate 
sequences, while still accounting for their repeated observation, the frequency of replicate 
sequences were counted as the square root of the total number of occurrences. The amino 
acid frequency at each site was computed (S3B Table). 
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2.3.8 Stability Matrices 
FoldX 124 was used to determine the mutability of sites 23-31, 52-56, and 76-86 
within the tenth type III domain of human fibronectin in the context of several structures 
cataloged in the Protein Data Bank 125 (PDBs: 1FNA, 1TTG, 2OBG, 2OCF, 2QBW, 3CSB, 
3CSG, 3K2M, 3QHT, 3RZW, 3UYO). After performing FoldX repair, random mutants 
were generated for each of the eleven structures by randomizing the BC, DE, and FG loop 
regions in accordance with the second generation diversity design scheme. At this point, 
baseline stabilities were individually calculated for each mutant. To analyze the stability 
impact upon residue substitution for each position in the diversified regions, all 19 natural 
residue substitutions were individually introduced to the random mutants. The change in 
stability (ΔΔGfolding) upon mutation was then calculated for each PDB structure’s collection 
of mutants. This process was iterated (n > 50) until the ΔΔGfolding associated with each 
position and residue converged to within 0.2 kcal/mol for at least five consecutive mutants. 
At each site, the stability impact upon substitution to each amino acid was calculated, 
creating stability matrices for each starting PDB. The sequences corresponding to the wild-
type structures were aligned to account for loop length diversity. Average ΔΔGfolding values 
were calculated for all 20 amino acids at each diversified site (S3A Table). 
 
2.3.9 Exposure 
The likelihood of a loop position to be proximal to or directly involved with a target 
binding interface is influenced both by exterior exposure of the side chain (i.e. solvent 
accessible surface area) as well as its proximity to a region offering sufficient diversified 
surface area to enable the required enthalpic interactions. The site-specific exposure score 
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is calculated as the product of the solvent accessible surface area 91 and an estimated 
likelihood of residing at the target binding interface. The latter was quantified on a sitewise 
basis, averaged across eleven Fn3 crystal structures, using a geometric algorithm. Using 
Python, the fibronectin orientation that presents maximal diversified surface is identified 
as follows. BC, DE, and FG loop residues are mutated to alanine to remove wild-type 
residue size bias. The area of accessible (i.e., visible in a two-dimensional projection as a 
planar approximation of the interface) diversified surface is calculated for each rotational 
orientation of fibronectin. The orientation that maximizes accessible view of the paratope, 
as well as any orientations within 5% of this projected area, is identified starting with a 
coarse-grained search and optimizing with a fine-grained search. For each site, the 
maximum area of accessible side chain surface within this set of optimized orientations is 
calculated. This calculation is repeated for all sites. Sitewise values are averaged across all 
Fn3 PDB models. 
 
2.4. Results 
2.4.1 Library design and construction 
As a collection of starting points for the evolution of diverse ligands, a 
combinatorial library was created with various levels of diversity throughout the potential 
paratope of the hydrophilic fibronectin loops (Table 1). Each loop varied in length as 
guided by natural sequence frequency 93. The core of the BC and FG loops – 2-5 sites and 
2-6 sites, respectively, depending on loop length – had full amino acid diversity biased to 
mimic the third heavy chain complementarity-determining region (CDR) of antibodies. 
Two sites spatially within the BC and FG loop cores were constrained based on previous 
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experimental results. V29, which benefits as a small, reasonably hydrophobic amino acid 
91,126, was constrained as A, S, or T. G79, which benefits from glycine bias 91, was mildly 
constrained to G, S, Y, D, N, or C to increase glycine frequency while mimicking CDRs. 
Twelve sites adjacent to the core of the BC and FG loops were afforded five levels of 
diversity: i) wild-type, ii) wild-type or serine (as a small, mid-hydrophilicity neutral 
interactor 127,128), iii) wild-type, serine, or tyrosine (the most generally effective side chain 
for complementarity 49), iv) moderate chemical diversity (A, C, D, G, N, S, T, or Y), or v) 
full antibody-mimicking amino acid diversity. All framework sites are conserved as the 
sequence of the tenth type III domain of human fibronectin with the hydrophilic mutations 
V1S, V4S, V11T, A12N, T16N, L19T, V45S, and V66Q 106 as well as the stabilizing D7N 
129. Five sub-libraries were constructed using separate DNA oligonucleotides with 
degenerate codons for each level of diversity. The five sub-libraries for each of the three 
loops were pooled at equimolar levels. 
The gene libraries were transformed into a yeast surface display system 113, which 
yielded 2.0x108 transformants. DNA sequencing of 57 random naïve clones indicated 61% 
had full-length sequences, 16% contained stop codons naturally arising from the CDR’ 
diversity, and 21% contained frameshifts. This finding was supported by flow cytometry 
analysis that revealed 64% of proteins were full-length as evaluated by the presence of a 
C-terminal c-myc epitope. Thus, the library contained 1.2x108 unique, full-length Fn3HP 
clones. 
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2.4.2 Selection and analysis of binding populations from first generation library 
To identify a diverse set of selective ligands for a range of protein epitopes, the 
pooled library was sorted, using magnetic beads with immobilized protein targets and 
fluorescence-activated cell sorting (FACS), to yield binders to goat immunoglobulin G 
(IgG), rabbit IgG, lysozyme, or transferrin. These targets were selected to provide a diverse 
set of epitopes for targeting. Following a single round of mutagenesis, then two rounds of 
magnetic bead sorting, an enriched population of mutants was isolated that demonstrated 
mid-affinity, selective binding to transferrin. Selectivity was evidenced by a 30:1 ratio of 
fibronectin-displaying yeast selected for binding transferrin relative to binding negative 
control proteins (avidin and lysozyme).  This population was then sorted for high-affinity 
binders via FACS. Similarly, though with one additional round of mutagenesis, mid- and 
high-affinity, selective binders for goat IgG, rabbit IgG, and lysozyme were identified (S2 
Fig.). 
The binding populations were sequenced via Illumina MiSeq resulting in 4.2x105 
sequences, including 1.1x105 unique sequences. Analysis of similar sequences, identified 
and clustered using an in-house algorithm, revealed 3,590 unique families of unrelated 
sequences. Thus, a broad set of evolutionary solutions was identified for Fn3HP-based 
ligands. 
Amino acid frequencies were measured at each site in the naïve and functionally 
evolved populations to reveal evolutionary impact. The amino acid distribution in evolved 
ligands exhibits substantial sitewise preferences in both the broadly diversified paratope 
core (Fig. 2C), in which the original library provided complementarity-biased diversity, 
and the adjacent sites (Fig. 2A) in which wild-type and neutral bias were implemented 
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along with lesser complementarity bias. For example, at site 30, N is depleted from 10% 
in the original library to 1% in evolved clones; conversely, K is enriched from 2% to 11%. 
At site 85, Y is depleted from 10% to 3% whereas P is enriched from 1% to 12%, 
suggesting a substantial evolutionary benefit. At site 24, S is depleted from 16% to 6%, 
and enrichment is broadly distributed by several amino acids. The sitewise amino acid 
distributions in the population of evolved fibronectin domains, and their deviation from the 
original unsorted library distributions, can be evaluated in a variety of ways to reveal 
evolutionary insight. 
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Figure 2-2. First generation sitewise amino acid distribution. (A) The amino acid 
frequencies at the indicated sites for the first generation library (white) and the 
binding populations (gray). Bars and error bars are mean ± standard deviation. 
Statistical significance, while adjusting for family wise error rate using Bonferroni 
method, was achieved at level α = 0.005 for all data with the exception of those denoted 
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( • ). (B) Solution structure (PDB: 1TTG) of wild-type fibronectin domain with 
backbone residues of diversified loop sites denoted by spheres. BC, DE, and FG loops 
are labeled as are several sites for reference. (C) The difference between the amino 
acid frequencies in the binding populations and the first generation library are shown 
for each amino acid at each site. The average across all fully diversified sites is also 
presented. Init. indicates the average amino acid frequency in the initial library across 
all CDR’ sites.  
 
2.4.3 Shannon Entropy 
Shannon entropy (H = -∑i=1-20 pi ln pi, where pi is the fraction of amino acid i at a 
particular site), which describes relative diversity ranging from 0 (fully conserved) to 4.3 
(5% of each amino acid) 130, was calculated at each site for the naïve and evolved 
populations to measure constraint within functional ligands. Diversity at 21 of 25 sites is 
more constrained in the evolved repertoire than in the unsorted library as evidenced by 
reductions in the Shannon entropies (average: -0.2 units; S3 Fig.). Twelve sites have 
reduction of at least 0.15 units. Notably, G52 (2.8 to 2.0) and G31 (2.7 to 2.1) are largely 
driven by 22% and 17% increases in constraint of wild-type G. D23 (2.6 to 2.2), N54 (2.8 
to 2.4), and T76 (2.8 to 2.4) are driven by broader constraint. 
 
2.4.4 Wild-Type Constraint 
Even with wild-type constraint averaging 39% in the edges of the BC loop in the 
original library, wild-type was further enriched in evolved sequences by an average of 
11%: D23 (46% to 55%), A24 (39% to 46%), P25 (29% to 40%), and G31 (40% to 56%). 
Conversely, at the sites in the middle of the loop, fully diversified with complementarity 
bias, wild-type enrichment was less frequent: absent at A26 (2% to 2%), V27 (<1% to 
<1%), and R30 (2% to <1%) but present at T28 (6% to 15%). 
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The FG loop exhibited increases in wild-type constraint throughout: T76, G77, 
R78, G79, D80, S81, P82, S84, and S85 all elevated wild-type with an average increase of 
6%. A83 also increased but with very few sequences available for analysis because of loop 
length variability. Also, wild-type was not considered at site 86 to eliminate the large, 
charged side chain K. 
In the peripheral DE loop, wild-type constraint was diminished at three of four sites: 
S53 (44% to 31%), S55 (44% to 28%), and T56 (29% to 27%). Yet at the other site, G52, 
wild-type was substantially enriched in evolved binders (35% to 57%). 
 
2.4.5 Enrichments Predicted by Proteome or Fibronectin Homologs 
The extent to which sitewise biases were correlative with wild-type or homologous 
residues was evaluated. Of 39 residues with an enrichment of at least 5% (in magnitude, 
not relative increase), 13 are wild-type, 13 are wild-type homologs (A26S, R30K, S55T, 
T76S, S84A, N86D, N86S, V29A, S53G, S53D, S55D, G79S, and S81G), and 13 are non-
homologous as defined by proteome-wide amino acid homology (BLOSUM62 131). 
Of the 26 residues with enrichment of non-wild-type amino acids, 14 (54%) are 
also enriched in fibronectin homologs (S3B Table). While these homolog enrichments 
support the concept of applying consensus design 35 to combinatorial evolution, the other 
12 residues (46%) highlight the limitations of such an approach (i.e., the functional 
capacity of mutations not observed in natural evolution). 
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2.4.6 Serine 
Serine was frequent in the naïve library adjacent to the fully diversified sites 
because of its purported ability to act as a neutral interactor, providing neither substantial 
detriment nor benefit. It was mildly reduced (from 29% to 24%) in the evolved repertoire. 
 
2.4.7 Sites with Complementarity Bias 
On average across all sites with full, complementarity-biased diversity, the biased 
distribution – based on the distribution observed in natural antibody repertoires – was 
generally preserved. Modest exceptions were that A and D were enriched by 3% each 
whereas N and Y were depleted by 3% each. 
 
2.4.8 Comparison of Evolutionary Probabilities from the Original and Evolved 
Repertoires 
The original and evolved sitewise amino acid frequencies were compared for their 
likelihood to yield functional ligands. The repertoire evident in the evolved population is a 
more efficient starting point for ligand discovery. Using leave-one-out cross-validation – 
with family clusters partitioned to ensure unbiased training sets (see Materials and Methods 
for details) – 6.6-fold more clones were more likely to be identified from the constrained 
repertoire versus the original library (Fig. 3A). The median increase in likelihood was 
795%; i.e., an evolved clone was 8-fold more likely to be identified from a combinatorial 
library based on the new repertoire than the original library. Notably, this original library 
already had constraint built into it from previous studies, detailed above (particularly 
constraint to a small hydrophobic residue at 29 and glycine bias at 79). 
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Figure 2-3. Distribution of evolutionary probabilities from the original and evolved 
repertoires. To estimate the likelihood of an evolved clone to have been identified from 
either the first generation repertoire or from that which is observed within the 
evolved population of binders, an exhaustive leave-one-out cross-validation 
(LOOCV) was conducted. The training set consisted of n-1 sequence clusters derived 
from the first generation mid-and high-affinity evolved binder data. Using the 
training set sequence clusters, a sitewise frequency matrix was calculated. The cross-
validation test set consisted of a single sequence cluster that had been excluded from 
the training set analysis. Each sequence within the test set was assigned a probability 
for being observed within the original library (Pnaive) and the training set (Pevolved). 
Log-odds score, log(Pevolved/Pnaïve), histograms are shown for test set sequences (A) and 
further evaluated on a sitewise basis (B). 
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The probability of evolution from the constrained population versus the original 
population was also evaluated on a sitewise basis (Fig. 3B). Sites exhibit a range of 
evolutionary enhancements. For example, sites 52 and 54 have 107% and 213% increased 
likelihood of ligand discovery from the constrained repertoire whereas sites 78 and 81 are 
essentially neutral (1% and 2% increase towards constrained repertoire). 
  
2.4.9 Loop Length Variation 
The BC and DE loops frequently evolved loops one amino acid shorter than wild-
type length but also exhibited frequent wild-type lengths (Fig. 4). Extended loops were 
very rare in both BC (2%) and DE (0.1%). Also, a two amino acid deletion in the BC loop, 
while present in 33% of the original library, only appeared in 2% of evolved domains. Loop 
lengths were more broadly distributed in the FG loop but with a notable evolutionary 
preference towards shorter loops. 
 
 
Figure 2-4. Loop length variation. Loop length frequencies in naïve and binder 
populations as identified by Illumina sequencing of first and second generation 
(details in Table 3). Bars and error bars represent mean ± standard deviation. 
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Table 2-4. High-throughput sequencing. Illumina sequencing statistics for 251 
basepair paired end run on MiSeq for six uniquely barcoded libraries. Collectively, 
7.2 million pass filter reads were obtained, including 25% PhiX control library. 
Within all pass filter read bases, 90% were above Q30 quality metric (99.9% read 
accuracy). Thorough sampling was observed across all six libraries with a coefficient 
of variance of 30%. 
 Generation 1 Generation 2 
  Bead Flow Bead Flow 
Total Sequences 181,716 239,934 259,519 225,205 
Unique Sequences 65,971 47,957 128,485 103,615 
Unique Families 3,334 256 3,733 1,234 
 
 
2.4.10 Design, construction, selection, and analysis of binding populations from second 
generation library 
A. Library Design Based on First Generation Evolved Repertoire 
The amino acid distributions observed in binding ligands evolved from the first 
generation library were used to design a second generation library, which enables further 
study of evolutionary repertoires from a more constrained library as well as evolution of 
useful ligands. Within the BC loop at site 23, wild-type D was enriched (46% in the naïve 
library to 55% in binders) whereas Y, introduced at 17% because of complementarity bias, 
was substantially depleted in binders to 8±1%. Small, mildly hydrophilic residues were 
also enriched – G (5% to 11%) and S (11% to 14%) – but not to levels comparable with 
wild-type bias. Thus, D23 was conserved in the second generation library. At site 24, wild-
type A was elevated (39% to 46%), Y was maintained (13% to 13%), and S was 
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substantially depleted (16% to 6%). Thus, the options of wild-type conservation and mild 
diversity were further explored in the second generation. At site 25, wild-type P was 
enriched (29% to 40%), Y was maintained (17% to 16%), S slightly declined (25% to 
17%), and H was enriched (6% to 8%). Wild-type conservation appears beneficial yet Y, 
S, and H warrant further consideration. At site 29, the more hydrophobic A was enriched 
(42% to 56%) whereas the more hydrophilic S and T were depleted (22% to 12% and 34% 
to 26%, respectively) but still frequent. Thus, second generation design maintained a 
distribution of AST. Y31 was enriched from 12% to 17% in binders. Glycine, which occurs 
with 31% frequency at this site within natural sequences of homologous proteins, increased 
in prevalence from 40% to 56%. Substantial decreases in S (18% to 9%), N (8% to 3%), 
and C (7% to 2%) were observed. The second generation library contained GY diversity. 
Wild-type G52 was enriched (35% to 57%) whereas S was depleted (23% to 11%). Wild-
type conservation appears strongly beneficial at site 52. At sites 53-55, Y and N were 
enriched or maintained whereas S was depleted, but still present at reasonable levels. Thus, 
the second generation library implemented YNST diversity at these sites. T56 exhibited 
similar results without S depletion leading to TYSN design. At FG loop site 76, enrichment 
was observed for both wild-type T (34% to 41%) and S (26% to 32%) whereas N (10% to 
3%) and Y (8% to 3%) were depleted in binders. Thus, the next design included T and S 
as well as the other small mid-hydrophilic G and A. At site 79, wild-type G was enriched 
(22% to 31%) as was S (19% to 27%). D (19% to 20%) was maintained but C (13% to 
5%), Y (11% to 5%), and N (15% to 9%) decreased. Thus, GSDN diversity was used in 
the second library. Wild-type S85 maintained (62% to 65%), which prompts future 
conservation. At site 86, N was mildly decreased (48% to 40%) while S increased from 
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23% to 28% and Y decreased from 10% to 5%. The second generation design was intended 
to be NS but was erroneously synthesized as conserved N. 
At G77, wild-type was enriched from 5% to 9% in binders. Y remained frequent in 
binders (20% to 16%), and D (11% to 18%) and T (4% to 8%) were enriched. Thus, G77 
was set to GSYADTNC in generation two. Though several enrichments and depletions are 
evident elsewhere, all other CDR’ sites will be maintained as CDR’. 
The second generation library (Table 2) was constructed from degenerate 
oligonucleotides. 4.2x109 yeast transformants were obtained. 71% were full-length as 
assessed by cytometry and corroborated by Sanger sequencing (67% full-length). 
 
B. Selection and Analysis 
Mid- and high-affinity binders to MET, lysozyme, and rabbit IgG, as well as mid-
affinity binders for tumor necrosis factor receptor superfamily member 10b, were evolved 
and sequenced using Illumina MiSeq with barcodes to identify mid- and high-affinity 
binders. Sequences were aligned, clustered, and counted, with accommodations to reduce 
overcounting of highly similar sequences, using an in-house algorithm. 4.8x105 sequences 
were collected with 2.3x105 identified as unique (Table 3). The sitewise differences 
between amino acid frequencies in the naïve library and selected binders were calculated 
at uniquely constrained sites (Fig. 5A) and CDR’ sites (Fig. 5B). 
 
 
 
 
35 
 
 
 
36 
 
 
Figure 2-5. Second generation sitewise amino acid distribution.  (A) The amino acid 
frequencies at the indicated sites for the second generation library (white) and the 
binding populations (gray). Bars and error bars are mean ± standard deviation. (B) 
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The difference between the amino acid frequencies in the binding population and the 
second generation library are shown for each amino acid at each site. The average 
across all fully diversified sites is also presented. Init. indicates the average amino acid 
frequency in the initial library across all CDR’ sites. 
 
Sites 24 and 25 exhibit similar results in which significant wild-type conservation 
was not maintained in binders (52% to 16% of A24 and 55% to 24% of P25) and the other 
amino acid options were elevated fairly uniformly. At site 29, alanine was increased (37% 
to 56%) while threonine was depleted (43% to 28%). At site 31, wild-type tyrosine is 
substantially enriched (53% to 92%) at the expense of glycine (45% to 7%). 
In the middle of the DE loop, sites 53-55, asparagines were depleted from their 
overly high starting points (36% to 29%, 41% to 23%, and 40% to 33%) while serines, 
which were more rare than designed in the naïve library, were increased (14 to 23%, 13% 
to 27%, and 13 to 17%). Y and T were essentially maintained thereby supporting the SYNT 
diversity when equally implemented. Asparagine was also decreased at site 56 (41% to 
24%), but wild-type threonine was preferentially increased (19% to 30%). 
At the edge of the FG loop, wild-type T76 was increased from 26% to 52% in 
binders while serine was decreased from 44% to 20%. At site 77, wild-type G (12% to 
15%) and aspartic acid (12% to 16%) were enriched, serine (21% to 22%) and asparagine 
(22% to 22%) were maintained, and tyrosine (9% to 3%) and cysteine (7% to 2%) were 
depleted. At site 79, the GDSN diversity was consistently maintained in binders. 
 
C. Sites with Complementarity Bias 
In the fully diversified sites, the antibody-inspired diversity was maintained for 
many amino acids. Sitewise exceptions include wild-type conservation at D80 (9% to 
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22%), T28 (4% to 11%), and S81 (14% to 18%) and enrichment of isoleucine and leucine 
at site 30 (4% to 38%). Slight overall exceptions – decrease in cysteine (7% to 4%) and 
increases in hydrophobics isoleucine, leucine, and valine (sum 8% to 15%) – all 
compensate for imperfections in the degenerate codons, yielding frequencies more in line 
with natural antibody repertoires. The decrease of cysteine residues is driven by a lack of 
enrichment of single-cysteine clones more than depletion of dual-cysteine clones, which is 
perhaps suggestive of beneficial disulfide bond formation (Fig. 6). Evaluation of cysteine 
pairs in dual-cysteine clones indicates a strong enrichment of clones with a cysteine in sites 
26-28, especially 27, of the BC loop and 80-84 of the FG loop. Simultaneous cysteines at 
sites 76 and 84 are also frequently selected in binders. 
 
 
Figure 2-6. Cysteine frequency analysis.  (A, B) Change in pairwise frequency of clones 
containing exactly two cysteines (high-affinity populations minus naïve library) for 
the first generation (A) and second generation (B) libraries. (C) Frequencies of clones 
containing the indicated number of cysteines in initial libraries and binder 
populations. 
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D. Loop Length Variation 
Loop length analysis indicated diverse lengths were used in binders with a 
preference for wild-type lengths, or one amino acid decreases, in the BC and DE loops and 
a broader distribution in the FG loop with preference for 1-3 residues less than wild-type 
(Fig. 4). The longest FG loop, which is only observed in the tenth type III domain of human 
fibronectin but not the other fourteen human type III domains, is rarely observed (2%) in 
binders. The shortest FG loop was also less frequently observed in binders (13%) than in 
the unsorted library (31%). 
 
E. Framework Mutations 
The framework sites that were intended for conservation were also analyzed within 
the naïve and binder sequences to identify mutations, occurring during oligonucleotide 
synthesis, gene assembly, or directed evolution, that were preferentially present in binding 
clones. Four mutations were enriched (Table 4). Notably, the P44S mutation, and to a lesser 
extent S43F, are likely introduced by polyadenylation of the 3’ tail by Taq polymerase 
during error-prone PCR 132 and then amplified by evolutionary selection. 
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Table 2-5. Enrichment of framework mutations. Full length fibronectin sequences 
from first and second generation naïve and binder populations were analyzed. Four 
framework positions demonstrated enrichment for non-wild type residues. 
Prevalence of these amino acids in natural homologs is shown in the two right most 
columns. Bottom row indicates median values of wild-type and any single mutant 
across all sites. 
 Frequency in this work  Natural Frequency 
Mutation 
First Generation Second Generation  
Wild-type Mutant Initial Binders Initial Binders  
I20V 0.5% 8% 0.5% 2%  16% 30% 
S43F 0.6% 10% 1% 12%  19% 1% 
P44S 17% 27% 11% 34%  23% 7% 
I88T 0.1% 1% 0.2% 6%  13% 3% 
median     
(all sites) <0.01% <0.01% <0.01% 0.01% 
 21% 2% 
 
 
F. Diversity 
The binders generated from the second generation library exhibit a range of sitewise 
amino acid frequency distributions that are not purely spatial (Fig. 7A). Four sites exhibit 
Shannon entropies 130,133 in excess of 3.5. Three additional sites are in excess of 3.0. Nine 
sites have entropies from 2.0 – 3.0. Six diversified sites exhibit Shannon entropies below 
2.0. Four sites were conserved, as designed, based on first generation library analysis. 
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Figure 2-7. Shannon entropy landscape among binding population.  (A) The α carbons 
of evaluated sites are shown in spheres colored based on Shannon entropy of binding 
sequences from the second generation campaigns. (B, C) The Shannon entropies at 
each site of second generation binders are plotted versus the number of amino acids 
that are tolerated at that site based on computational stability predictions. (B) Sites 
with solvent accessible surface area (in other fibronectin domain mutants) ≥40%. 
Pearson coefficient = 0.63. Slope = 0.13. (C) Sites with solvent accessible surface area 
<40%. Pearson coefficient = 0.22. Slope = 0.04. 
 
2.4.11 Binder phenotypic characterization 
By constraining diversity at select sites, we aim to improve the balance of inter- 
and intra-molecular interaction evolution and reduce destabilization upon mutation. Thus, 
we evaluated the stability of several fibronectin mutant populations: binders from both 
library generations in this work and binders evolved from binary (fully conserved 
framework, fully diversified loops) libraries from previous literature as well as the naïve 
second generation population and the parental fibronectin domains (human and hydrophilic 
mutant) (Fig. 8A). The first, second, and third quartile stabilities are higher for the first and 
second generation libraries relative to binders from less biased libraries. Further still, the 
median stability of the less biased library binders is less than even that of the naïve 
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members of the second generation library (p < 0.05). Note that Fn3HP is of essentially 
equivalent stability as Fn3 (84 ºC vs. 85 ºC). 
 
 
Figure 2-8. Clonal characterizations.  (A) Thermal stabilities of wild-type (WT) 
fibronectin 134 and Fn3HP are shown. Median (black line), second and third quartiles 
(gray box), upper and lower inner fences (vertical lines), and outliers (diamonds) are 
shown for a sampling of clones from binarily diversified traditional libraries 93,122,134 
(n=15, Trad. Bind.) and three populations of the current study: first generation 
library binders, second generation naïve library, and second generation library 
binders. (B) Affinity titrations. Yeast displaying Fn3HP variants were incubated with 
the indicated concentration of biotinylated target molecule. Binding was detected by 
streptavidin-fluorophore and flow cytometry. Data points are from a single 
representative experiment. Affinities were calculated as 150 ±60 pM (rabbit IgG, 
clone 0.6.2, black triangles), 4 ±3 nM (lysozyme, clone 0.6.3, gray squares), and 11 nM 
(MET, clone 3.4.3, white circles). 
 
In addition to yielding stable binders, the second generation library yields high-
affinity binders with little to no evolution. Three binder campaigns continued with 
additional sorts to identify the strongest binders in the population. Rabbit IgG and 
lysozyme binders were characterized following two rounds of magnetic bead selection, one 
round of cytometry sorting at target concentrations of 50 nM and a final round of cytometry 
sorting at 1 nM, wherein the top 1% of binding events were isolated. Titrations curves of 
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representative clones from the most stringently sorted, non-evolved rabbit IgG and 
lysozyme populations (Fig. 8B) revealed affinities of 150±60 pM and 4±3 nM, 
respectively. High-affinity MET binders were isolated following three iterations of 
evolution, each iteration consisting of two magnetic bead selections, one cytometry sort for 
full-length clones, and one round of error-prone PCR. A representative clone from the 
evolved MET binding population yielded an affinity of 11 nM (Fig. 8B). 
 
2.4.12 Library Design Principles 
The high-throughput binder engineering and analysis described herein provides one 
means of identifying the extents of diversification, as well as the relevant amino acids, at 
each site. To further explore the broad sequence data set of highly functional clones 
resulting from this study, we examined if any computational means could have guided this 
library refinement; i.e. if any computable parameters correlate with the evolved repertoire. 
The FoldX algorithm 124,135 was used to predict each site’s tolerance to mutation. The 
change in stability (∆∆Gfolding) upon mutation across >500 theoretical library variants (see 
Materials and Methods) was predicted for each of the twenty amino acids at each site. The 
mutational tolerance was assessed in terms of the number of minimally destabilizing 
(∆∆Gfolding < 0.75 kcal/mol) amino acid substitutions allowed at each site. Observed amino 
acid diversity (Shannon entropy) in evolved binders correlated with computational 
mutational tolerance at exposed sites (Fig. 7B). While no correlation was observed for less 
exposed sites (Fig. 7C), it should be noted that the key outliers are the sites most distant 
from the paratope center (D23 and S85). 
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More broadly, four elements were evaluated for their correlation with evolved 
repertoires: sitewise amino acid frequencies from natural fibronectin homologs, sitewise 
computational stabilities of each amino acid at each site within the context of diverse 
fibronectin clones, complementarity-biased amino acid distributions observed in antibody 
CDRs, and sitewise sidechain exposure. The first two elements – frequency in natural 
homologs and computational stability – provide sitewise amino acid distributions; 
complementarity bias provides a single site-independent amino acid distribution; and the 
fourth element – residue exposure – provides a sitewise weight. We examined the ability 
of these four elements to combine to generate sitewise amino acid distributions that 
matched the experimentally observed frequencies. The relative weights of the first three 
elements were allowed to vary for each site based purely on the fourth element: solvent 
and target accessibility of that site (Eq. 1). Sitewise frequencies in natural homologs were 
calculated from 58,058 homologs from the Pfam database 136. Sitewise computational 
stabilities were calculated using FoldX as described above. Complementarity bias was 
calculated as the amino acid distribution observed in expressed human and mouse antibody 
CDR-H3 sequences 58. Solvent accessibility is the relative solvent accessible surface area 
137 of each side chain averaged over 11 fibronectin structures. Target accessibility was 
scored based on the orientation of the amino acid side chain relative to the rest of the 
diversified paratope (detailed in Materials and Methods). 
The relative weights of homolog frequency, computational stability, and 
complementarity bias were computed that, when linearly combined, yield a sitewise amino 
acid distribution that is most consistent with the evolved distribution. Weights were 
calculated for both an exposure-dependent and exposure-independent term, which were 
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summed. The weights provide a relative comparison of the predictive value of each 
parameter. To evaluate the predictive value overall, the parameters were compared to an 
unbiased control input matrix (uniformly 5% of each amino acid). Weighted inclusion of 
all elements yields a library design that matches the experimentally evolved distribution 22 
standard deviations superior to designs based on unbiased input matrices  (S3 Fig.). For 
well-exposed sites, amino acid diversity is effectively mimicked by 62% complementarity 
bias, 30% stability computation, and 8% natural frequency (Fig. 9). At sites with less 
exposure, natural amino acid frequency should be more heavily weighted at the expense of 
stability and, less so, complementarity. Design based on a single element is inferior to 
randomness for stability, marginally effective (2 standard deviations above random) for 
natural frequency, and strongly effective (16 standard deviations above random) for 
complementarity. In short, the evolved repertoire correlates strongly with complementarity 
and moderately with computed stability and frequency in natural homologs, varying 
dependent upon sidechain exposure. 
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Figure 2-9. Correlative parametric analysis of amino acid distributions.  Sitewise 
evaluation of theoretical stability upon mutation and natural sequence frequency, as 
well as overall amino acid prevalence at binding interfaces of antibodies (i.e. 
complementarity), generate sitewise amino acid frequencies. The ability of these 
frequencies – scaled linearly based on solvent exposure and target exposure (Equation 
1 and S3 Fig.) – to collectively mimic the observed sitewise amino acid distributions 
in binding populations is evaluated. The optimal weights for each contributing data 
set as a function of exposure are shown. 
 
2.5. Discussion 
In the pursuit of a broadly functional combinatorial library capable of yielding 
binders to numerous targets, the benefit of diversification is unclear for sites peripheral 
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108,138,139 to a ‘hot spot’ that enthalpically drives high-affinity binding 107,108,140. Moreover, 
the location of the hot spot can differ across different epitopes being targeted by a scaffold. 
These peripheral sites can (a) directly contact target, (b,c) impact neighboring residue 
orientation to improve interfacial enthalpy or reduce entropic penalty upon binding, and/or 
(d) stabilize the protein. Yet these potential benefits can be offset by the inverse impacts: 
make unfavorable interfacial contact, worsen neighboring residue orientation, and/or 
destabilize the protein. If sufficient ‘hot spot’ interfacial area is not yet present for high-
affinity binding, then additional sites must be diversified to enable favorable interaction. 
At some point, this expanded paratope provides sufficient interface for strong, specific 
affinity. Similar tradeoffs can be considered for peripheral sites. Given the typical 
detriment of random mutation, 19,141,142 the average peripheral mutation will hinder all four 
elements thereby suggesting against diversity. Though as a corollary, on average, 
mutations in the ‘hot spot’ will negatively impact the last two elements by worsening the 
entropic penalty upon binding and destabilizing the protein because of imperfect 
interactions with the conserved peripherals. Thus, peripherals need to be chosen to make 
neutral to good contact with: (a) intermolecular target; (b,c) intramolecular neighbors 
involved in binding; and (d) all intramolecular neighbors. For a-c, since beneficial 
interactions will be unlikely, amino acids – such as serine 48,55,128 – that yield relatively 
neutral interactions may be wise. For d, beneficial interactions are likely for the wild-type 
residue and conserved neighbors based on their coevolution so conservation should be the 
aim. Since the precise locations of the hot spots and these transitions will vary for each 
new ligand-target interface (Fig. 1C), we hypothesized the evolved repertoires will exhibit 
a gradient of diversity from extensive diversity in the potential paratope hot spot to full 
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conservation in the framework. Importantly, this gradient includes moderate diversity, with 
structural bias, within the paratope interfacing with target yet peripheral to the hot spot. 
Moreover, more mild diversity is included adjacent to the interfacial residues to yield 
optimal intramolecular contacts with the newly identified paratope. The range of Shannon 
entropies (Fig. 7) and amino acid frequency distributions (Figs. 2 and 5) across many 
binding sequences against several targets support the benefit of a gradient of diversities 
within combinatorial libraries. The particular amino acid distributions support the 
hypothesized benefits of wild-type conservation, serine bias, and complementarity bias, at 
appropriate sites. 
Sitewise optimization of this gradient between intra- and inter-molecular 
interaction biases can be achieved with broad, high-throughput binder generation and deep 
sequencing as demonstrated here. Yet this requires a sufficiently effective library to 
generate numerous binders, which may be difficult for new scaffolds or paratopes. Analysis 
conducted in the current study (Fig. 9) provides further evidence that initial combinatorial 
library design can be guided by complementarity-determining residues and, when 
available, natural homolog frequencies, stability data (theoretical or experimental), and 
side chain exposure to solvent and target. Ongoing studies can quantify the values of 
complementarity, stability, natural sequence frequency, exposure – and potentially other 
metrics – in the context of other protein topologies and other functions, such as catalysis. 
Sitewise optimization of amino acid frequency, with a range of diversities, can be 
implemented in numerous ways. Trimer phosphoramidite codons can be used in 
oligonucleotide synthesis, 74 which enables precise control over each distribution but 
elevates synthesis complexity and cost. Independent oligonucleotides can be synthesized 
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for each loop sequence, which further elevates control by enabling pairwise (and higher 
order) site design albeit at an elevated synthesis scope. Simpler, less expensive single-
nucleotide mixed degenerate oligonucleotide synthesis can approximate many amino acid 
distributions, especially with the inclusion of unbalanced nucleotide frequencies as used in 
this study. The amino acid distribution within antibody CDR-H3 can be closely 
approximated by unbalanced single-nucleotide methods 91, but it must compromise on the 
genetic code connectivity of glycine, tyrosine, and cysteine. Achieving the desired high 
frequencies of tyrosine (20%) and glycine (16%) yields much more cysteine than desired 
(10%). In these libraries, we opted to maintain high tyrosine (17%) while limiting cysteine 
(5%) at the expense of low glycine (4%). Wild-type glycine bias at sites G52 and G79, as 
well as G77 in the second generation library, enabled this successful compromise as 
glycine at fully diversified sites was only marginally enriched in binders relative to the 
original library (2.7% to 4.0% in the first generation; 3.8% to 4.7% in the second 
generation). Thus, selective sitewise bias is able to effectively provide the evolutionary 
benefit of the presence of glycine within the DE and FG loops. 
Note that the sublibrary synthesis approach in generation one (Table 1) yields 
coupling between sites within each loop. For example, wild-type D23 conservation pulls 
wild-type conservation in other BC sites during generation one analysis. In the absence of 
this coupling in generation two analysis, wild-type conservation at other BC sites (A24, 
P25, and Y31) is reduced. In the DE loop, wild-type G52 conservation pulls N54 
conservation, which converts to N54 depletion in generation two in the absence of G52 
coupling. Thus, when evaluating a new scaffold or paratope design, sublibrary construction 
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enables analysis of numerous diversification strategies, but care must be taken to consider 
coupled sites. 
While cysteines were overall depleted from binding sequences relative to the naïve 
library, select inter- and intra-loop cysteine pairs were enriched. These occurred at 
proximal locations that are structurally sensible for disulfide bond formation, but further 
validation is needed to confirm the existence of disulfide bonding. Enhanced evolutionary 
efficiency of this class of clones warrants consideration of biased design to drive the 
conformational restriction beneficial to numerous topologies including stapled helical 
peptides 143, shark new antigen receptors 144, camelid antibody domains 145, and previous 
fibronectin clones 92. Yet, while entropically beneficial, this conformational restriction may 
limit the diversity of paratopes that a library can present. Moreover, it eliminates the 
benefits of cysteine-free ligands: intracellular use, efficient cytoplasmic production in 
bacteria, and genetically introduced cysteines for site-specific thiol chemistry. 
In conclusion, the extent of diversity and particular amino acid distributions 
consistent with a broad capacity for evolution of new binding activity were determined for 
a combinatorial library of a hydrophilic fibronectin domain. A gradient of diversity 
including sitewise constraints was revealed in evolved clones, which is consistent with 
natural antibody repertoires but converse to current synthetic scaffold combinatorial library 
designs. Importantly, the extensive dataset allowed for initial characterization of a broadly 
applicable data driven library design model that guides the most beneficial distribution of 
amino acids at each position. 
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Figure S2-1. Schematic of Study. Ligands to six different targets are generated using yeast 
display of Fn3HP mutants with magnetic and fluorescence selections. Deep sequencing 
reveals functional ligand sequences. Multiple informatics analyses indicate sitewise amino 
acid frequencies and their implications, relative evolutionary fitness of constrained library 
design, and the correlation of constrained designs with computable parameters.  
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Figure S2-2. Binder selection via fluorescence activated cell sorting (FACS). Diverse 
populations of evolved clones were isolated via cytometry. Two representative campaigns, 
goat IgG and lysozyme are shown (left column) with 50 nM multivalent target (3:1 
stoichiometry of target preloaded on streptavidin-AlexaFluor488). Specificity controls 
(right column) were conducted under identical multivalent labeling conditions where non-
cognate proteins lysozyme and rabbit IgG were incubated with the evolved goat IgG and 
lysozyme populations, respectively. Binding clones within the gated region (solid line) 
were isolated from each target sample for further analysis. The analogous gated regions 
(dashed lines) within the control samples are shown for comparison.  
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Figure S2-3. Correlative parametric analysis of amino acid distributions. Sitewise 
evaluation of theoretical stability upon mutation and natural sequence frequency, as well 
as overall amino acid prevalence at binding interfaces of antibodies (i.e. complementarity), 
generate sitewise amino acid frequencies. The ability of these frequencies – scaled linearly 
based on solvent exposure and target exposure (Equation 1) – to collectively mimic the 
observed sitewise amino acid distributions in binding populations is evaluated. The optimal 
weights for each contributing data set as a function of exposure are shown. (A-C) For the 
indicated weights of each metric, the other free parameters were varied to optimize the 
match between modeled sitewise amino acid distributions and experimentally observed 
sequences. The qualities of the fits are presented as the number of standard deviations 
above the fit obtained if unbiased data are used (i.e. uniformly 5% amino acid diversity 
rather than stability, homology, and complementarity bias). (A) Relative success when 
limited to two data inputs. Exposure independent (α) and dependent (β) weights are varied, 
subject to the indicated average weight, to maximize fit. (B) Sensitivity of exposure 
independent weights (α). All α values are fixed as indicated (note that all α’s sum to 1 so 
complementarity weight is implicit). Exposure dependent weights are varied to maximize 
fit. 55% complementarity, 45% natural sequence frequency, and 0% theoretical stability 
optimize fit. (C) As in (B) but with set β values and varied α values.  
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Table S2-1. Hydrophilic fibronectin (Fn3HP) sequence information and library 
oligonucleotides. (A) Fn3HP framework amino acid and DNA sequence. All framework 
sites are conserved as the sequence of the tenth type III domain of human fibronectin with 
the hydrophilic mutations V1S, V4S, V11T, A12N, T16N, L19T, V45S, and V66Q 106, 
underlined, as well as the stabilizing D7N 129, shown with overbar.  
 
SSDSPR𝑁𝑁�LEV TNATPNSLTI SWxxxxxxxx xYRITYGETG GNSPSQEFTV PxxxxxATIS GLKPGQDYTI TVYAVxxxxx 
xxxxxxPISI NYRTEIDKPS Q 
TCC TCC GAC TCT CCG CGT AAC CTG GAG GTT ACC AAC GCA ACT CCG AAC TCT CTG ACT ATT TCT TGG 
NNN NNN NNN NNN NNN NNN NNN NNN NNN TAC CGT ATC ACC TAC GGC GAA ACT GGT GGT AAC TCC CCG 
AGC CAG GAA TTC ACT GTT CCG NNN NNN NNN NNN NNN GCG ACC ATC AGC GGT CTG AAA CCG GGC CAG 
GAT TAT ACC ATT ACC GTG TAC GCT GTA NNN NNN NNN NNN NNN NNN NNN NNN NNN NNN NNN CCA ATC 
AGC ATC AAT TAT CGC ACC GAA ATC GAC AAA CCG TCT CAG 
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(B) Oligonucleotide DNA sequences used for constructing generation one library. 
Sequences are composed of standard nucleotides (ACGT), degenerate nucleotides 
(RYMKSWHBVDN), and a specialty codon mix (xyz) which uses the following 
nucleotide frequencies : 20% A, 15% C, 25% G, and 40% T at site 1, 50% A, 25% C, 15% 
G, and 10% T at site 2, and 0% A, 45% C, 10% G, and 45% T at site 3. Oligos are arranged 
by loop (BC, DE, FG), sublibraries a-e, and amino acid length of the diversified region 
within the loop.  
 
Loop/Sublib/Len (AA) 
 
Oligo Sequence  
BC/a/10 
 
ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/b/10 
 
ACTCTCTGACTATTTCTTGGKMTKCCYCCxyzxyzxyzxyzDCTxyzRGCTACCGTATCACCTACGGCGAAAC 
BC/c/10 
 
ACTCTCTGACTATTTCTTGGKMCKMTYMTxyzxyzxyzxyzDCTxyzDRTTACCGTATCACCTACGGCGAAAC 
BC/d/10 
 
ACTCTCTGACTATTTCTTGGDVTDVTDVTxyzxyzxyzxyzDCTxyzDVTTACCGTATCACCTACGGCGAAAC 
BC/e/10 
 
ACTCTCTGACTATTTCTTGGxyzxyzxyzxyzxyzxyzxyzDCTxyzxyzTACCGTATCACCTACGGCGAAAC 
BC/a/9 
 
ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/b/9 
 
ACTCTCTGACTATTTCTTGGKMTKCCYCCxyzxyzxyzDCTxyzRGCTACCGTATCACCTACGGCGAAAC 
BC/c/9 
 
ACTCTCTGACTATTTCTTGGKMCKMTYMTxyzxyzxyzDCTxyzDRTTACCGTATCACCTACGGCGAAAC 
BC/d/9 
 
ACTCTCTGACTATTTCTTGGDVTDVTDVTxyzxyzxyzDCTxyzDVTTACCGTATCACCTACGGCGAAAC 
BC/e/9 
 
ACTCTCTGACTATTTCTTGGxyzxyzxyzxyzxyzxyzDCTxyzxyzTACCGTATCACCTACGGCGAAAC 
BC/a/8 
 
ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/b/8 
 
ACTCTCTGACTATTTCTTGGKMTKCCYCCxyzxyzDCTxyzRGCTACCGTATCACCTACGGCGAAAC 
BC/c/8 
 
ACTCTCTGACTATTTCTTGGKMCKMTYMTxyzxyzDCTxyzDRTTACCGTATCACCTACGGCGAAAC 
BC/d/8 
 
ACTCTCTGACTATTTCTTGGDVTDVTDVTxyzxyzDCTxyzDVTTACCGTATCACCTACGGCGAAAC 
BC/e/8 
 
ACTCTCTGACTATTTCTTGGxyzxyzxyzxyzxyzDCTxyzxyzTACCGTATCACCTACGGCGAAAC 
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BC/a/7 
 
ACTCTCTGACTATTTCTTGGGACGCACCAxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/b/7 
 
ACTCTCTGACTATTTCTTGGKMTKCCYCCxyzDCTxyzRGCTACCGTATCACCTACGGCGAAAC 
BC/c/7 
 
ACTCTCTGACTATTTCTTGGKMCKMTYMTxyzDCTxyzDRTTACCGTATCACCTACGGCGAAAC 
BC/d/7 
 
ACTCTCTGACTATTTCTTGGDVTDVTDVTxyzDCTxyzDVTTACCGTATCACCTACGGCGAAAC 
BC/e/7 
 
ACTCTCTGACTATTTCTTGGxyzxyzxyzxyzDCTxyzxyzTACCGTATCACCTACGGCGAAAC 
DE/a/6 
 
CGAGCCAGGAATTCACTGTTCCGGGATCATCAAACTCAACAGCGACCATCAGCGGTCTGAAAC 
DE/b/6 
 
CGAGCCAGGAATTCACTGTTCCGRGCTCCTCCARTTCCASCGCGACCATCAGCGGTCTGAAAC 
DE/c/6 
 
CGAGCCAGGAATTCACTGTTCCGDRTWMTWMTWMTWMTWMTGCGACCATCAGCGGTCTGAAAC 
DE/d/6 
 
CGAGCCAGGAATTCACTGTTCCGDVTDVTDVTDVTDVTDVTGCGACCATCAGCGGTCTGAAAC 
DE/e/6 
 
CGAGCCAGGAATTCACTGTTCCGxyzxyzxyzxyzxyzxyzGCGACCATCAGCGGTCTGAAAC 
DE/a/5 
 
CGAGCCAGGAATTCACTGTTCCGGGATCAAACTCAACAGCGACCATCAGCGGTCTGAAAC 
DE/b/5 
 
CGAGCCAGGAATTCACTGTTCCGRGCTCCARTTCCASCGCGACCATCAGCGGTCTGAAAC 
DE/c/5 
 
CGAGCCAGGAATTCACTGTTCCGDRTWMTWMTWMTWMTGCGACCATCAGCGGTCTGAAAC 
DE/d/5 
 
CGAGCCAGGAATTCACTGTTCCGDVTDVTDVTDVTDVTGCGACCATCAGCGGTCTGAAAC 
DE/e/5 
 
CGAGCCAGGAATTCACTGTTCCGxyzxyzxyzxyzxyzGCGACCATCAGCGGTCTGAAAC 
DE/a/4 
 
CGAGCCAGGAATTCACTGTTCCGGGATCATCAACAGCGACCATCAGCGGTCTGAAAC 
DE/b/4 
 
CGAGCCAGGAATTCACTGTTCCGRGCTCCTCCASCGCGACCATCAGCGGTCTGAAAC 
DE/c/4 
 
CGAGCCAGGAATTCACTGTTCCGDRTWMTWMTWMTGCGACCATCAGCGGTCTGAAAC 
DE/d/4 
 
CGAGCCAGGAATTCACTGTTCCGDVTDVTDVTDVTGCGACCATCAGCGGTCTGAAAC 
DE/e/4 
 
CGAGCCAGGAATTCACTGTTCCGxyzxyzxyzxyzGCGACCATCAGCGGTCTGAAAC 
FG/a/11 
 
CATTACCGTGTACGCTGTAACAxyzxyzDRTxyzxyzxyzxyzxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/b/11 
 
CATTACCGTGTACGCTGTAASCxyzxyzDRTxyzxyzxyzxyzxyzTCCARTCCAATCAGCATCAATTATCGCAC 
FG/c/11 
 
CATTACCGTGTACGCTGTAWMTxyzxyzDRTxyzxyzxyzxyzxyzWMTWMTCCAATCAGCATCAATTATCGCAC 
FG/d/11 
 
CATTACCGTGTACGCTGTADVTxyzxyzDRTxyzxyzxyzxyzxyzDVTDVTCCAATCAGCATCAATTATCGCAC 
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FG/e/11 
 
CATTACCGTGTACGCTGTAxyzxyzxyzDRTxyzxyzxyzxyzxyzxyzxyzCCAATCAGCATCAATTATCGCAC 
FG/a/10 
 
CATTACCGTGTACGCTGTAACAxyzxyzDRTxyzxyzxyzxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/b/10 
 
CATTACCGTGTACGCTGTAASCxyzxyzDRTxyzxyzxyzxyzTCCARTCCAATCAGCATCAATTATCGCAC 
FG/c/10 
 
CATTACCGTGTACGCTGTAWMTxyzxyzDRTxyzxyzxyzxyzWMTWMTCCAATCAGCATCAATTATCGCAC 
FG/d/10 
 
CATTACCGTGTACGCTGTADVTxyzxyzDRTxyzxyzxyzxyzDVTDVTCCAATCAGCATCAATTATCGCAC 
FG/e/10 
 
CATTACCGTGTACGCTGTAxyzxyzxyzDRTxyzxyzxyzxyzxyzxyzCCAATCAGCATCAATTATCGCAC 
FG/a/9 
 
CATTACCGTGTACGCTGTAACAxyzxyzDRTxyzxyzxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/b/9 
 
CATTACCGTGTACGCTGTAASCxyzxyzDRTxyzxyzxyzTCCARTCCAATCAGCATCAATTATCGCAC 
FG/c/9 
 
CATTACCGTGTACGCTGTAWMTxyzxyzDRTxyzxyzxyzWMTWMTCCAATCAGCATCAATTATCGCAC 
FG/d/9 
 
CATTACCGTGTACGCTGTADVTxyzxyzDRTxyzxyzxyzDVTDVTCCAATCAGCATCAATTATCGCAC 
FG/e/9 
 
CATTACCGTGTACGCTGTAxyzxyzxyzDRTxyzxyzxyzxyzxyzCCAATCAGCATCAATTATCGCAC 
FG/a/8 
 
CATTACCGTGTACGCTGTAACAxyzxyzDRTxyzxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/b/8 
 
CATTACCGTGTACGCTGTAASCxyzxyzDRTxyzxyzTCCARTCCAATCAGCATCAATTATCGCAC 
FG/c/8 
 
CATTACCGTGTACGCTGTAWMTxyzxyzDRTxyzxyzWMTWMTCCAATCAGCATCAATTATCGCAC 
FG/d/8 
 
CATTACCGTGTACGCTGTADVTxyzxyzDRTxyzxyzDVTDVTCCAATCAGCATCAATTATCGCAC 
FG/e/8 
 
CATTACCGTGTACGCTGTAxyzxyzxyzDRTxyzxyzxyzxyzCCAATCAGCATCAATTATCGCAC 
FG/a/7 
 
CATTACCGTGTACGCTGTAACAxyzxyzDRTxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/b/7 
 
CATTACCGTGTACGCTGTAASCxyzxyzDRTxyzTCCARTCCAATCAGCATCAATTATCGCAC 
FG/c/7 
 
CATTACCGTGTACGCTGTAWMTxyzxyzDRTxyzWMTWMTCCAATCAGCATCAATTATCGCAC 
FG/d/7 
 
CATTACCGTGTACGCTGTADVTxyzxyzDRTxyzDVTDVTCCAATCAGCATCAATTATCGCAC 
FG/e/7 
 
CATTACCGTGTACGCTGTAxyzxyzxyzDRTxyzxyzxyzCCAATCAGCATCAATTATCGCAC  
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Table S2-2. Oligonucleotide DNA sequences used for constructing generation two 
library. Sequences are composed of standard nucleotides (ACGT), degenerate nucleotides 
(RYMKSWHBVDN), and a specialty codon mix (xyz) which uses the following 
nucleotide frequencies : 20% A, 15% C, 25% G, and 40% T at site 1, 50% A, 25% C, 15% 
G, and 10% T at site 2, and 0% A, 45% C, 10% G, and 45% T at site 3. Oligos are arranged 
by loop (BC, DE, FG), loop specific sublibraries, and amino acid length of the diversified 
region within the loop.  
 
Loop/Sublib/Len (AA) Oligo Sequence  
BC/a/10 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/b/10 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/c/10 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/d/10 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/e/10 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/f/10 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/g/10 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/h/10 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/a/9 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/b/9 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/c/9 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/d/9 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/e/9 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/f/9 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/g/9 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
62 
 
BC/h/9 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/a/8 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/b/8 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/c/8 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/d/8 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/e/8 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/f/8 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
BC/g/8 ACTCTCTGACTATTTCTTGGGACGCACCAxyzxyzDCTxyzGGATACCGTATCACCTACGGCGAAAC 
BC/h/8 ACTCTCTGACTATTTCTTGGGACDMTYMTxyzxyzDCTxyzTATTACCGTATCACCTACGGCGAAAC 
DE/a/5 CGAGCCAGGAATTCACTGTTCCGGGAWMTWMTWMTWMTGCGACCATCAGCGGTCTGAAAC 
DE/a/4 CGAGCCAGGAATTCACTGTTCCGGGAWMTWMTWMTGCGACCATCAGCGGTCTGAAAC 
FG/a/11 CATTACCGTGTACGCTGTARSCDVTxyzRRCxyzxyzxyzxyzxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/a/10 CATTACCGTGTACGCTGTARSCDVTxyzRRCxyzxyzxyzxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/a/9 CATTACCGTGTACGCTGTARSCDVTxyzRRCxyzxyzxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/a/8 CATTACCGTGTACGCTGTARSCDVTxyzRRCxyzxyzTCAAACCCAATCAGCATCAATTATCGCAC 
FG/a/7 CATTACCGTGTACGCTGTARSCDVTxyzRRCxyzTCAAACCCAATCAGCATCAATTATCGCAC  
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Table S2-3. Correlative parametric analysis of amino acid distributions - input 
matrices. Library design can be guided by information regarding each position’s 
mutational tolerance and naturally evolved sequence to reduce the prevalence of overly 
destabilizing mutations as well as identifying structurally stabilizing mutations.  
Additionally, the chemical diversity found at the interfaces of well characterized natural 
binders, such as the complementarity determining regions (CDR) of antibodies, can be 
applied to protein scaffolds to accommodate for strong binding interactions. Here, a model 
for library design was built based on a linear combination of (A) computational stability, 
(B) natural homolog sequence frequency, and (C) CDR diversity input matrices.  These 
three elements were weighted based on the (D) target exposure (i.e. proximity to the 
binding interface) and solvent exposed surface area (i.e. orientation and packing) of each 
site. 
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A. Computational sitewise assessment of changes in stability (ΔΔG, kcal/mol) upon mutation. Conducted in FoldX. 
 D23 A24 P25 A26 V27 T28 V29 R30 Y31 G52 S53 K54 S55 T56 
A 0.34 - 0.28 - (0.31) (0.30) 1.67 0.23 0.06 1.70 (0.09) 0.73 (0.23) 0.26 
C 0.37 0.29 0.42 0.01 (0.24) (0.21) 1.28 0.86 (0.15) 3.38 (0.22) 0.86 0.07 0.03 
D - 0.73 0.72 (0.08) (0.03) (0.34) 3.28 0.65 1.51 5.39 0.00 0.93 (0.00) 0.97 
E 0.18 0.64 0.56 (0.25) (0.25) (0.48) 3.24 0.39 0.29 5.24 (0.48) 0.55 (0.02) (0.13) 
F (0.22) 0.51 0.75 (0.50) (0.16) (0.44) 4.17 0.18 (0.33) 6.16 (0.28) (0.06) (0.36) (0.16) 
G 1.11 0.35 0.15 0.21 0.02 (0.33) 2.54 0.76 0.34 - 0.20 1.70 0.05 0.75 
H 0.59 0.73 1.50 0.10 0.33 (0.15) 4.09 0.91 0.75 6.14 0.14 0.96 0.03 0.54 
I 0.30 0.98 0.64 (0.07) (0.07) (0.01) (0.31) 0.81 0.40 11.73 (0.40) 0.95 0.16 (0.03) 
K (0.04) 0.13 0.49 (0.37) (0.38) (0.57) 3.01 (0.00) (0.46) 4.76 (0.73) - (0.56) (0.56) 
L (0.24) 0.38 0.02 (0.47) (0.56) (0.48) 0.82 (0.06) (0.47) 6.31 (0.71) (0.31) (0.38) (0.25) 
M (0.19) 0.04 (0.47) (0.57) (0.58) (0.53) 0.81 0.07 (0.84) 4.41 (0.78) (0.32) (0.45) (0.91) 
N 0.35 0.32 0.52 (0.07) (0.24) (0.30) 2.13 0.64 0.65 4.25 (0.04) 0.75 (0.54) 0.63 
P 2.35 (0.59) - (0.08) 1.28 (0.06) 3.89 2.73 2.37 3.52 0.28 3.58 (0.08) 1.71 
Q 0.18 0.40 0.49 (0.26) (0.25) (0.35) 3.04 0.11 0.06 5.13 (0.39) 0.49 (0.29) (0.10) 
R 0.12 0.16 0.74 (0.32) (0.22) (0.51) 4.14 - (0.40) 5.01 (0.53) (0.12) (0.83) (0.51) 
S 0.62 0.24 0.19 0.19 (0.27) (0.23) 2.43 0.79 0.03 3.21 - 0.84 - (0.17) 
T 0.71 0.73 0.61 0.37 (0.18) - 1.16 1.12 1.16 8.01 0.32 1.23 0.70 - 
V 0.62 0.82 0.71 0.20 - 0.12 - 0.90 0.86 8.15 0.03 1.25 0.40 0.07 
W 0.17 1.03 1.87 (0.50) 0.69 (0.19) 7.81 0.49 0.45 7.10 (0.17) 0.03 (0.08) (0.14) 
Y (0.12) 0.45 1.36 (0.45) 0.01 (0.39) 6.36 0.29 - 6.31 (0.27) 0.00 (0.29) (0.10) 
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 T76 G77 R78 G79 D80 S81 P82 A83 S84 S85 K86 
A (0.07) 0.46 0.45 0.37 0.02 (0.04) (0.70) (0.15) (0.34) (0.06) 0.34 
C (0.07) 0.38 0.68 0.44 0.04 0.06 (0.65) 0.04 (0.20) (0.13) 0.32 
D 1.17 0.68 0.60 0.15 - (0.03) (0.61) (0.01) 0.05 (0.15) 0.51 
E 0.58 0.72 0.17 0.27 (0.15) (0.12) (0.79) (0.04) 0.02 (0.12) 0.23 
F (0.69) (0.14) 0.03 0.11 (0.24) (0.30) (1.13) (0.30) (0.36) (0.23) (0.36) 
G 0.45 - 0.70 - (0.39) (0.51) (0.60) 0.14 0.17 0.41 0.19 
H 0.97 0.91 0.44 0.40 0.13 0.27 (0.58) 0.04 0.31 0.49 0.31 
I (0.98) 0.68 0.47 1.00 0.62 0.30 (0.92) (0.14) (0.47) 0.03 0.79 
K (0.11) 0.15 (0.02) (0.15) (0.44) (0.29) (1.08) (0.38) (0.38) (0.17) (0.06) 
L (1.16) 0.06 (0.09) 0.01 (0.27) (0.25) (1.03) (0.39) (0.95) (0.49) (0.10) 
M (1.37) (0.27) 0.05 0.14 (0.29) (0.23) (1.06) (0.45) (1.28) (0.63) (0.33) 
N 0.38 0.24 0.45 0.12 (0.14) (0.09) (0.66) (0.10) (0.08) (0.17) 0.41 
P 1.30 1.43 0.64 2.26 1.17 1.70 - 0.53 2.03 0.40 1.32 
Q 0.18 0.57 0.03 0.20 (0.13) (0.20) (0.93) (0.29) (0.31) (0.16) 0.14 
R 0.37 0.18 - 0.09 (0.23) (0.22) (0.76) (0.23) (0.55) (0.09) (0.00) 
S 0.26 0.34 0.57 0.41 (0.18) - (0.36) 0.00 0.02 (0.08) 0.38 
T - 0.74 0.69 0.84 0.40 0.33 (0.38) 0.10 0.02 0.01 0.86 
V (0.55) 0.99 0.64 0.98 0.54 0.43 (0.57) 0.04 (0.19) 0.04 0.92 
W 1.10 0.52 0.45 0.32 (0.08) 0.07 (0.89) (0.16) (0.19) 0.29 (0.20) 
Y 0.03 0.03 0.10 0.19 (0.17) (0.22) (1.07) (0.24) (0.18) 0.06 (0.23) 
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B. Natural sequence frequency for the tenth type III domain of human fibronectin: pfam database summary. Below the full 
amino acid table, the four most frequent residues at each site are listed. 
 V S D V P R D L E V V A A T P T S L L 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
A 13.1% 12.6% 3.2% 28.6% 1.6% 4.5% 4.1% 2.1% 4.3% 15.0% 4.6% 11.2% 10.1% 2.0% 10.4% 1.7% 6.6% 11.2% 2.9% 
C 0.5% - - 1.2% - - - - - 2.2% 0.7% 0.6% 0.7% - 0.6% 0.6% 1.0% 3.5% 0.5% 
D 1.5% 0.8% 16.0% - 0.7% 1.0% 13.4% - 3.7% 0.9% 3.9% 15.8% 1.8% 4.3% 8.8% 13.9% 1.8% - 3.1% 
E 3.5% 1.1% 9.6% 0.8% 0.8% 6.9% 6.2% - 13.3% 2.2% 5.6% 11.8% 3.1% 2.7% 8.6% 5.5% 5.1% - 4.7% 
F 0.8% - - 1.2% - 1.6% 0.8% 5.0% 1.1% 5.1% 1.9% 0.7% 0.9% 0.9% - 1.3% 1.2% 4.4% 2.5% 
G 7.1% 22.2% 3.8% 3.0% 4.1% 8.8% 9.1% - 1.6% 2.1% 2.7% 6.7% 4.7% 7.2% 5.0% 2.9% 4.5% 0.6% 1.2% 
H 0.6% - 1.6% - - 2.1% 1.9% - 4.8% - 1.5% 1.6% 1.1% 0.9% 2.3% 2.8% 1.9% - 2.4% 
I 2.7% - 0.6% 7.4% 1.2% 2.1% 2.3% 11.8% 2.2% 11.7% 7.2% 1.4% 13.1% 0.8% 1.0% 1.0% - 21.8% 4.3% 
K 1.8% 3.6% 4.0% 1.9% 0.6% 8.5% 5.1% - 11.5% 1.2% 4.7% 3.3% 3.9% 2.8% 11.7% 2.8% 3.3% - 5.4% 
L 13.2% 0.6% 1.3% 7.6% 0.8% 5.2% 1.4% 42.5% 1.5% 8.4% 6.5% 1.5% 7.8% 1.8% 1.1% 1.1% - 19.6% 12.1% 
M 3.9% - - 1.4% - 1.2% - 2.0% 0.9% 0.9% 1.4% 0.8% 1.3% 0.6% 0.9% - 0.6% 5.6% 2.0% 
N 0.8% 2.0% 4.3% 0.8% 1.2% 1.8% 25.6% - 3.6% 1.0% 2.4% 11.1% 2.2% 8.5% 3.5% 11.8% 3.3% - 3.9% 
P 24.0% 14.3% 41.0% 11.1% 81.9% 1.8% 6.4% 8.7% 2.0% 2.0% 1.0% 4.5% 2.9% 0.6% 12.9% - - - 0.6% 
Q 2.1% 2.5% 5.1% 1.5% 0.9% 9.6% 3.4% 0.6% 9.2% 0.9% 2.3% 3.2% 2.4% 2.1% 3.3% 2.5% 3.5% - 4.8% 
R 1.9% 2.4% 2.7% 1.1% - 14.0% 3.1% - 11.1% 0.9% 3.6% 3.0% 3.7% 3.4% 4.9% 5.2% 2.7% - 7.9% 
S 4.3% 28.4% 3.1% 3.1% 2.0% 10.4% 9.0% 0.8% 9.2% 3.1% 14.0% 13.1% 6.8% 22.1% 16.2% 14.8% 45.8% - 9.8% 
T 4.4% 7.3% 1.5% 5.2% 1.5% 12.4% 5.4% 1.7% 14.0% 5.2% 18.7% 5.2% 7.4% 35.6% 4.9% 27.6% 13.4% 0.9% 21.5% 
V 11.6% 0.7% 1.4% 22.8% 1.1% 5.7% 1.5% 21.7% 4.6% 34.8% 14.7% 3.3% 23.4% 1.5% 1.4% 2.6% 1.3% 28.7% 7.8% 
W - - - - - - - - - 0.7% - 0.7% 1.3% 0.9% 0.8% - 1.1% 1.0% 1.2% 
Y 1.9% - - 0.6% - 1.6% - - 0.7% 1.2% 2.2% 0.5% 1.1% 0.8% 1.2% 1.1% 1.9% - 1.4% 
Most Frequent                  
1 P (0.24) 
S 
(0.28) 
P 
(0.41) 
A 
(0.29) 
P 
(0.82) 
R 
(0.14) 
N 
(0.26) 
L 
(0.43) 
T 
(0.14) 
V 
(0.35) 
T 
(0.19) 
D 
(0.16) 
V 
(0.23) 
T 
(0.36) 
S 
(0.16) 
T 
(0.28) 
S 
(0.46) 
V 
(0.29) 
T 
(0.21) 
2 L (0.13) 
G 
(0.22) 
D 
(0.16) 
V 
(0.23) 
G 
(0.04) 
T 
(0.12) 
D 
(0.13) 
V 
(0.22) 
E 
(0.13) 
A 
(0.15) 
V 
(0.15) 
S 
(0.13) 
I 
(0.13) 
S 
(0.22) 
P 
(0.13) 
S 
(0.15) 
T 
(0.13) 
I 
(0.22) 
L 
(0.12) 
3 A (0.13) 
P 
(0.14) 
E 
(0.1) 
P 
(0.11) 
S 
(0.02) 
S 
(0.1) 
G 
(0.09) 
I 
(0.12) 
K 
(0.12) 
I 
(0.12) 
S 
(0.14) 
E 
(0.12) 
A 
(0.1) 
N 
(0.08) 
K 
(0.12) 
D 
(0.14) 
A 
(0.07) 
L 
(0.2) 
S 
(0.1) 
4 V (0.12) 
A 
(0.13) 
Q 
(0.05) 
L 
(0.08) 
A 
(0.02) 
Q 
(0.1) 
S 
(0.09) 
P 
(0.09) 
R 
(0.11) 
L 
(0.08) 
I 
(0.07) 
A 
(0.11) 
L 
(0.08) 
G 
(0.07) 
A 
(0.1) 
N 
(0.12) 
E 
(0.05) 
A 
(0.11) 
R 
(0.08) 
  
67 
 
 
 I S W D A P A V T V R Y Y R I T Y G E 
 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
A 1.9% 6.8% - 2.6% 18.2% 2.2% 15.0% 9.2% 4.5% 6.9% 2.0% 3.9% 3.1% 2.1% 1.4% 2.9% 1.3% 4.8% 3.0% 
C - 1.0% - - - - - 1.8% - 0.7% - 0.7% 1.0% - - 0.8% 1.8% 1.8% 0.7% 
D - 1.3% - 16.5% 2.1% 3.7% 4.4% 6.4% 17.5% 6.2% 10.9% 2.2% 2.2% 4.2% - 3.0% 0.6% 2.5% 7.2% 
E - 5.8% 0.5% 15.2% 6.2% 1.6% 9.4% 4.8% 5.6% 2.1% 6.3% 4.4% 2.9% 9.6% 0.6% 13.6% 1.6% 2.3% 23.9% 
F 2.1% 0.6% 1.6% - - - - 3.0% 0.6% 4.0% - 2.9% 8.9% 1.2% 1.0% 2.0% 6.0% 1.6% 0.9% 
G - 2.4% 0.5% 3.0% 4.2% 3.1% 13.5% 11.1% 4.8% 11.5% 18.1% 30.7% 4.5% 2.9% 1.3% 5.9% 1.1% 13.5% - 
H - 2.7% - 1.8% 1.5% 0.7% 1.2% 2.1% 1.6% 0.7% 1.9% 5.3% 1.4% 1.7% - 1.5% 2.2% 2.4% 1.6% 
I 16.1% 1.0% - 0.8% 2.3% - 2.2% 6.5% 1.9% 24.3% 1.7% 3.0% 3.7% 10.9% 37.3% 2.7% 3.4% 5.1% 4.0% 
K - 6.3% - 8.9% 8.5% 1.6% 4.9% 3.0% 3.3% 0.6% 6.3% 3.4% 1.6% 9.5% 0.7% 4.6% 3.4% 8.8% 7.3% 
L 44.5% 1.3% 0.7% 2.1% 2.6% 0.8% 4.1% 8.4% 1.8% 6.8% 5.1% 3.5% 2.3% 6.0% 17.6% 5.1% 5.4% 3.2% 4.4% 
M 1.3% 1.3% - 0.6% 1.1% - 0.6% 1.6% - 0.9% 0.5% 1.0% - 1.0% 1.1% 0.9% 1.8% 1.3% 0.7% 
N - 4.7% - 8.4% 2.2% 2.4% 5.3% 5.1% 12.1% 3.2% 5.4% 6.6% 1.7% 3.9% 0.5% 4.1% 0.9% 5.0% 2.2% 
P 0.7% 1.1% 0.7% 3.7% 22.6% 73.0% 6.8% 5.6% 9.9% 3.0% 1.3% 1.2% 3.5% 3.7% 0.6% 0.8% - 1.4% 8.5% 
Q - 6.5% - 7.8% 2.5% 1.3% 4.3% 3.1% 3.7% 0.9% 6.8% 3.1% 1.2% 6.1% 0.6% 7.9% 2.1% 4.9% 5.3% 
R - 6.0% - 3.8% 5.1% 0.6% 3.0% 2.3% 2.6% 0.6% 10.6% 3.1% 0.8% 15.5% - 5.7% 4.5% 12.2% 7.1% 
S - 31.6% - 9.6% 8.4% 4.4% 13.9% 8.0% 14.7% 2.5% 7.4% 11.5% 6.5% 3.7% 0.6% 10.4% 0.9% 9.1% 3.8% 
T 0.6% 16.1% - 12.7% 4.8% 1.4% 4.8% 4.0% 11.7% 2.7% 12.3% 1.9% 1.4% 5.8% 1.9% 17.6% 0.8% 5.5% 3.2% 
V 29.7% 2.3% - 1.4% 6.6% 1.9% 4.9% 8.4% 2.1% 20.4% 2.0% 2.2% 3.3% 9.2% 31.6% 5.6% 4.6% 6.7% 8.2% 
W 0.9% - 92.4% - - - - - - - - 0.9% 1.0% 0.6% - 0.5% 4.8% 2.0% 1.0% 
Y - 0.8% 0.8% - - - 0.8% 5.2% 0.8% 1.4% 0.5% 8.4% 48.4% 2.4% 1.8% 4.3% 52.4% 5.7% 6.4% 
Most Frequent                  
1 L (0.45) 
S 
(0.32) 
W 
(0.92) 
D 
(0.17) 
P 
(0.23) 
P 
(0.73) 
A 
(0.15) 
G 
(0.11) 
D 
(0.17) 
I 
(0.24) 
G 
(0.18) 
G 
(0.31) 
Y 
(0.48) 
R 
(0.15) 
I 
(0.37) 
T 
(0.18) 
Y 
(0.52) 
G 
(0.14) 
E 
(0.24) 
2 V (0.3) 
T 
(0.16) 
F 
(0.02) 
E 
(0.15) 
A 
(0.18) 
S 
(0.04) 
S 
(0.14) 
A 
(0.09) 
S 
(0.15) 
V 
(0.2) 
T 
(0.12) 
S 
(0.12) 
F 
(0.09) 
I 
(0.11) 
V 
(0.32) 
E 
(0.14) 
F 
(0.06) 
R 
(0.12) 
P 
(0.09) 
3 I (0.16) 
A 
(0.07) 
Y 
(0.01) 
T 
(0.13) 
K 
(0.09) 
D 
(0.04) 
G 
(0.14) 
V 
(0.08) 
N 
(0.12) 
G 
(0.11) 
D 
(0.11) 
Y 
(0.08) 
S 
(0.06) 
E 
(0.1) 
L 
(0.18) 
S 
(0.1) 
L 
(0.05) 
S 
(0.09) 
V 
(0.08) 
4 F (0.02) 
Q 
(0.07) 
P 
(0.01) 
S 
(0.1) 
S 
(0.08) 
G 
(0.03) 
E 
(0.09) 
L 
(0.08) 
T 
(0.12) 
A 
(0.07) 
R 
(0.11) 
N 
(0.07) 
G 
(0.04) 
K 
(0.1) 
T 
(0.02) 
Q 
(0.08) 
W 
(0.05) 
K 
(0.09) 
K 
(0.07) 
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 T G G N S P V Q E F T V P G S K S T A 
 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 
A 6.3% 5.8% 6.1% 2.8% 6.5% 4.1% 6.5% 4.3% 7.4% 3.9% 4.9% 6.3% 5.4% 8.6% 6.5% 5.7% 4.3% 2.6% 16.7% 
C 1.6% 1.5% 1.1% 0.6% 1.5% - 1.0% 0.6% 1.3% 1.7% 1.5% 1.7% 0.7% 2.0% 1.2% - 2.8% 1.2% 4.4% 
D 3.8% 9.9% 7.5% 13.3% 6.2% 6.8% 2.2% 4.1% 8.0% 1.5% 4.9% 1.6% 7.6% 5.3% 7.8% 6.1% 4.8% 2.6% 1.4% 
E 7.7% 5.0% 6.7% 12.4% 6.7% 11.4% 4.2% 8.7% 23.7% 2.8% 5.4% 2.8% 7.7% 3.1% 5.3% 12.6% 3.6% 9.0% 3.1% 
F 1.6% 1.3% 1.1% 1.2% 1.0% 1.4% 3.3% 0.6% 0.5% 10.6% 0.5% 1.6% 0.6% 0.8% 0.8% 0.8% 1.6% 3.0% 6.4% 
G 0.7% 19.6% 27.6% 6.1% 9.7% 5.4% 2.6% 4.9% 2.9% 2.4% 3.1% 1.5% 3.6% 32.9% 3.3% 2.2% 2.9% 1.6% 2.8% 
H 0.9% 1.5% 1.2% 2.6% 1.5% 1.4% 0.6% 3.5% 2.1% 2.0% 1.4% 0.8% 1.7% 1.8% 2.6% 2.3% 1.8% 2.1% 4.2% 
I 6.8% 3.3% 1.6% 1.8% 1.4% 2.2% 11.9% 1.6% 1.4% 8.4% 2.8% 12.1% 1.7% 2.8% 2.1% 2.2% 1.5% 2.3% 6.2% 
K 8.4% 8.4% 5.6% 8.0% 7.4% 6.0% 2.7% 13.3% 7.2% 2.9% 5.2% 2.6% 5.9% 3.9% 4.2% 15.5% 2.6% 4.0% 3.4% 
L 7.3% 4.0% 2.9% 2.8% 2.9% 2.8% 10.0% 4.2% 1.5% 11.7% 3.7% 11.2% 2.2% 2.2% 2.7% 3.9% 5.2% 3.6% 5.1% 
M 2.1% 1.4% 1.2% 1.3% 0.8% 0.7% 3.1% 1.5% 0.9% 2.9% 1.2% 1.7% 0.7% 0.6% 0.6% 1.0% 1.3% 1.2% 2.0% 
N 2.8% 6.6% 2.8% 14.5% 3.6% 2.7% 2.0% 4.7% 6.3% 3.4% 6.4% 1.9% 5.0% 5.7% 9.2% 4.8% 8.9% 5.1% 2.1% 
P 2.9% 2.1% 2.7% 2.7% 1.3% 22.7% 0.8% 2.0% 2.2% 0.9% 3.6% 0.7% 28.2% 3.3% 3.8% 2.3% 3.0% 2.7% 2.1% 
Q 2.6% 4.5% 3.5% 4.2% 5.2% 4.2% 1.2% 16.5% 3.9% 2.0% 4.6% 1.4% 3.2% 1.6% 3.0% 9.5% 3.3% 4.1% 2.5% 
R 5.5% 5.3% 7.4% 5.9% 6.9% 4.1% 4.2% 9.3% 6.4% 3.6% 6.7% 2.4% 3.3% 3.3% 4.0% 10.4% 5.6% 5.5% 2.1% 
S 9.2% 8.2% 9.1% 6.2% 18.8% 6.9% 4.3% 7.1% 6.7% 3.3% 12.6% 3.3% 8.4% 8.1% 18.9% 4.8% 17.1% 17.2% 4.1% 
T 14.9% 3.3% 5.2% 6.5% 10.8% 7.1% 8.9% 5.2% 8.1% 4.0% 23.6% 6.9% 7.5% 5.8% 16.9% 7.7% 24.0% 23.3% 5.5% 
V 11.8% 4.1% 2.7% 2.4% 3.7% 2.1% 21.5% 2.2% 5.2% 14.5% 5.9% 36.2% 5.3% 5.5% 4.7% 5.0% 3.3% 4.5% 11.5% 
W 0.6% 1.1% 1.4% 1.3% 1.7% 6.2% 5.5% 3.1% 2.9% 8.9% 1.0% 1.1% - 1.9% 1.0% 1.9% 0.6% 2.1% 1.1% 
Y 2.5% 3.3% 2.5% 3.4% 2.5% 1.5% 3.5% 2.4% 1.3% 8.7% 1.0% 2.2% 0.8% 0.8% 1.3% 0.9% 1.8% 2.3% 13.2% 
Most Frequent                  
1 T (0.15) G (0.2) G (0.28) N (0.15) S (0.19) P (0.23) V (0.21) Q (0.16) E (0.24) 
V 
(0.14) 
T 
(0.24) 
V 
(0.36) 
P 
(0.28) 
G 
(0.33) 
S 
(0.19) 
K 
(0.15) 
T 
(0.24) 
T 
(0.23) 
A 
(0.17) 
2 V (0.12) D (0.1) S (0.09) D (0.13) T (0.11) E (0.11) I (0.12) K (0.13) T (0.08) 
L 
(0.12) 
S 
(0.13) 
I 
(0.12) 
S 
(0.08) 
A 
(0.09) 
T 
(0.17) 
E 
(0.13) 
S 
(0.17) 
S 
(0.17) 
Y 
(0.13) 
3 S (0.09) K (0.08) D (0.07) E (0.12) G (0.1) T (0.07) L (0.1) R (0.09) D (0.08) 
F 
(0.11) 
R 
(0.07) 
L 
(0.11) 
E 
(0.08) 
S 
(0.08) 
N 
(0.09) 
R 
(0.1) 
N 
(0.09) 
E 
(0.09) 
V 
(0.12) 
4 K (0.08) S (0.08) R (0.07) K (0.08) K (0.07) S (0.07) T (0.09) E (0.09) A (0.07) 
W 
(0.09) 
N 
(0.06) 
T 
(0.07) 
D 
(0.08) 
T 
(0.06) 
D 
(0.08) 
Q 
(0.1) 
R 
(0.06) 
R 
(0.06) 
F 
(0.06) 
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 T I S G L K P G V D Y T I T V Y A V T 
 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 
A 1.9% 3.0% 3.3% 3.3% 1.0% 3.5% 6.7% 6.1% 5.3% 3.8% 1.7% 2.7% 3.0% 2.1% 2.1% 3.2% 45.5% 2.2% 2.7% 
C 0.8% 0.9% 0.5% - - - 0.7% - 1.6% - - 0.7% 0.9% 1.1% - 1.1% 1.1% 1.5% 1.1% 
D 4.0% 2.9% 6.3% 11.7% 0.9% 3.6% 2.4% 7.2% - 11.5% - 3.3% 1.0% 2.1% 1.3% 0.9% 1.8% 0.5% 2.2% 
E 5.9% 1.0% 7.3% 4.1% 1.0% 10.9% 9.9% 3.2% 3.1% 21.7% 1.9% 11.0% 1.3% 6.4% 3.3% 3.1% 6.0% 3.8% 5.9% 
F 1.1% 6.1% 1.1% 0.8% 3.2% 1.1% 1.4% 3.0% 1.1% 0.5% 4.4% 1.3% 24.9% 0.8% 0.8% 11.4% - 8.2% 3.2% 
G 0.6% - 3.1% 38.1% - 0.9% 1.5% 41.5% 0.8% 1.6% 1.4% 2.6% 1.8% 2.5% 2.8% 1.2% 5.5% 0.9% 1.1% 
H 2.0% - 2.5% 2.6% - 2.3% 0.9% 2.1% 2.2% 2.0% 2.9% 1.8% - 1.8% 0.5% 2.9% 1.0% 1.2% 1.1% 
I 4.3% 22.4% 0.9% 0.7% 4.5% 5.1% 1.9% 0.5% 4.2% 1.1% 1.2% 2.5% 18.2% 0.9% 12.5% 3.5% 1.1% 13.3% 2.0% 
K 6.7% 0.9% 7.4% 4.3% 0.5% 16.6% 3.9% 2.4% 4.5% 7.4% 1.8% 8.4% 0.9% 6.1% 1.6% 5.5% 3.9% 1.1% 4.3% 
L 5.7% 21.9% 1.7% 1.2% 71.2% 5.8% 1.9% 3.0% 11.6% 4.8% 4.2% 6.0% 13.9% 2.8% 15.3% 8.2% 2.2% 12.6% 2.7% 
M 1.3% 2.0% 0.8% 0.5% 1.8% 1.6% 0.6% 0.6% 2.1% 0.8% 0.8% 0.9% 2.8% 0.7% 1.6% 1.8% 0.5% 1.9% 0.9% 
N 4.6% 1.1% 5.3% 13.6% 0.7% 4.0% 3.0% 10.9% 2.7% 6.6% 1.2% 6.9% 0.9% 4.9% 2.4% 1.7% 2.6% 1.1% 19.9% 
P 2.5% 0.8% 4.2% 1.9% 0.5% 1.4% 45.8% - - 2.7% 1.0% 1.9% 0.6% 1.2% 1.4% 1.1% 3.9% 1.0% 1.7% 
Q 3.5% 1.5% 4.7% 2.7% 0.7% 8.3% 2.6% 1.6% 3.2% 6.2% 0.9% 6.4% - 5.4% 0.9% 5.2% 4.1% 0.9% 4.1% 
R 6.5% 0.8% 5.2% 3.0% 1.3% 9.5% 2.1% 2.3% 5.3% 4.5% 2.2% 5.7% - 21.1% 1.1% 8.7% 4.8% 0.9% 5.4% 
S 6.1% 0.8% 17.6% 5.4% 0.8% 7.9% 5.0% 7.5% 5.7% 9.2% 1.1% 10.5% 0.7% 11.7% 1.0% 4.7% 7.5% 1.6% 10.1% 
T 31.6% 2.3% 23.2% 2.4% 3.3% 10.4% 6.0% 2.6% 31.5% 11.6% 1.4% 20.9% 1.5% 22.4% 1.9% 4.9% 5.0% 3.0% 24.3% 
V 9.4% 28.2% 2.4% 1.3% 6.3% 5.3% 2.3% 0.8% 13.1% 2.2% 2.0% 3.9% 21.3% 1.5% 46.6% 4.4% 1.9% 34.7% 2.9% 
W - - 0.7% - - - - 0.7% - 0.6% 0.5% - - 1.1% - 2.0% - 0.8% 0.5% 
Y 1.1% 2.2% 1.9% 1.7% 0.9% 1.4% 1.1% 3.1% 0.7% - 68.5% 2.0% 4.5% 3.3% 2.0% 24.5% 0.8% 8.7% 3.9% 
Most Frequent                  
1 T (0.32) 
V 
(0.28) 
T 
(0.23) 
G 
(0.38) 
L 
(0.71) 
K 
(0.17) 
P 
(0.46) 
G 
(0.41) 
T 
(0.31) 
E 
(0.22) 
Y 
(0.69) 
T 
(0.21) 
F 
(0.25) 
T 
(0.22) 
V 
(0.47) 
Y 
(0.25) 
A 
(0.46) 
V 
(0.35) 
T 
(0.24) 
2 V (0.09) 
I 
(0.22) 
S 
(0.18) 
N 
(0.14) 
V 
(0.06) 
E 
(0.11) 
E 
(0.1) 
N 
(0.11) 
V 
(0.13) 
T 
(0.12) 
F 
(0.04) 
E 
(0.11) 
V 
(0.21) 
R 
(0.21) 
L 
(0.15) 
F 
(0.11) 
S 
(0.07) 
I 
(0.13) 
N 
(0.2) 
3 K (0.07) 
L 
(0.22) 
K 
(0.07) 
D 
(0.12) 
I 
(0.04) 
T 
(0.1) 
A 
(0.07) 
S 
(0.08) 
L 
(0.12) 
D 
(0.12) 
L 
(0.04) 
S 
(0.1) 
I 
(0.18) 
S 
(0.12) 
I 
(0.13) 
R 
(0.09) 
E 
(0.06) 
L 
(0.13) 
S 
(0.1) 
4 R (0.06) 
F 
(0.06) 
E 
(0.07) 
S 
(0.05) 
T 
(0.03) 
R 
(0.09) 
T 
(0.06) 
D 
(0.07) 
S 
(0.06) 
S 
(0.09) 
H 
(0.03) 
K 
(0.08) 
L 
(0.14) 
E 
(0.06) 
E 
(0.03) 
L 
(0.08) 
G 
(0.05) 
Y 
(0.09) 
E 
(0.06) 
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 G R G D S P A S S K P I S I N Y R T 
 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 
A 18.6% 6.7% 8.8% 1.1% 8.1% 5.6% 42.2% 10.0% 6.6% 2.6% 8.7% 11.4% 7.0% 6.1% 4.8% 4.2% 8.4% 9.4% 
C 0.7% - 1.1% 0.7% 2.0% 0.8% 1.1% 2.6% 1.0% - - 1.6% 0.7% 1.0% - - - - 
D 2.6% 0.6% 0.6% 22.8% 0.7% 1.3% - 1.7% 4.3% 1.3% 2.3% 0.7% 1.2% 3.4% 8.8% 2.2% 2.1% 1.0% 
E 5.3% 7.6% 1.5% 17.5% 0.8% 5.3% 2.7% 10.2% 2.4% 19.6% 4.3% 1.2% 1.3% 5.3% 7.8% 10.5% 14.6% 1.8% 
F 4.5% 2.0% 4.6% 3.5% 3.7% 2.2% 2.6% 2.5% 1.7% 0.5% - 7.1% - 4.0% - 14.1% 2.5% 0.6% 
G 14.6% - 49.6% 1.1% 9.1% 2.5% 8.6% 13.9% 23.6% 7.0% 8.3% 4.0% 32.0% 6.1% 36.5% 4.7% 2.3% 2.8% 
H 1.7% 3.0% 0.8% 1.1% 0.8% 1.2% - 1.9% 0.6% 2.2% 0.8% 0.5% - - 0.6% 3.4% 1.0% - 
I 2.9% 2.3% 2.1% 4.3% 3.4% 6.5% 5.8% 1.8% 1.3% 0.7% 2.4% 13.2% - 14.8% - 1.3% - 1.1% 
K 4.9% 13.9% 0.8% 2.8% 3.9% 5.6% 1.0% 3.4% 1.0% 21.3% 1.7% 2.0% 0.8% 1.3% 2.7% 4.1% 9.0% 1.0% 
L 2.8% 3.0% 2.3% 4.0% 2.5% 4.0% 6.7% 2.7% 1.2% 1.9% 0.6% 14.2% - 15.4% 0.7% 4.4% 1.6% 2.1% 
M 1.5% 1.1% 1.2% 0.6% 1.0% 3.2% 2.3% 0.8% - 0.6% - 3.7% - 2.5% - 1.2% - 0.5% 
N 7.6% 1.7% 5.5% 13.4% 6.4% 1.7% 1.4% 5.0% 15.6% 10.2% 3.3% 1.1% 2.5% 0.9% 11.5% 1.1% 1.0% 0.7% 
P 3.4% - 1.0% - - 23.6% - - - 0.5% 55.1% 0.6% - 2.0% 3.5% 11.1% 19.0% 6.4% 
Q 3.3% 5.2% 1.4% 4.7% 3.0% 5.4% 1.6% 4.9% 2.0% 9.7% 1.8% 1.2% 1.2% 1.4% 2.6% 2.2% 5.4% 0.8% 
R 1.9% 31.2% 0.8% 5.7% 7.4% 8.2% 2.6% 5.7% 1.4% 12.1% 1.3% 0.8% 1.0% 1.3% 1.4% 1.9% 16.3% 0.5% 
S 7.6% 1.7% 3.5% 1.7% 19.4% 2.0% 1.2% 15.8% 21.7% 2.8% 2.9% 0.7% 45.9% 2.5% 14.9% 5.0% 7.6% 55.5% 
T 3.0% 2.5% 3.7% 3.0% 11.4% 4.3% 1.6% 7.7% 7.9% 3.0% 3.0% 2.6% 4.5% 4.2% 2.8% 1.6% 3.0% 13.0% 
V 6.8% 5.4% 3.1% 7.2% 12.0% 12.7% 13.6% 4.9% 4.7% 1.3% 1.8% 24.1% - 22.6% - 3.5% 0.8% 1.4% 
W 0.6% - 0.5% - - - 0.7% - - - - 1.4% - 2.1% - 9.5% 2.3% - 
Y 5.7% 10.9% 7.1% 3.7% 4.3% 3.3% 3.2% 4.0% 2.1% 2.1% 0.6% 7.8% - 2.6% - 13.6% 1.8% - 
Most Frequent                 
1 A (0.19) 
R 
(0.31) 
G 
(0.5) 
D 
(0.23) 
S 
(0.19) 
P 
(0.24) 
A 
(0.42) 
S 
(0.16) 
G 
(0.24) 
K 
(0.21) 
P 
(0.55) 
V 
(0.24) 
S 
(0.46) 
V 
(0.23) 
G 
(0.37) 
F 
(0.14) 
P 
(0.19) 
S 
(0.55) 
2 G (0.15) 
K 
(0.14) 
A 
(0.09) 
E 
(0.18) 
V 
(0.12) 
V 
(0.13) 
V 
(0.14) 
G 
(0.14) 
S 
(0.22) 
E 
(0.2) 
A 
(0.09) 
L 
(0.14) 
G 
(0.32) 
L 
(0.15) 
S 
(0.15) 
Y 
(0.14) 
R 
(0.16) 
T 
(0.13) 
3 N (0.08) 
Y 
(0.11) 
Y 
(0.07) 
N 
(0.13) 
T 
(0.11) 
R 
(0.08) 
G 
(0.09) 
E 
(0.1) 
N 
(0.16) 
R 
(0.12) 
G 
(0.08) 
I 
(0.13) 
A 
(0.07) 
I 
(0.15) 
N 
(0.11) 
P 
(0.11) 
E 
(0.15) 
A 
(0.09) 
4 S (0.08) 
E 
(0.08) 
N 
(0.06) 
V 
(0.07) 
G 
(0.09) 
I 
(0.07) 
L 
(0.07) 
A 
(0.1) 
T 
(0.08) 
N 
(0.1) 
E 
(0.04) 
A 
(0.11) 
T 
(0.04) 
A 
(0.06) 
D 
(0.09) 
E 
(0.11) 
K 
(0.09) 
P 
(0.06) 
 
  
71 
 
C. Complementarity distribution mimicking CDRH3 of antibodies (CDR’), modified from previous work (Hackel et al., 
2010).  
 
CDR’ amino acid frequency distribution: 
  
A   0.06  
C   0.05  
D   0.11  
E   0.02  
F   0.03  
G   0.04  
H   0.06  
I   0.02  
K   0.02  
L   0.02  
M   0.00  
N   0.09  
P   0.04  
Q   0.01  
R   0.03  
S   0.13  
T   0.05  
V   0.03  
W   0.01  
Y   0.17  
Z   0.03  
 
Nucleotide composition of codon design: 
A1 C1 G1 T1 A2 C2 G2 T2 A3 C3 G3 T3 
0.20 0.15 0.25 0.40 0.50 0.25 0.15 0.10 0.00 0.45 0.10 0.45 
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D. Target exposure and solvent exposed surface area (SASA) for the BC, DE, and FG loops of fibronectin.  
 
 
Position Target Exposure SASA 
D23 0.68 0.35 
A24 0.90 0.32 
P25 0.70 0.10 
A26 0.79 0.75 
V27 0.69 0.57 
T28 0.84 0.75 
V29 0.46 0.03 
R30 0.90 0.49 
Y31 0.37 0.43 
G52 0.54 0.12 
S53 0.94 0.83 
K54 0.68 0.64 
S55 0.85 0.41 
T56 0.93 0.48 
T76 0.39 0.08 
G77 0.60 0.48 
R78 0.79 0.81 
G79 0.72 0.77 
D80 0.70 0.74 
S81 0.54 0.69 
P82 0.59 0.76 
A83 0.76 0.81 
S84 0.52 0.54 
S85 0.61 0.14 
K86 0.58 0.88 
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Table S2-4. Illumina primer design. Conserved framework positions with regions or sites 
having low diversity, as is the case with conserved framework positions, require additional 
considerations during sample preparation to ensure a high level of accuracy during the 
MiSeq run. The inclusion of variable length degenerate sequence (N4-8) at 5’ and 3’ ends 
allow the conserved sites to be offset.  Based on TruSeq guidelines, adapter indices are 
designed to have balanced G/T and C/A content, the following 6 adapter index tags were 
selected: AD005,6,12,14,18,19. Schematic below demonstrates the two-step PCR used for 
amplicon library construction. Colored regions of schematic indicate (from left to right) 
TruSeq universal adapter (red), target primer (cyan), gene of interest (gray), reverse target 
primer (green), multiplex primer 2.0 (yellow), Illumina index (blue), and Illumina PCR 
primer (purple). Table at bottom lists individual sequences with item names corresponding 
to PCR schematic. 
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Item Name Length Sequence 
RB1 59 caagcagaagacggcatacgagatCACTGTgtgactggagttcagacgtgtgctcttcc 
RB2 59 caagcagaagacggcatacgagatATTGGCgtgactggagttcagacgtgtgctcttcc 
RB3 59 caagcagaagacggcatacgagatTACAAGgtgactggagttcagacgtgtgctcttcc 
RB4 59 caagcagaagacggcatacgagatTTTCACgtgactggagttcagacgtgtgctcttcc 
RB5 59 caagcagaagacggcatacgagatGGAACTgtgactggagttcagacgtgtgctcttcc 
RB6 59 caagcagaagacggcatacgagatGCGGACgtgactggagttcagacgtgtgctcttcc 
FB 51 aatgatacggcgaccaccgagatctacactctttccctacacgacgctctt  
RA1 49 GTTCAGACGTGTGCTCTTCCGATCTNNNNATAAGCTTTTGTTCGGATCC 
RA2 50 GTTCAGACGTGTGCTCTTCCGATCTNNNNNATAAGCTTTTGTTCGGATCC 
RA3 51 GTTCAGACGTGTGCTCTTCCGATCTNNNNNNATAAGCTTTTGTTCGGATCC 
RA4 52 GTTCAGACGTGTGCTCTTCCGATCTNNNNNNNATAAGCTTTTGTTCGGATCC 
RA5 53 GTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNATAAGCTTTTGTTCGGATCC 
FA1 51 TTTCCCTACACGACGCTCTTCCGATCTNNNNACTACGCTCTGCAGGCTAGT 
FA2 52 TTTCCCTACACGACGCTCTTCCGATCTNNNNNACTACGCTCTGCAGGCTAGT 
FA3 53 TTTCCCTACACGACGCTCTTCCGATCTNNNNNNACTACGCTCTGCAGGCTAGT 
FA4 54 TTTCCCTACACGACGCTCTTCCGATCTNNNNNNNACTACGCTCTGCAGGCTAGT 
FA5 55 TTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNACTACGCTCTGCAGGCTAGT 
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Chapter 3 – ScaffoldSeq: Software for characterization of 
directed evolution populations 
Adapted from: Daniel R. Woldring, Patrick V. Holec and Benjamin J. Hackel. 
“ScaffoldSeq: Software for characterization of directed evolution populations.”  Proteins: 
Structure, Function, and Bioinformatics, 2016. Vol 84(7), 869-874. 
3.1. Synopsis  
ScaffoldSeq is software designed for the numerous applications – including 
directed evolution analysis – in which a user generates a population of DNA sequences 
encoding for partially diverse proteins with related functions and would like to characterize 
the single site and pairwise amino acid frequencies across the population. A common 
scenario for enzyme maturation, antibody screening, and alternative scaffold engineering 
involves naïve and evolved populations that contain diversified regions, varying in both 
sequence and length, within a conserved framework. Analyzing the diversified regions of 
such populations is facilitated by high-throughput sequencing platforms; however, length 
variability within these regions (e.g. antibody CDRs) encumbers the alignment process. To 
overcome this challenge, the ScaffoldSeq algorithm takes advantage of conserved 
framework sequences to quickly identify diverse regions. Beyond this, unintended biases 
in sequence frequency are generated throughout the experimental workflow required to 
evolve and isolate clones of interest prior to DNA sequencing. ScaffoldSeq software 
uniquely handles this issue by providing tools to quantify and remove background 
sequences, cluster similar protein families, and dampen the impact of dominant clones. The 
software produces graphical and tabular summaries for each region of interest, allowing 
users to evaluate diversity in a site-specific manner as well as identify epistatic pairwise 
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interactions. The code and detailed information are freely available at 
http://research.cems.umn.edu/hackel.  
3.2. Introduction 
Sequence analysis of diverse protein populations with related functions is valuable 
in characterizing antibody58,146–148 repertoires, evaluating homologs (such as for consensus 
design35), guiding combinatorial library design for de novo protein discovery61, and 
performing deep mutational scanning149,150 to elucidate evolution, e.g. of stability, binding, 
or catalysis. Sequence analysis can identify – on a sitewise or multi-site motif level – amino 
acid frequencies that are consistent with the discovery and evolution of stable, functional 
molecules. These amino acid frequencies can be implemented combinatorially in libraries or 
precisely in clones. The increased availability of broad data sets of functionally homologous, 
partially diverse proteins mirrors the growth in deep sequencing and bioinformatics mining. 
Realizing benefit from these advances requires techniques and software for efficient, 
accurate, consistent analysis throughout and across fields.  
Here we discuss software to analyze diverse protein populations for such purposes. 
As a particular type of example, we highlight the analysis of populations of small protein 
scaffolds (fibronectin type III61 and Gp2 domains151) in which three or two regions, 
respectively, were highly diversified and evolved for various binding functions. The 
software input is DNA sequences (FASTA/FASTQ); for example, a population encoding 
for protein domains engineered to bind various epitopes on an antigen. The primary outputs 
are sitewise amino acid frequency matrices, pairwise epistasis analyses – including 
epistatic frequency distributions and identification of key positive and negative correlates 
– and metrics of sequence diversity. The analysis workflow differentiates itself from 
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existing tools and methods of others152–159 by being customizable, via a dynamic, easily-
navigated user interface, and allows removal of background sequences (e.g., non-
functional clones unintentionally isolated during a protein library screen), evaluation and 
clustering of highly similar sequences, and dominant clone weight dampening. Output files 
are generated as graphical summaries and in comma-separated value format to facilitate 
downstream application and project-specific data interrogation (Fig. 1). Along with the 
annotated script, an accompanying Software Walkthrough provides a detailed guide for 
users as exemplified by Gp2 directed evolution analysis. Beyond the ligand-specific 
scientific value of sitewise and pairwise amino acid frequency data, analysis of the 
affibody160, fibronectin and Gp2 ligand evolution data reveals the benefits of variable 
dampening of dominant clones. 
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Figure 3-1. ScaffoldSeq evaluates high-throughput sequence data to characterize the 
diversity within directed evolution and natural populations. The regions of interest 
within a collection of proteins are identified using tunable similarity thresholds 
associated with reference sequences. Background sequences are quantified and 
excluded from the analysis (optional). Highly similar clones are clustered. Population 
heterogeneities are further elucidated by dampening the impact of highly frequent 
unique clones. The software generates output files that detail sitewise amino acid 
distributions and identify pairwise epistasis. 
 
3.3. Materials and Methods 
3.3.1 Interface Design 
Scripts, developed using Python (v2.7) with default libraries to ease portability, are 
compatible with Windows 7/8, Mac OS X and Linux OS. An intuitive interface guides the user 
through the sequence analysis menus and allows for command line execution. While workflow 
settings are customizable for essentially any protein, default profiles for fibronectin61, 
affibody160, DARPin161, knottin (kalata B1)78 and Gp2151 are included.  Each unique profile 
containing scaffold-specific parameters and settings declared within the job submission menu 
are saved via Python’s pickle module to separately store setting arrays outside the main 
interface. This allows users to easily retrieve and view settings from prior analyses. A step-by-
step tutorial is included as a resource to guide users through selecting the appropriate job 
settings (see Software Walkthrough).  
 
3.3.2 Sequence Alignment 
Quality, relevant sequences are parsed from the FASTA/FASTQ input file by looping 
through individual reads, locating conserved anchors at the 5’ and 3’ ends of the gene of 
interest, and removing segments outside of the anchors. Trimmed sequences of acceptable size 
(dictated by gene length and allowed length variation, such as from loop length diversity) are 
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aligned to a user-input reference sequence using a cross-correlation test with Python’s difflib 
module. This alignment depends on a sufficient fraction of matching nucleotides within the 
framework regions, directly outside of the diversified regions of interest, having at least 80% 
matching nucleotides. While the algorithm does not enable FASTQ read quality filtering, the 
framework alignment threshold can be adjusted by the user with discretion (see Software 
Walkthrough). This has the effect of searching along a trimmed sequence for the transition 
between a conserved region and a diversified region of interest. The identification method 
provides rapid location of diversified regions even in cases where the composition and length 
of the region of interest are not specifically known, which in turn has the advantage of 
accurately accounting for specific library designs involving loop length diversity within 
antibody fragments162,163 and small scaffolds such as fibronectin93 and Gp2151. Length 
differences are accounted for by inclusion of gap indicators, “-“, to maintain alignment in 
conserved regions. 
 
3.3.3 Background Consideration 
Background sequences or noise should be accounted for based on the specific 
experiments that yielded the sequence set. In directed evolution, functional clones are often 
isolated by survival selections or screening via genotype-phenotype display 
technologies113,164–166 coupled with cell panning167, bead sorting115, or flow cytometry116. 
Survival and selection techniques yield a small fraction of false positives or background, 
which can be quantified via control experiments (non-random ‘false’ positives resulting from 
poor assay design must be accounted for separately). These unwanted, random clones, which 
are the rarest sequences within the data set, are excluded from the analysis by removing either 
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a user-defined fraction of the rarest sequences (e.g. 2% for example directed evolution 
population isolated by yeast display and magnetic bead sorting) or all sequences with fewer 
than a user-defined number of occurrences. Accounting for assay-specific background levels 
has the additional advantage of sufficiently compensating for read error rates of next-
generation sequencing platforms, which tend to be <1%168. 
 
3.3.4 Family Clustering and Frequency Calculation with Dampening 
Sampling bias introduced by dominant motifs and selection methods are 
detrimental to the statistical analysis of raw sequence data169,170. To compensate for these 
biases, ScaffoldSeq allows for separate correction factors to be associated with motif 
clustering and individual sequence contributions. Similar sequences (default: 80% identity 
in diversified sites) can be clustered into families, which facilitate identification of key 
motifs. Families provide an additional metric for population diversity (sequences, unique 
sequences, and families), which, in turn, enables broader characterization of the sequence 
set. Notwithstanding, the diversity of a population can be obscured by a given family 
similar to how a prominent sequence can upstage all other members of a family. To correct 
for these imbalances and rather emphasize the heterogeneity of functional clones when 
appropriate, a dampening exponent can be applied to the frequency of unique sequences to 
lower the impact of dominant sequences61,151 (Equation 1). 
 
𝑓𝑓′(𝑥𝑥𝑖𝑖)  = ∑ �∑ 𝑓𝑓(𝑥𝑥𝑖𝑖)𝑘𝑘𝑚𝑚 �1 𝑑𝑑⁄𝑘𝑘
∑ �∑ �∑ 𝑓𝑓(𝑥𝑥𝑖𝑖)𝑘𝑘𝑚𝑚 �1 𝑑𝑑⁄𝑘𝑘 �𝑖𝑖       (1) 
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where f(xi) is the frequency of amino acid i at site x; km is the mth sequence in family k; and 
f’ is the dampened frequency with dth root dampening. 
Traditional sequence analysis often treats each sequence as a distinct solution to a 
problem. However, within a population, two non-identical, but highly similar sequences 
may share a common structural or functional motif, akin to providing comparable solutions 
to the same problem. By lowering the Sequence Similarity Threshold, the ScaffoldSeq 
algorithm defines a broader range of related sequences to be a common solution. The 
contribution of each common solution (i.e. dominant clones and their common-motif 
variants) can be tuned to suit the needs of the analysis by using family clustering in 
combination with dampening. 
The Frequency Dampening Power (1/d) will typically be within the range of 0.25 
– 1. As this value approaches zero, the data set will be treated as though all duplicate 
sequences were removed. A value of 1 has the effect of weighting all sequences equally 
and, consequently, negates all impact of clustering, irrespective of the Sequence Similarity 
Threshold. Frequency Dampening Power of 0.5 is suggested for sequence data sets that 
contain a relatively high number of occurrences for a few dominant clones. Sensitivity 
analyses (Fig. 2) guide selection of appropriate parameter value. 
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Figure 3-2. Sensitivity analyses. (A) Apparent sitewise diversity (i.e. Shannon 
entropy130) within binding populations from recent studies is shown as a function of 
dampening the effect of dominant sequences by modulating the frequency dampening 
parameter, d (Equation 1). The family cluster similarity threshold is set at 80% for 
data from all three scaffolds: hydrophilic fibronectin (Fn3HP)61, Gp2151, and affibody 
(unpublished). Data analyses were conducted with frequency dampening coefficient 
ranging from 1 (no dampening) to 4 (heavy dampening). Each line shows the Shannon 
entropy of a single site of interest. Conclusions: Accounting for dominant clones, via 
frequency dampening, has a greater impact on less diverse populations. Dampening 
uniquely affects each site, as demonstrated by changes in the rank order between 
levels of dampening. (B) Shannon entropy, averaged across all diversified sites for 
each scaffold, is shown for a range of frequency dampening coefficients and sequence 
similarity clustering thresholds. On the left, the similarity threshold is set at 80%. 
Data analyses were conducted with frequency dampening coefficient ranging from 1 
(no dampening) to 4 (heavily dampened). On the right, the frequency dampening 
coefficient is set to 2 and the similarity threshold is varied. Shannon entropy (𝑯𝑯 =
−∑ 𝒇𝒇𝒊𝒊 𝐥𝐥𝐥𝐥𝐥𝐥𝟐𝟐 𝒇𝒇𝒊𝒊
𝟐𝟐𝟐𝟐
𝒊𝒊=𝟏𝟏 , where 𝒇𝒇𝒊𝒊 is the fraction of amino acid i at a particular site) describes 
relative diversity within the range of 0 (fully conserved) to 4.3 (5% of each amino 
acid). 
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3.3.5 Pairwise Interactions 
Sitewise amino acid frequencies, 𝑓𝑓(𝑥𝑥𝑖𝑖), are most relevant when each site acts 
independently. In reality, cohorts of residues are likely to interact under evolutionary 
pressure171–173. Therefore, ScaffoldSeq also compares pairwise residue distributions from 
full-length evolved sequences relative to those predicted by the region specific independent 
frequency matrix, which empowers identification of positive and negative epistasis174 
(Supplementary Fig. S1-2).  Specifically, mutual information, 𝑀𝑀𝑀𝑀(𝑥𝑥,𝑦𝑦), is calculated for 
each pair of sites, x and y (Equation 2). Each of the 400 possible amino acid combinations 
for a site-pair are evaluated based on the predicted sitewise frequency product, ƒ(xi)ƒ(yj) 
and experimentally observed pairwise frequency, ƒ(xi,yj) (Supplementary Equation S1). 
For each of the amino acid-specific contributions, positive values indicate the propensity 
of two mutations to occur more often than would be predicted by a sitewise frequency 
analysis alone. Mutations that do not occur within the data set are excluded. The summation 
of these residue-specific values yields the mutual information for that site-pair. The amino 
acid-specific components of the mutual information calculation are also output to facilitate 
epistasis analysis. Mutual information from raw sequences is vulnerable to inaccuracies 
driven by sequence alignments in multiple scenarios. Broadly diverse or quickly evolving 
sites with high entropy tend to yield larger mutual information scores, irrespective of paired 
interaction175. Countering these effects through normalization techniques has been 
discussed176–179. Bias is also propagated through redundant sequences and prominent 
families of highly similar clones170. Previous corrective efforts include removing all 
duplicates153 and weighting sequence counts inversely proportional to the total cluster 
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size180. Additionally, high background can arise from small samples sizes181, but can be 
offset by low count correction180.  While the ScaffoldSeq algorithm largely overcomes 
these issues via dampening, clustering, and background removal, the mutual information 
output data incorporates the average product corrected method179 (Equation 3) 
 𝑀𝑀𝑀𝑀(𝑥𝑥,𝑦𝑦) = ∑ ∑ 𝑓𝑓�𝑥𝑥𝑖𝑖 ,𝑦𝑦𝑗𝑗�  log2 𝑓𝑓�𝑥𝑥𝑖𝑖,𝑦𝑦𝑗𝑗�𝑓𝑓(𝑥𝑥𝑖𝑖)𝑓𝑓�𝑦𝑦𝑗𝑗�𝑗𝑗𝑖𝑖  (2) 
 𝑀𝑀𝑀𝑀𝑝𝑝(𝑥𝑥,𝑦𝑦) = 𝑀𝑀𝑀𝑀(𝑥𝑥, 𝑦𝑦) −  𝑀𝑀𝑀𝑀(𝑥𝑥,∗)∗𝑀𝑀𝑀𝑀(∗,𝑦𝑦)𝑀𝑀𝑀𝑀(∗,∗)   (3) 
where MI(x,*) and MI(*,y) are the average mutual information values of site-pairs 
involving site x and y, respectively. MI(*,*) is the average mutual information values 
across all site-pairs. 
 
3.4. Results and Discussion 
 
ScaffoldSeq has been developed, optimized through extensive testing, and made 
available for public use along with documentation to facilitate implementation across 
various applications for the aforementioned functions.182 Upon completion of the sequence 
analysis, ScaffoldSeq publishes data in comma-separated value format summarizing each 
stage of the workflow depicted in Fig. 1. Output data include the total number of quality 
sequences that were parsed by ScaffoldSeq, number of occurrences for each unique protein 
sequence, background threshold count by which sequence removal was determined, 
dampening coefficient applied (d), number of family clusters, and protein sequence and 
frequency for unique clones within each cluster. Sitewise amino acid counts and frequency 
distributions are presented in matrix form. Following this, lead clones from the population 
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(i.e. most prevalent clone from each sequence cluster) are enumerated in rank order. 
Pairwise similarity distances are computed for each lead clone based on the relative 
Hamming distance as well as the revised BLOSUM64 score matrix183. Many analyses are 
afforded by the ScaffoldSeq output beyond those included in the default package. One 
potential application is demonstrated whereby the list of lead clones from each family is 
used to construct a phylogenetic tree, allowing for visual assessment of high level diversity 
(Fig. 3).  Pairwise diversity analysis, evaluated via mutual information and residue-specific 
epistasis, is conducted for all 400 pairs of residues, i and j, at all pairs of sites, x and y 
(further discussion in Supplementary Figs. S1-2). 
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Figure 3-3. Family clustering performed within ScaffoldSeq can be further evaluated in 
a phylogenetic tree visualization. The list of dominant sequences within each clustered 
family, directly output from ScaffoldSeq in the .csv file, were input into the seqpdist 
and seqlinkage functions within MATLAB. Horizontal lines on the far right indicate 
each unique sequence. The x-axis quantifies the distances between sequences based 
on the Jukes-Cantor method and blosum50 scoring matrix. The data sets originate 
from evolved populations of high affinity binders, sequenced by Illumina MiSeq, were 
analyzed using ScaffoldSeq. Analysis parameters for the Gp2 scaffold (top) and 
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hydrophilic fibronectin (Fn3HP; bottom) populations included a clustering threshold 
of 0.85 and 0.95, respectively and an assay background filter of 10 for both datasets. 
 
 
High-throughput evolution (directed or natural) and deep sequencing can 
substantially advance our knowledge of sequence-function relationships to yield improved 
mutant or combinatorial library designs. In addition to enlightening analysis of single 
proteins, sitewise (single and paired) consideration of inter- and intra-molecular 
interactions – quantified via evolutionary prevalence – can aid combinatorial library 
designs for de novo protein discovery. ScaffoldSeq facilitates such analyses. 
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Figure S3-1. Histogram of mutual information. (A) and residue-specific epistasis (B) 
values. In a recent study (Woldring, et al., 2015), high-throughput sequencing was 
used to elucidate the sequence-function landscape of a hydrophilic fibronectin 
(Fn3HP) combinatorial library. From a naïve library offering diversity at 26 solvent 
exposed positions, >105 unique strong binding ligands were evolved. ScaffoldSeq used 
these sequence data to calculate sitewise amino acid distributions as well as conduct 
pairwise analysis over the 325 possible site-pair combinations. (A) The corrected 
mutual information, 𝑴𝑴𝑴𝑴𝑷𝑷(𝒙𝒙,𝒚𝒚), is calculated for each pairwise combination of two 
positions, x and y (Dunn, et al., 2008). (B) The average product correction method was 
applied to each combination of amino acids at all 325 site-pairs.  
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Figure S3-2. High affinity binders evolved from a hydrophilic fibronectin (Fn3HP) 
combinatorial library were Illumina sequenced and analyzed within ScaffoldSeq 
(Woldring, et al., 2015). Residue-specific epistasis (RSEC; equation S4) is calculated 
for each pairwise combination of residues, i and j, at a two positions, x and y. (A) At 
each pair of sites, the total number of occurrences yielding a value above 0.17 are in 
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red on the bottom half of the figure. The summation of simultaneous mutations that 
yield 𝑹𝑹𝑹𝑹𝑹𝑹𝑪𝑪�𝒙𝒙𝒊𝒊𝒚𝒚𝒋𝒋� values below a threshold of -0.09 are shown in blue on the top 
portion. Light or dark shades indicate a single occurrence or two occurrences, 
respectively. (B) The highest and lowest observed RSEC and covariance (equation S9) 
values are shown for a representative set of residues and sites. The specific mutations 
are along the x-axis. Listed below the mutations is the median distance (angstroms) 
between the two sites based on Fn3 structural information from the protein data 
bank. Pairwise analysis provides additional information for directed evolution studies 
and focused library design. The existence of strong correlations, both positive and 
negative, are found within select pairs of sites, highlighting the potential impact of 
amino acid choice at diversified sites. In the context of library design, this information 
can be supplemented with other sources of data such as crystal structures (C; PDB 
ID – 1TTG) or stability calculations (Woldring, et al., 2015).  
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Equations S1-9. Pairwise analysis conducted by ScaffoldSeq uses residue-specific 
epistasis (equation S1) to quantify the disparity between two mutations 
simultaneously occurring in the observed population, 𝑓𝑓(𝑥𝑥𝑖𝑖,𝑦𝑦𝑗𝑗), and that which you 
would otherwise predict based on the frequency of each isolated mutation occurring 
within the same population, 𝑓𝑓(𝑥𝑥𝑖𝑖)𝑓𝑓(𝑦𝑦𝑗𝑗). Positive values indicate the propensity of two 
mutations to occur more often than would be predicted by a sitewise frequency 
analysis alone. Mutual information is calculated by summing over all residue-specific 
epistasis  combinations at two sites (equation S2). To reduced the inherent bias 
associated with entropy in this metric, the average product correction method, 
discussed previously (Dunn, et al. 2008), is shown in equation S3. In the present work, 
a similar technique was applied to residue-specific epistasis (equation 4). Supporting 
equations for the average product correction method are shown in equations S5-8. 
The covariance of two mutations is stated in equation S9. 
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3.7. ScaffoldSeq – Software Walkthrough 
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3.8. Software Walkthrough
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3.8.1 Overview 
ScaffoldSeq is software designed for the 
numerous applications – including 
directed evolution analysis – in which a 
user generates a population of DNA 
sequences encoding for partially diverse 
proteins with related functions and 
would like to characterize the single site 
and pairwise amino acid frequencies 
across the population. Importantly, the 
software provides tools to cluster similar 
protein families, dampen the impact of 
dominant clones, remove background, 
and evaluate diversity. 
3.8.2 Workflow 
1. ScaffoldSeq reads high-throughput DNA 
sequences from FASTA/FASTQ files. 
2. Regions of interest are parsed; unique 
sequences are enumerated.  
3. Background sequences (i.e. the rarest 
clones) are quantified and omitted from 
analysis, if desired.  
4. Highly similar clones are clustered. 
5. Dampen dominant clones. 
6. Output graphical and tabular results for 
(a) sitewise amino acid frequency and (b) 
pair-wise epistasis analysis. 
3.8.3 Downloads (Two Options) 
http://research.cems.umn.edu/hackel 
https://github.com/HackelLab-UMN 
 
 
 
Figure SW1: ScaffoldSeq workflow. 
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Example Aim: Evaluate sitewise and pairwise amino acid frequencies 
within the evolved regions in a population of synthetic ligands 
 
Figure SW2: Representative sequence analysis scenario. The Gp2 scaffold151 was analyzed using an 
in-development version of ScaffoldSeq, similar to a previous study61. From the 45-amino acid parental domain 
(PDB: 2WNM), a combinatorial library was employed whereby the two solvent exposed loops (red) were 
diversified in genetic sequence as well as length, with the inclusion of 6, 7, or 8 residues within each of the two 
regions. Populations of high-affinity binding clones evolved from this library were sequenced across the entire 
indicated gene (Illumina MiSeq, paired-end). Raw sequences were groomed using PANDAseq119, producing FASTA 
files of full-length reads (see Paired-end Assembly section). Using the FASTA files, ScaffoldSeq evaluated the 
sitewise and pairwise diversity throughout the two regions of interest (red). To be included in the analysis, an 
entry within the FASTA file must contain matching segments for both the 5’ / 3’ anchors (blue) as well as the 
framework regions (gray) adjacent to the diversified regions (red). Default anchor and framework matching 
thresholds are 100% and 80%, respectively. This identifies the appropriate genes and localizes the analysis to the 
intended regions even within a diverse population. Note that the conserved framework positions (gray) are 
excluded from all future analysis. To analyze the full gene sequences, simply specify the anchor and framework 
sequences to be directly adjacent to, but not overlapping with the gene region. In the following walkthrough, 
analysis parameters were set at 0.25 for dampening (1/d) with a similarity clustering threshold of 0.8. 
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ScaffoldSeq.py is compatible with any common operating system (Windows 7/8/10, Mac OS X or 
Linux OS) that has Python 2.7 installed.  
The software package can be downloaded from either the Hackel Lab research page 
(http://research.cems.umn.edu/hackel/Hackel/Publications.html) or the GitHub repository 
(https://github.com/HackelLab-UMN).  
The script is intended to run via the operating system command line or Python terminal, rather 
than IDLE. Start by ensuring that both the sequence data file and ScaffoldSeq.py are located in the 
same directory. Then navigate to this directory using the command prompt and load the program, 
for example:  
C:\User\Profile\GitHub\ScaffoldSeq>ScaffoldSeq.py  
An introduction screen will then be shown. 
 
Press any key to continue. The Main Menu is navigated using keyboard arrows (←→↑↓), then 
pressing Enter. You can exit at any time by pressing Esc. 
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Sequence analysis parameters can be specified within Settings.  
 
Sequence Similarity Threshold specifies the minimum fraction of sitewise amino acid matches 
required to place two sequences of the same region into a common cluster. Frequency Dampening 
Power (1/d) operates on the individual family clusters by applying a weight to the total count of 
each residue-position pair, as shown in Equation 1: 
𝑓𝑓′(𝑥𝑥𝑖𝑖)  = ∑ �∑ 𝑓𝑓(𝑥𝑥𝑖𝑖)𝑘𝑘𝑚𝑚 �1 𝑑𝑑⁄𝑘𝑘
∑ �∑ �∑ 𝑓𝑓(𝑥𝑥𝑖𝑖)𝑘𝑘𝑚𝑚 �1 𝑑𝑑⁄𝑘𝑘 �𝑖𝑖       (1) 
where fi,j is the observed occurrence of amino acid i at site j within the mth sequence of family k; 
and f’ is the dampened frequency with dth root dampening. Traditional sequence analysis often 
treats each sequence as a distinct solution to a problem. However, within a population, two non-
identical, but highly similar sequences may share a common structural or functional motif, akin 
to providing comparable solutions to the same problem. By lowering the Sequence Similarity 
Threshold, the ScaffoldSeq algorithm defines a broader range of related sequences to be a 
common solution. The contribution of each common solution (i.e. dominant clones and their 
common-motif variants) can be tuned to suit the needs of the analysis by using family clustering 
in combination with dampening. 
The Frequency Dampening Power (1/d) will typically be within the range of 0.25 – 1. As this value 
approaches zero, the data set will be treated as though all duplicate sequences were removed. A 
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value of 1 has the effect of weighting all sequences equally and, consequently, negates all impact 
of clustering, irrespective of the Sequence Similarity Threshold. Frequency Dampening Power of 
0.5 is suggested for sequence data sets that contain a relatively high number of occurrences for a 
few dominant clones. 
Maximum Sequence Count sets an upper limit for the number of sequences included in the 
analysis. This can be set to limiting values to speed analysis time for preliminary explorations. 
Background sequences or noise should be accounted for based on the specific experiments that 
yielded the sequence set. Assay Background Filter refers to a quantifiable, assay-specific level of 
false positives or background. The Filter Coefficient is the ratio of total events to false positives. If 
this ratio is unknown, the Assay Background Filter can be turned off using the left and right arrow 
keys. When turned off (see below), the minimum number of occurrences (Hard Cap Filter) can be 
specified. All unique sequences that are observed less often than this value will be neglected in 
the analysis. Toggling Pairwise Analysis On/Off gives the option of performing this 
computationally expensive feature.  
Selecting Return to Main Menu will save these settings.  
 
From the Main Menu, the Start Job option leads to a screen where the FASTA/FASTQ input file 
and scaffold specific DNA information are entered. Job Name will become the leading name of 
the output files. The input FASTA/FASTQ File is specified on the second row.  
DNA sequences should be entered using all caps. Sequences can be typed in manually or pasted 
into the appropriate field by first selecting the field using the arrow keys, then right clicking and 
selecting paste. The Windows keyboard shortcut ctrl-c will likely not be accessible within the 
Python terminal.  
Gene Start refers to all nucleotides within the gene of interest that lead up to the first diversified 
region. The 5’ Anchor and 3’ Anchor fields should be conserved nucleotide sequences that directly 
precede and follow the gene of interest, respectively. These are commonly in the form of 
restriction enzyme cut sites or adapter sequences that were part of the amplicon sample 
preparation prior to high-throughput sequencing run. The Gene Start nucleotides should be a 
conserved region that directly follows the 5’ Anchor and directly precedes the first diversified 
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region. If multiple Diversified Regions are being investigated, the DNA After Region field should 
include all nucleotides directly following the selected Region and lead up to the next Diversified 
Region. The nucleotides that follow the final Diversified Region must begin directly following the 
diversified region and end at the nucleotide preceding the 3’ Anchor sequence. Note that both 
the Anchor matching threshold and the framework threshold are adjustable global variables 
within the script (ScaffoldSeq.py): adaptor_tolerance (default: 100%) and 
framework_match_threshold (default: 80%), respectively.  
The following example coincides with the scenario shown in Figure 2. 
 
As nucleotides are entered into the Gene Start and DNA After Region fields, the Translated Gene 
of Interest section will populate.  
When analyzing Diversified Regions, the nucleotides within that region should not be keyed in; 
however, the total number of amino acids within the diversified region must be specified with the 
Minimum and Maximum Loop Size fields. The Diversified Regions will be displayed as dashes, “-“, 
at the bottom of the screen. The amino acids that are displayed as letters at the bottom will not 
be included in the sitewise or pair-wise analysis. They are displayed to assist the user in ensuring 
the diversified regions are accurately positioned for the analysis.  
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For analyses that harbor loop length diversity within the diversified region, the position of 
insertion can be selected following the Minimum and Maximum Loop Size fields. The loop length 
diversity sites are indicated as ‘+’ within the translated sequence. 
 
Additional sequence regions can be included in the analysis by using the keyboard arrows to 
specify the # of diversified regions. Selecting Save will store the settings to a file in the working 
directory. 
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All custom settings saved by the user will be located within the Load Job menu for future use. 
 
Use the arrow keys to browse summaries for each of the saved jobs.  
 
Upon selecting a job from with the Saved Files, you enter the Job Settings environment. At this 
point, press Accept to start the job. Confirm by pressing any key or Esc to abort.  
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As the script is performing each task, a brief status is delivered to the user as shown in the next 
image. Note that both the sequence file and ScaffoldSeq.py should be contained within the 
current working directory. Failure to do so will result in an error at which point the user must 
verify that (a) the sequence data file is located within the current directory and (b) the file name 
was entered properly. Proper implementation will produce incremental status updates 
resembling the following: 
 
Output files consists of sitewise amino acid frequency heatmaps (shown below) and tabular 
summaries (*.csv) of family clusters for each region of interest. If Pairwise Analysis was selected, 
an additional tabular summary (*.csv) is output, which includes mutual information (Equation 2) 
– with and without average product correction179 (Equation 3) – and epistasis (amino acid-specific 
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components of mutual information). Supporting equations for epistasis are shown in equations 
5-7. 
 𝑀𝑀𝑀𝑀(𝑥𝑥,𝑦𝑦) = ∑ ∑ 𝑓𝑓�𝑥𝑥𝑖𝑖 ,𝑦𝑦𝑗𝑗�  log2 𝑓𝑓�𝑥𝑥𝑖𝑖,𝑦𝑦𝑗𝑗�𝑓𝑓(𝑥𝑥𝑖𝑖)𝑓𝑓�𝑦𝑦𝑗𝑗�𝑗𝑗𝑖𝑖  (2) 
 𝑀𝑀𝑀𝑀𝑝𝑝(𝑥𝑥,𝑦𝑦) = 𝑀𝑀𝑀𝑀(𝑥𝑥,𝑦𝑦) −  𝑀𝑀𝑀𝑀(𝑥𝑥,∗)∗𝑀𝑀𝑀𝑀(∗,𝑦𝑦)𝑀𝑀𝑀𝑀(∗,∗)  (3) 
where MI(x,*) and MI(*,y) are the mean mutual information values of site-pairs involving site x 
and y, respectively. MI(*,*) is the mean mutual information values across all site-pairs.  
 Residue−Specific Epistasis: RSE�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗� = 𝑓𝑓�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗�𝑙𝑙𝑙𝑙𝑙𝑙 � 𝑓𝑓�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗�𝑓𝑓�𝑥𝑥𝑖𝑖�𝑓𝑓�𝑦𝑦𝑗𝑗�� (4) 
 RSE, corrected: RSEC�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗� = 𝑅𝑅𝑅𝑅𝑅𝑅�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗� −  𝑅𝑅𝑅𝑅𝑅𝑅(𝑥𝑥𝑖𝑖,∗)∗𝑅𝑅𝑅𝑅𝑅𝑅�∗,𝑦𝑦𝑗𝑗�𝑅𝑅𝑅𝑅𝑅𝑅(∗,∗)  (5) 
 𝑅𝑅𝑅𝑅𝑅𝑅(𝑥𝑥𝑖𝑖,∗) = 1𝜌𝜌(𝜎𝜎−1)∑ ∑ 𝑓𝑓�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗�𝑙𝑙𝑙𝑙𝑙𝑙 � 𝑓𝑓�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗�𝑓𝑓�𝑥𝑥𝑖𝑖�𝑓𝑓�𝑦𝑦𝑗𝑗��𝑗𝑗𝑦𝑦,𝑦𝑦≠𝑥𝑥  (6) 
 𝑅𝑅𝑅𝑅𝑅𝑅(∗,∗) = 2
𝜌𝜌2(𝜎𝜎2−𝜎𝜎)∑ ∑ 𝑓𝑓�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗�𝑙𝑙𝑙𝑙𝑙𝑙 � 𝑓𝑓�𝑥𝑥𝑖𝑖𝑦𝑦𝑗𝑗�𝑓𝑓�𝑥𝑥𝑖𝑖�𝑓𝑓�𝑦𝑦𝑗𝑗��𝑖𝑖,𝑗𝑗𝑥𝑥,𝑦𝑦,𝑦𝑦≠𝑥𝑥  (7) 
where x and y are individual positions, i and j are amino acids, 𝜌𝜌 is the number of residue options 
at each position and 𝜎𝜎 is the total number of sites. Additional algorithms that improve upon 
mutual information have been described by others175–178,184. 
 
3.8.4 Representative Output Figures 
The figures below demonstrate the graphical output provided by ScaffoldSeq. The visualization 
modules (matplotlib, pandas, numpy) required for figure output are not included within default 
Python install. These are easily installed using pip via command line 
(pip.pypa.io/en/stable/reference/pip_install/). 
Sitewise amino acid frequency heatmaps are shown for each region of interest with a color scale 
bar having default range 0 – 60%. Pairwise analysis is summarized by a histogram which includes 
mutual information using the average product correction method.  
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Mutual Information (MIP) 325 Site-pairs 
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3.8.5 Silent Mode 
To run the software in the absence of the dynamic interface, ScaffoldSeq can be executed from 
the command prompt in silent mode. This is done by including a text file (e.g. jobname.txt) as the 
single argument for ScaffoldSeq: 
C:\User\Profile\GitHub\ScaffoldSeq>ScaffoldSeq.py jobname.txt 
The job text file must include a complete list of predetermined settings and parameters, shown 
below: 
Job Name:  
FASTA/FASTQ File:  
Gene Start:  
5' Anchor:  
3' Anchor:  
# of Diversified Regions:  
DNA After Region: 
Minimum Region Length:  
Maximum Region Length:  
Insert after # Position: 
Sequence Similarity Threshold: 
Frequency Dampening Power:  
Maximum Sequence Count:  
Assay Background Filter:  
Pairwise Analysis:  
Filter Coefficient:  
 
A sample job file is included in the software package. The file contents are shown below: 
Job Name: Fibronectin_Fn3HP 
FASTA/FASTQ File: High_affinity.fasta 
Gene Start: 
TCCTCCGACTCTCCGCGTAACCTGGAGGTTACCAACGCAACTCCGAACTCTCTGACTATTTCTTG
G 
5' Anchor: GCTAGC 
3' Anchor: GGATCC 
# of Diversified Regions: 3 
DNA After Region: 
TACCGTATCACCTACGGCGAAACTGGTGGTAACTCCCCGAGCCAGGAATTCACTGTTCCG,GCGA
CCATCAGCGGTCTGAAACCGGGCCAGGATTATACCATTACCGTGTACGCTGTA,CCAATCAGCAT
CAATTATCGCACCGAAATCGACAAACCGTCTCAG 
Minimum Region Length: 6,3,6 
Maximum Region Length: 11,7,12 
Insert after # Position: 3,1,3 
Sequence Similarity Threshold: 0.8 
Frequency Dampening Power: 1 
Maximum Sequence Count: 10000 
Assay Background Filter: On 
Pairwise Analysis: Off 
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Filter Coefficient: 10 
 
Upon running a job using silent mode, the window should display brief descriptions of progress: 
 
 
 
Output files will be exported to the working directory.  
3.8.6 Runtime and Memory Requirements 
The analyses discussed in this walkthrough were conducted on a standard desktop PC (Windows 
10, Intel i5 4590 @3.3GHz, 16GB RAM). The RAM requirements are dictated by the total number 
of unique sequences being processed, while the overall runtime governed by the total number of 
clusters. As a representative high-RAM test case mimicking the analysis of a naïve or unselected 
population not requiring clustering, 1x107 unique clones were pseudo-randomly generated in the 
framework of the Gp2 scaffold with NNK codons at each diversified position. This analysis required 
2 hours to run with a peak RAM usage of 4.2GB. With 10-fold fewer sequences, this process takes 
only 12 minutes (400MB). As a representative long-runtime test case mimicking the analysis of 
broadly diverse population of matured clones, 1x107 sequences (10% unique) were generated in 
the framework of the Gp2 such that 1x105 family clusters were organized. The more 
computationally demanding tasks of clustering added 4 hours to the total runtime. When allowing 
for 1x104 clusters, this results in an 18-fold reduction in time required for clustering.  
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3.8.7 Paired-end Assembly 
Multiple algorithms185–188 exist for processing paired-end reads. The above examples used 
PANDAseq119 for assembling quality sequences into FASTA files. Below, is a basic template 
for using this method. The forward [-f] and reverse [-r] reads are input as separate FASTQ 
files. Multi-threading [-T] can be enabled for CPU-bound situations. A sequence quality 
threshold [-t] can be adjusted to reduce the presence of low-quality reads. This process 
generates an output file [-w]. 
 
module load pandaseq 
FOR = HACKEL_S1_L001_R1_001.fastq 
REV = HACKEL_S1_L001_R2_001.fastq 
OUT = panda_assembled.fasta 
pandaseq -f $FOR -r $REV -T 4 -t 0.99 –w >$OUT 
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Chapter 4 – A gradient of sitewise diversity promotes 
evolutionary fitness for binder discovery in a three-helix bundle 
protein scaffold  
Adapted from:  Daniel R. Woldring, Patrick V. Holec, Lawrence A. Stern, Yang Du, and 
Benjamin J. Hackel.  “A gradient of sitewise diversity promotes evolutionary fitness for 
binder discovery in a three-helix bundle protein scaffold.” Biochemistry. March 2017. DOI: 
10.1021/acs.biochem.6b01142  
4.1. Synopsis  
Engineered proteins provide clinically and industrially impactful molecules and 
utility within fundamental research. Yet, inefficiencies in discovering lead variants with 
new desired function, while maintaining stability, hinder progress. Improved function, 
which can result from a few strategic mutations, is fundamentally separate from 
discovering novel function, which often requires large leaps in sequence space. While a 
highly diverse combinatorial library covering immense sequence space would empower 
protein discovery, the ability to sample only a minor subset of sequence space and the 
typical destabilization of random mutations preclude this strategy. A balance must be 
reached. At library scale, compounding several destabilizing mutations renders many 
variants unable to properly fold and devoid of function. Broadly searching sequence space 
while reducing destabilization may enhance evolution. We exemplify this balance with 
affibody, a three-helix bundle protein scaffold. Using natural ligand datasets, stability and 
structural computations, and deep sequencing thousands of binding variants, a protein 
library was designed on a sitewise basis with a gradient of mutational levels across 29% of 
the protein. In direct competition of biased and uniform libraries, both with 1x109 variants, 
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for discovery of 6x104 ligands (5x103 clusters) toward seven targets, biased amino acid 
frequency increased ligand discovery 13±3-fold. Evolutionarily favorable amino acids, 
both globally and site-specifically, are further elucidated. The sitewise amino acid bias aids 
evolutionary discovery by reducing mutant destabilization as evidenced by 15ºC higher 
midpoint of denaturation relative to unbiased mutants (62±4ºC vs. 47±11ºC, p<0.001). 
Sitewise diversification, identified by high throughput evolution and rational library 
design, improves discovery efficiency. 
4.2. Introduction 
Molecular recognition ligands are valuable tools in fundamental biology, medicine, and 
industrial biotechnology. Engineered ligands enable control over binding epitope, affinity, 
selectivity, and the biophysical properties of the ligand. Protein ligands are frequently 
engineered by modulating amino acids in a select region – known as the paratope – of a 
protein while conserving a stable underlying framework.189 A variety of protein topologies 
have demonstrated efficacy as scaffolds for evolution of novel binding function including 
natural immune repertoires of antibodies190 and variable lymphocyte receptors191 as well 
as a multitude of synthetically-diversified scaffolds189,192. One particular example, the 
affibody domain, has been effectively used as a ligand scaffold including evolution of 
binding to numerous targets, with affinities as strong as 20 pM, and application to 
diagnostics, molecular imaging, and therapy.193,194 The affibody is a 58-residue, three-helix 
bundle derived from the Z domain of Staphylococcal protein A. It is readily expressed 
recombinantly in bacteria, highly soluble, and reversibly unfolds with a wild type midpoint 
of 72ºC195, although engineered mutants have exhibited destabilization to denaturation 
midpoints of 37-65ºC (mean: 49ºC)195–200. Mutants with novel binding activity have been 
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discovered and evolved from combinatorial libraries with diversity at 13 residues on one 
face of the N-terminal and middle helices. Each of the 13 sites was diversified to the 20 
natural amino acids using broadly distributed NNK codons. Library screening has been 
performed using phage display193,201,202, ribosome display,203,204 and bacterial display200,205–
207; yeast display was used for framework evolution208. 
Evolution of novel binding function necessitates mutation of sufficient paratope area to 
drive the new intermolecular interaction209 while maintaining sufficient intramolecular 
stability. Mutation of intramolecularly-critical sites or mutation of semi-tolerant sites to 
suboptimal amino acids can limit evolutionary potential despite the introduction of an 
otherwise effective paratope.21,67,210–213 Thus, identification of the mutational tolerance of 
each site – within the context of a diverse array of sequences possible within a 
combinatorial library – can aid evolution. Implementation of variable diversities at each 
site – both in entropy and specific amino acid preferences – has proven to enhance 
evolutionary efficacy in synthetic fibronectin domain libraries51,57 and natural58 and 
synthetic53 antibody repertoires. Sitewise constraint has also been implemented in designed 
ankyrin repeat proteins46,59,60 and fibronectin domain sheet libraries214,215 using rational 
bias. Sitewise constraint has not yet been published for the affibody domain. Amino acid 
bias, across sites, has been implemented using amino acids frequently observed in protein-
protein interfaces, particularly tyrosine and serine47–51, as well as glycine in loop paratopes. 
Sitewise bias has been identified via natural antibody repertoire mimicry56, wild-type 
constraint51, structural analysis46, and high-throughput evolution and deep sequencing57. 
Identification of detrimental mutations via deep scanning strategies has also been 
studied.149,216–219 Computational prediction of mutational impacts on stability42,44,45,220 and 
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functional maturation221,222, though not functional discovery, have been extensively studied 
and could be used to guide library design. 
The current study aimed to identify the sitewise amino acid diversities consistent 
with efficient evolution of a broad array of binding function (i.e. creation of a single library 
containing specific binders to a multitude of targets) and examine the drivers and 
implications of these amino acid preferences. We provide a platform for designing small 
protein libraries in terms of deciding which residues to include or avoid at individual 
positions. The effectiveness of this approach is demonstrated in the context of discovering 
high affinity variants from an affibody library. 
4.3. Materials and Methods 
4.3.1 Preliminary Library Design (First Generation) 
As a preliminary attempt to identify the most beneficial diversification strategy for 
the three-helix affibody scaffold, a combinatorial library was designed which incorporated 
a wide variety of mutations across select sites. While, traditionally, the affibody scaffold 
is uniformly mutated at thirteen positions using all 20 natural amino acids, it is largely 
unknown which amino acids are most effective at any particular site. To better understand 
these functional diversities, fifteen solvent exposed sites throughout helix 1 and 2 (classic 
thirteen and sites E15 and I31) were mutated using five separate levels of diversity: i) wild-
type (WT) residue, ii) WT or serine (small size and promotes neutral interaction54), iii) 
WT, serine, or tyrosine (frequently drives binding affinity and specificity49,223), iv) relaxed, 
moderate diversity (A, C, D, G, N, S, T, or Y), or v) full diversity mimicking the chemical 
composition of the third antibody heavy chain complementarity-determining region (CDR-
H3). These five combinatorial libraries were separately constructed on the DNA level, then 
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pooled to form the first generation library. Any single variant within the initial library 
exhibited sitewise mutations from only one of the five combinatorial sub-libraries. 
 
4.3.2 Gradient Sitewise (GS) Library Design (Second Generation) 
The GS library was designed in a sitewise manner by balancing numerous data 
inputs. Numerous sites were constrained in their amino acid diversity (details in Supporting 
Information). Amino acid diversity at likely hot spot affibody positions was guided by 
amino acid prevalence in natural antibody interfaces (Abysis database; CDR-H3 diversity, 
Kabat sites 95-102) and previously evolved affibodies found in literature193–195,197,199–
203,206,224–247 as well as those generated in-house with the first generation library. The 
prevalence of each amino acid, except Gly and Arg, were calculated based on equally 
weighted CDR-H3 diversity via Abysis and previously evolved binder data, yielding the 
codon design which we call B* for the rest of the manuscript (Figure S1). The BLC* codon 
closely mimics this design, while also emphasizing low cysteine content (0.5% in BLC* vs 
2.5% in B*). 
 
4.3.3 Solvent Accessible Surface Area (SASA) 
PDB files for affibody (PBD ID: 1H0T, 1LP1, 2B88, 2KZI, 2OKT, 3MZW) were 
processed using GetArea137 to calculate SASA relative to random coil (probe radius, 1.4 
Å). At each site, the median value across all six structures was reported. For PDBs that 
included multiple affibody chains, the mean SASA of the chains was determined prior to 
calculating median values among all structures. 
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4.3.4 Computational Stability 
t each of the thirteen classically diversified sites (9, 10, 11, 13, 14, 17, 18, 24, 25, 
27, 28, 32, 35) and for each naturally occurring amino acid, the change in stability 
(ΔΔGfolding) upon mutation was calculated with FoldX248. First, an affibody structure was 
randomly mutated in accordance with the first generation library design to calculate 
baseline stability. Next, ΔΔGfolding was calculated for each single mutation (all 19 natural 
amino acids substituted, separately, into each site) versus the parental mutant. This process 
of saturation scanning was repeated for 312 randomly generated parental mutants across 
five affibody PDBs (PDB ID: 1H0T, 1LP1, 2B88, 2KZI, 3MZW).  The median ΔΔGfolding 
was then calculated for each residue-site combination for the thirteen classically diversified 
sites. 312 iterations were demonstrated as sufficient for convergence of the 
(de)stabilization values. 
   
4.3.5 Natural Homolog Analysis 
Pfam136 family B (PF02216) was accessed in April 2013 to retrieve 1,484 total 
sequences, 119 of which were unique. Rather than equally weighting all 1,484 sequences, 
the unique sequences were given a weight dictated by the square root of the number of 
occurrences for that sequence. Using this adjusted weighting, a sitewise amino acid 
distribution was calculated (Table S2). 
  
4.3.6 Relative Helix Propensity 
Empirical data from several published studies249–254 were collectively used to 
calculate relative propensities of each natural amino acid within helical secondary 
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structures. The values from the previous studies were linearly averaged, based on 
destabilizing energetics of folding relative to glycine (propensity = 0) and alanine 
(propensity = 1). Using this normalized scale, the propensity of proline is calculated to be 
-2.7. 
 
4.3.7 Library Construction 
Each combinatorial library was built using synthetic oligonucleotides (IDT DNA) 
with degenerative codons, which were assembled by overlap extension PCR. Library genes 
were transformed into EBY100 S. cerevisiae yeast via electroporation255 wherein the 
library fragments homologously recombined with linearized pCT vector to yield a 
construct that enabled yeast surface display of the encoded proteins113. Transformation 
efficiency was quantified using dilution plating with SD-CAA selective media. Sanger 
sequencing of initial libraries was performed for quality control. 
 
4.3.8 Binder Selection 
Yeast libraries were grown in SD-CAA selective media (16.8 g/L sodium citrate 
dihydrate, 3.9 g/L citric acid, 20.0 g/L dextrose, 6.7 g/L yeast nitrogen base, 5.0 g/L 
casamino acids) at 30 ºC with shaking at 250 rpm. Surface display was achieved by 
switching to SG-CAA media (10.2 g/L sodium phosphate dibasic heptahydrate, 8.6 g/L 
sodium phosphate monobasic monohydrate, 19.0 g/L galactose, 1.0 g/L dextrose, 6.7 g/L 
yeast nitrogen base, 5.0 g/L casamino acids) with incubation at 30°C with shaking at 250 
rpm for 16 hours. Induced libraries were enriched for affibody variants that specifically 
bound each of the several protein targets (first generation: lysozyme and rabbit 
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immunoglobulin G (IgG); second generation: death receptor 5, transferrin, cytochrome C, 
glucose-6-phosphate dehydrogenase, CD276, MET and a G-protein-coupled receptor; 
separate enrichments performed in parallel) using both magnetic streptavidin coated bead 
sorting256 and fluorescence activated cell sorting257. Each round of bead sorting consisted 
of two incubations (two hours each) of induced yeast with either bare beads or beads pre-
incubated with an arbitrary biotinylated protein for depleting non-specific binding 
interactions. Following the depletions, the remaining yeast cells were incubated with beads 
with biotinylated target for two hours and washed twice with PBSA. Yields for both non-
specific binding and target binding were quantified using serial dilution plating. 
Populations that demonstrated strong specificity (> 10-fold) of target binding relative to 
non-specific binding were isolated for sequence analysis. For all populations, after two 
rounds of enrichment using target labeled beads, flow cytometry was conducted. 
Preparation for cytometry consisted of incubating an induced yeast population with 100 
nM biotinylated target and 67 nM of anti-c-Myc epitope tag antibody (9E10, Biolegend) 
in PBSA for 30 minutes at room temperature. Following the primary labeling step, cells 
were washed with PBSA, incubated with AlexaFluor647-conjugated goat anti-mouse 
antibody and AlexaFluor488-conjugated streptavidin for 15 minutes at 4°C, and then 
washed with cold PBSA. If target binding was observed, all binding events above 
background, denoted as high stringency binders, were isolated for sequence analysis. Ultra-
high stringency binding populations (Figure S5-S7) were obtained through one additional 
round of cytometry sorting using 5 nM biotinylated target and a stricter sorting gate. In the 
event that no binding was detected, all full-length, c-Myc positive events were isolated for 
evolution. Plasmid DNA was zymoprepped from yeast, subjected to dual error-prone PCR 
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efforts on the full gene and on shuffled helices258, and electroporated into yeast for 
additional iterations of bead sorting and flow cytometry. 
 
4.3.9 Affinity and Specificity Analysis 
Representative variants were randomly chosen from the high and ultra-high 
stringency populations (Figure S6A and Figure S6B, respectively). Each variant was 
induced in yeast, incubated with anti-c-Myc antibody and at various concentrations of their 
respective target, washed with cold PBSA, incubated with AlexaFluor647-conjugated goat 
anti-mouse antibody and AlexaFluor488-conjugated streptavidin for 15 minutes at 4°C, 
and then washed with cold PBSA. Extent of binding was measured via flow cytometry and 
normalized based on the maximum signal strength associated with each target and the 
background fluorescence of target-free yeast. Dissociation constants (KD) were calculated 
by fitting the data to a two-state binding curve (n=3). Specificity was assessed by separately 
incubating each high stringency variant with multiple non-target biotinylated proteins at 
100 nM or with target protein at 50 nM. The extent of binding, normalized by maximum 
possible fluorescence associated with each target, is then compared between target and 
non-target samples (Figure S8). 
 
4.3.10 High-throughput Sequence Analysis 
The plasmid DNA from the initial libraries as well as the enriched populations – 
both high stringency cytometry detectable and magnetic bead selective – were isolated for 
sequence analysis with a Zymoprep kit (Zymo Research). Illumina MiSeq adapter and 
indexing sequences were added via PCR. Paired-end (250 base pair) analysis yielded 18 
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x106 quality reads. Raw paired-end read output was groomed and assembled with 
PANDAseq using a quality score threshold of 0.99, then converted to FASTA119. FASTA 
sequence files were processed using ScaffoldSeq259. A sequence homology threshold of 
80% was used for clustering similar variants. Clusters were then dampened using a factor 
of 0.25 to account for enriched sequence frequency while gaining information diversity 
from less frequent variants. 
 
4.3.11 Library of Origin Analysis 
Sequence variants from the initial and evolved populations were assessed for having 
originated from each of the three library designs. The probability of finding a particular 
sequence within each of the three sublibraries (NNK, GS, and GSLC) is calculated as the 
quantity P(k)S. This equation takes into account the amino acid, i, present at each position, 
j, of the sequence, k. The frequency of i at position j within the sitewise amino acid design 
of sublibrary S is given by 𝑓𝑓?̅?𝑠,𝑖𝑖,𝑗𝑗. The library origin probability, P(k)S, is then obtained by 
taking the product across each of the 17 potentially diversified sites (Equation 1). Amino 
acids not offered within a particular sublibrary (e.g. Arg at site 11 within the GS design or 
Tyr at site 6 of the NNK design) were given a default value of 1 x10-4 rather than zero to 
account for random errors during library construction, evolution of binders, and DNA 
sequencing.  
  (1) 
Each sequence was then binned with the sublibrary that yielded the greatest library origin 
probability. Within each sublibrary bin, the number of occurrences, n, of each unique 
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sequence, v, was tallied and square rooted to normalize the contribution of dominant 
variants. The total sequence count, 𝑁𝑁𝑅𝑅, within each of the three sublibraries is the 
summation of normalized counts for each unique variant (Equation 2). Rare variants, 
having been observed fewer than ten times, were excluded from the analysis. 
  (2) 
 
4.3.12 Stability Measurements 
Individual variants were randomly selected from cytometry detectable binding 
populations. Each gene was shuttled into a pET-24 derivative to include a C-terminal six-
histidine tag, expressed in BL21(DE3) bacteria, and purified using cobalt resin columns57. 
Purified proteins were diluted in PBS to 1 mg/mL and assessed via circular dichroism using 
a Jasco J815 instrument. Temperature scans were conducted using a range of 20-90°C 
(1°C/min) while monitoring the 220 nm wavelength. Midpoints of thermal denaturation 
were calculated assuming a standard two-state unfolding curve. For reducing conditions, 
dithiothreitol (DTT) was prepared fresh and added to the samples to yield a final 
concentration of 2 mM DTT, then incubated at room temperature for 30 minutes. 
 
4.4. Results and Discussion 
4.4.1 First Generation Library 
We sought to identify sites, within the typically diversified paratope, that would 
provide the most substantial benefit from constrained diversity. The main approach to 
identify sites, and their amino acid preferences, was high-throughput ligand engineering 
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and deep sequencing analysis. Thus, we designed, constructed, and screened a 
combinatorial library of affibody domains to discover and evolve functional variants. With 
an aim to improve the binder frequency to generate a diverse set of functional sequences, 
modest constraint at select sites was introduced in the initial library. Evaluation of the 
solvent-accessible surface area (Table 1) and spatial orientation at the 13 classically 
diversified sites revealed three sites that were hypothesized to provide more evolutionary 
benefit from at least partial wild-type constraint. Q9 is only 19% accessible to solvent 
(Figure 1, orange). N11 is 51% accessible but predominantly facing away from the evolved 
binding surface (Figure 1, yellow). R27 is at the core of the paratope but only 27% 
accessible (Figure 1, blue). The other diversified sites range from 33-90% accessible 
(median: 71%). Two sites that were previously conserved, E15 and I31, were modestly 
accessible (38% and 27%) and oriented near the evolved binding surface (Figure 1, green 
and violet). Mild diversity of these sites was hypothesized to provide evolutionary benefit.  
 
Figure 4-1. Affibody structure with constrained sites highlighted. Side chains are shown 
for Q9 (orange), N11 (yellow), E15 (green), R27 (blue), and I31 (violet) in four solved 
122 
 
affibody structures232,236,244,260. The other ten classically diversified sites are shown in 
red. 
 
Thus, a combinatorial library was constructed from five sub-libraries in which these 
constrained sites were varied from wild-type conservation to full amino acid diversity 
(Table 1). The other ten typical paratope sites were broadly diversified to all 20 amino 
acids using complementarity-biased amino acid frequencies47–51. The library, constructed 
by overlap extension PCR of degenerate oligonucleotides and homologous recombination 
in a yeast display system, contained 4x108 variants. The library generally matched the 
intended design (median absolute deviation from design, |fobserved – fdesign| = 0.8%) although 
tyrosine and cysteine were modestly higher than desired while alanine and aspartic acid 
content were lower than designed (Figure S2A). 
Table 4-1. First generation library design.  The site, wild-type (WT) amino acid, 
relative solvent-accessible surface area (SASA), and diversity in the published and 
first generation libraries are presented for sites in the N-terminal and middle helix of 
affibody. 
Sitea WT SASA(%) Previous Librariesb 1st Generation Libraryc,d 
N6 A 78 N A 
K7 K 79 K K 
E8 E 39 E E 
Q9 Q 19 20 N / NS / NSYT / 12 / 20* 
Q10 Q 66 20 20* 
N11 N 51 20 N / NS / NSYT / 12 / 20* 
A12 A 4 A A 
F13 F 33 20 20* 
Y14 Y 72 20 20* 
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E15 E 38 E E / EA / DSYA / 12 / 20* 
I16 I 0 I I 
L17 L 10 20 20* 
H18 H 67 20 20* 
E24 E 88 20 20* 
E25 E 90 20 20* 
Q26 Q 23 Q Q 
R27 R 27 20 R/RS/RSYCHP/ 12/ 20* 
N28 N 71 20 20* 
A29 A 74 A A 
F30 F 10 F F 
I31 I 27 I I / IS / ISYCFN / 12 / 20* 
Q32 Q 72 20 20* 
S33 S 44 K A 
L34 L 1 L L 
K35 K 76 20 20* 
D36 D 66 D D 
a. Sites 1-5 and 37-58 were conserved as wild-type (Table S1). 
b. “20” represents a mixture of all twenty amino acids using NNK degenerate codons. 
c. “20*” denotes a mixture of all 20 amino acids weighted based on frequency in 
antibody repertoire but with reduced glycine because of the helical structure (Figure 
S1). 
d. “/” separates sub-library designs  
 
Specific binders to hen egg lysozyme and rabbit IgG were discovered and evolved 
from the combinatorial library using yeast display with magnetic and flow cytometry 
selections. Deep sequencing of the evolved variants yielded 6x104 unique sequences in 523 
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diverse families. Numerous amino acids, at specific sites, exhibited substantial enrichment 
or depletion from the unselected to the evolved populations, which is indicative of the 
benefit or detriment of that amino acid at that site in functional affibodies (Figure 2). These 
data inform effective design of an improved combinatorial library. 
 
Figure 4-2. Sitewise amino acid preferences in the context of the first generation library. 
The change in amino acid frequency, between the unselected and evolved populations 
(fevolved – funselected), is shown for each amino acid at each site. 20* represents the 
aggregated frequencies of the 10 sites with broad diversity (20* in Table 1). 6x104 
unique evolved sequences were used. 
 
4.4.2 Second Generation Library Design: Overall 
A second generation library was designed to further evaluate sitewise preferences 
in the context of a more focused design. On a sitewise basis, amino acids were favored that 
(i) appeared frequently in binder sequences from the first generation library (Figure 2) and 
345 published binder sequences (Figure 3A); (ii) are computationally predicted to be stable 
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in the context of diverse paratopes (Figure 3B); and (iii) occur naturally in affibody 
homologs (Figure 4A). Broad diversity was favored in sites that are (i) solvent accessible 
and oriented towards the proposed binding interface (Table 1, Figure 1); (ii) broadly 
diverse in natural homologs (Figure 4B); and (iii) computationally predicted to be stable to 
multiple mutations (Figure 3B). Generally at all sites, amino acids were favored that (i) 
appear frequently in antibody CDR-H3 (bioinf.org.uk/Abysis; Kabat sites 95-102) (Figure 
5A), which has also been implemented in previous synthetic libraries47–51; and (ii) favor 
helix formation249–254 (Figure 5B). Each undiversified framework position, where 
mutational diversity is unlikely to provide added quality to the overall library design, was 
conserved as wild-type in the context of the optimized affibody framework196. Library 
design details are provided in the Supporting Information (Table S3). Commentary on the 
broadly diversified distribution, cysteine content, and non-traditionally diversified sites 
follows. 
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Figure 4-3. (A) Sitewise amino acid preferences from published affibody evolution. The 
change in amino acid frequency, between the unselected and evolved populations 
(fevolved – funselected), is shown for each amino acid at each of the thirteen traditionally 
mutated sites. 345 unique evolved sequences were used from numerous 
references.75,193–195,197,199–203,206,224–228,230–247 (B) Computed destabilization upon mutation 
in the context of diverse paratopes. The median change in folding free energy (∆∆Gf) 
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upon mutation to the indicated amino acid at the indicated site was computed using 
FoldX. Saturation scanning (calculation of all mutants) was performed at each site 
for 312 random library variants with five affibody structures. For each site, the 
median destabilization and number of tolerated amino acids (mutants with ∆∆Gf < 
1.5 kcal/mol) are also presented. 
 
Figure 4-4. Sitewise amino acid preferences from affibody homologs. (A) The amino 
acid frequencies of 1,484 (119 unique) proteins from Pfam136 family B, PF02216, 
which are homologous to the affibody sequence, are shown for each amino acid at 
each site. (B) The Shannon entropy, 𝑯𝑯(𝑿𝑿) =  ∑−𝒇𝒇𝒂𝒂𝒂𝒂 𝒍𝒍𝒍𝒍𝒍𝒍𝟐𝟐𝟐𝟐 𝒇𝒇𝒂𝒂𝒂𝒂, of each site is 
indicated. 
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Figure 4-5. Aggregate amino acid preferences from natural proteins. (A) The amino 
acid frequencies observed throughout the third complementarity determining region 
of antibody heavy chains (CDR-H3; Kabat sites 95-102). (B) The relative helical 
propensity of each amino acid, based on observed destabilization of helical secondary 
structure when used for substitution, is calculated as the aggregate of several previous 
studies249–254. The ranges indicate one standard deviation above and below the mean 
for each residue. Helix propensity of proline (*), calculated to be -2.7, is outside the 
presented range. 
 
4.4.3 Second Generation Library Design: Broadly Diversified Sites 
At sites that were predicted to benefit from broad diversity, a biased distribution 
was implemented based 50% on mimicking antibody CDR-H3 diversity and 50% on 
mimicking evolved affibody sequences in the heavily diversified sites (Figure 2, 20* 
column). There are two exceptions to this balanced design: glycine and arginine. Glycine 
is frequently observed (12%) in antibody CDR-H3, predominantly for conformational 
flexibility52–54, but does not generally support helical structure (Figure 5B) and was not 
enriched in functional variants from the first generation library (Figure 2).  Thus, glycine 
content was set based on equally weighting frequency in homologous proteins (2%) and 
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forecasted frequency in enriched binders (7%, Figure S1), yielding 5% after 
renormalization. Arginine has been shown to correlate with non-specific binding when 
moderately present at binding interfaces54,55. Thus, although arginine was modestly 
enriched in published binders (9% naïve to 12% evolved, though not all studies included 
counter-selections for specificity) and slightly enriched in binders from our first generation 
library (2.6% to 3.5%), arginine content in the second generation library was restricted to 
its frequency in affibody homologs: 3%. This broadly diverse distribution, denoted as B* 
(broad), was designed to facilitate high-affinity, specific binding interactions as well as 
accommodate for stable helices. 
 
4.4.4 Second Generation Library Design: Cysteine 
Cysteine content in the first generation library was higher than designed (Figure S2A) 
and was strongly increased in evolved binders (9% to 18%, p < 0.001) at five broadly 
diversified sites – 10, 13, 14, 17, and 28 – and maintained or reduced at all other sites 
(Figure 6A). Notably, variants with zero or one cysteine were depleted (p < 0.001) in 
evolved binders whereas variants with at least two cysteines were either maintained or 
enriched (p < 0.001, Figure 6B). These sites of cysteine enrichment are spatially clustered 
(Figure 6C) and several pairs exhibit substantial epistasis (Figure 6D). The variants having 
two cysteines predominantly came from the lysozyme binding population with cysteines 
at sites 10 and 28 across four families. Variants with four cysteines were mostly generated 
from the rabbit IgG binding population with cysteines at sites 10, 13, 14, and 17 across 57 
families (Figure S3A). The importance of potential disulfide formation was evaluated by 
assessing thermal stability in oxidizing and reducing environments. Four evolved variants, 
each with unique cysteine locations, exhibited substantially greater thermal stability in the 
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oxidized state (Figure 6E, Figure S3B). Collectively, these observations are consistent with 
the evolutionary benefit of disulfide bonds.  
It is possible that cysteine enrichment resulted from a need for enhanced 
stabilization in light of the extent of diversification including newly varied sites 15 and 31. 
This idea is supported by analysis of the subset of evolved binders with wild-type E15 and 
I31 in which variants with 0 or 1 cysteine are not depleted in the functional population (p 
= 0.16, Figure 6B). Morevoer, in previously published binders from NNK libraries, which 
conserve E15 and I31, only site 28 exhibited cysteine enrichment (Figure 3A). We aimed 
to evaluate the ability to evolve affibody ligands with limited cysteines, both to require 
intramolecular stability in the absence of disulfide bonds and because cysteine-containing 
variants may hinder production in E. coli, increase likelihood of aggregation or oligomer 
formation during purification, and complicate the use of thiol chemistries in downstream 
applications. Thus, in the second generation library experiments an additional broad 
distribution, BLC*, was tested that has lower cysteine frequency (0.5%). 
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Figure 4-6. (A) Cysteine content in the first generation initial library (solid, white 
bars) was higher than intended (striped, light bars) and was strongly increased within 
evolved variants (solid, dark bars) at five broadly diversified sites. (B) The propensity 
of cysteine(s) within single variants from the first generation initial and evolved 
populations as well as a subset of evolved variants where wild-type residues are 
observed at positions E15 and I31 (light gray bars). (C) Cysteine rich positions 
observed within the first generation evolved variants are labeled and highlighted in 
gold. (D) Residue specific epistasis74 was quantified for every observed combination 
of amino acid and position. The three most prominent cysteine pairs within the first 
generation evolved variants are indicated. (E) The change in thermal denaturation 
midpoint (ΔTm) between reducing (red) and non-reducing (black) conditions is shown 
for two high affinity variants with the most prevalent cysteine pairings (indicated 
above each plot). 
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4.4.5 Second Generation Library Design: Broadened Paratope 
Sites 6, 15, 31, and 36 are not traditionally diversified, but natural sequence 
diversity in affibody homologs (Figure 4A), computational mutational tolerance (Figure 
3B), solvent accessibility (Table 1), and amino acid frequency in evolved affibody 
sequences (Figure 2) inform mild diversification at these sites. Natural diversity at site 6 is 
high (Shannon entropy: 0.49, Figure 4). Mutations to E and A in the context of a HER2 
binder were not destabilizing196. The site is exposed to solvent and could be expected to 
interact with target in many cases; in fact the HER2 ligand mutants impacted affinity. Thus, 
mild diversity (NSYT) was tested. Site 15 is naturally diverse (Shannon entropy: 0.39) and 
tolerant of mutation (15 residues), but is pointed away from the paratope and only 38% 
accessible to solvent. Despite 55% E on natural homologs, biased E was strongly depleted 
in binding populations (38% to 18%) from the initial library. Wild-type Q (30% in 
homologs) is conserved in published libraries. S is present naturally (1%) and enriched in 
binders (5% to 15%). V (10% naturally and enriched 3% to 5% in binders) will also be 
considered. Thus, QSEV diversity was allowed. I31 is conserved in previous libraries and 
naturally (96% I; Shannon entropy: 0.08) and is predicted to be poorly tolerant of mutation 
(only eight tolerant residues). Yet it is in the center of the planned paratope and tolerated 
diversity in the first generation library analyses. I was maintained at high levels (33% to 
32%) but most other amino acids were also tolerated with the most significant depletions 
being S (18% to 10%) and Y (11% to 8%). A 30:70 mixture of I and the B* codon was 
used. D36 is conserved in previous libraries and naturally (80% D, 18% E, Shannon 
entropy: 0.20). Yet it is solvent accessible (66%), could be expected to contact target in 
some cases, and is computationally predicted to be tolerant to mutation. Diversity could be 
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beneficial both inter- and intra-molecularly although such diversity should be minimal to 
limit detriment. DN diversity was used. Collectively, these mild diversifications were 
evaluated within the second generation library. 
 
4.4.6 Selections and Evolution from Second Generation Library 
We aimed to evaluate the discovery and evolutionary efficacy of sitewise designs. 
Thus, we competed the second generation library design, GS, versus the traditional NNK 
library with broad, near-uniform diversity. We also included the modified second 
generation library, GSLC, which has reduced cysteine content as well as modifications in 
the genetically coupled amino acid preferences (BLC*, details below). The second 
generation libraries (Table S1 and Figure S1) were synthesized with custom degenerate 
oligonucleotides assembled by overlap extension PCR and introduced into the yeast display 
system by homologous recombination. 1x109 variants were achieved for each of the three 
library designs. High-throughput sequence analysis of each library revealed the expected 
distributions on an amino acid basis (median absolute deviation from design, |fobserved – 
fdesign| = 0.5%; Figure S2B-D). To evaluate generalizable discovery/evolutionary efficacy, 
the pooled libraries were used to identify binders to a broad panel of seven new targets: 
death receptor 5, transferrin, cytochrome C, glucose-6-phosphate dehydrogenase, CD276, 
MET, and a GPCR. Specific binders were discovered and evolved from the combinatorial 
library using yeast display with magnetic and flow cytometry selections (Figure S5B). 
Affibody variants discovered and evolved from the second generation library exhibited 
affinities of 2 ± 2 to 82 ± 23 nM (Figure S6A) with high target specificity (Figure S8). 
Deep sequencing of the evolved variants yielded 6 x104 unique protein sequences in 5 x103 
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diverse families, where families were dictated by having at least 80% homology throughout 
the library positions. 
The study aimed to identify site-specific amino acid preferences consistent with 
evolutionary efficacy for a broad array of epitopes. Thus, multiple targets – each with 
numerous potential epitopes – were used for binder discovery and evolution. While target-
specific – and more importantly, epitope-specific – preferences may be present, the 
diversity of evolved sequences (6x104 unique sequences in 5x103 families) mitigates the 
impact of such biases on the broad analysis. 
 
4.4.7 Library Efficacy Comparison 
The library origin of the evolved binders was determined by probabilistic sequence 
analysis after clustering into families based on 80% similarity (Materials and Methods). 
Variants from the GS library were enriched whereas variants from the NNK library were 
depleted relative to the initial library (p < 0.001, Figure 7), which demonstrates improved 
evolutionary efficiency of the sitewise amino acid preferences in the GS library design. 
This evolutionary benefit of the GS design is even more striking (Figure S7) in a population 
that was further enriched for even stronger affinity binding (0.9 ± 0.1 to 5 ± 2 nM affinities; 
Figure S6). These results summarize the collective advantage of sitewise constraint in 
evolutionary discovery. Additional analyses and experiments, which follow, were 
performed to further elucidate the molecular aspects of this advantage. 
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Figure 4-7. Enrichment of second generation libraries. Sequences were analyzed for 
the likelihood of originating from either the NNK, GS, or GSLC library designs. The 
change in prevalence (frequency in functional population – frequency in naïve 
library) between the initial library and binding populations is shown. Significant 
enrichment of the GS library was observed at the expense of depletion of both NNK 
and GSLC (p < 0.001 for GS vs. each). 
 
GS was also superior to GSLC, which only differed in the codon design at the nine 
broadly diversified sites. Thus, the evolutionary preference for the B* codon design over 
the BLC* codon was examined to elucidate relative efficacies of each amino acid. As noted, 
the motivation to create BLC* was to reduce cysteine content (2.5% to 0.5%) to isolate 
disulfide-free and thiol-free binders. Unlike the first generation library, in the context of 
additional amino acid diversity constraint in the second generation library, the cysteine 
content is depleted during evolution (Figure 8). In particular for the GS library, variants 
with two or more cysteines are dramatically reduced (59-fold for two-cysteine variants and 
51-fold for three-cysteine variants). Cysteine depletion is observed during evolution of 
binders from the NNK library but to a reduced extent (2- and 28-fold for two- and three-
cysteine variants, respectively) relative to the sitewise constrained library. 
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Figure 4-8. From the second generation libraries, both the NNK and GS designs yielded 
fewer cysteines in the evolved populations compared to the initial libraries. The absolute 
(A) and relative (B) changes in frequency are shown. These modest levels were even 
slightly depleted among evolved variants. 
 
Via genetic code coupling, cysteine reduction also results in reduction of F, S, L, 
Y, W, G, and R; the aim for the antibody- and first generation affibody-inspired amino acid 
distribution also results in increase of D, E, H, K, N, and Q (Figure 9A). Of the amino acids 
with higher frequency in the initial B* codon sites vs. BLC*, W and L are enriched and F 
and Y are maintained at high levels upon binder evolution (Figure 9BC). Conversely, S, 
G, R, and C are depleted. This is consistent with evolutionary benefit of these aromatics 
and hydrophobics leading to superiority of B* despite the evolutionary inefficiency of S, 
G, R, and C. Notably, the results support the aforementioned rationalized reduction of G 
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and R relative to antibody CDR-H3. Of the amino acids with lower frequency in the initial 
B* codon sites vs. BLC*, H, K, N, and Q are reduced or maintained at low levels. 
Conversely, E is enriched and D is maintained at a high level. These results suggest that 
depleted H, K, N, and Q also contribute to B* superiority vs. BLC* whereas depleted E 
hinders B*. 
 
Figure 4-9. Nine sites were offered at least 50% GS/GSLC diversity (Q10, Y14, L17, H18, 
E25, N28, I31, Q32, K35). A comparison between the initial and evolved amino acid 
frequencies at these sites is shown. (A) Individual frequencies for each of the three 
sub-libraries. (B) Absolute and (C) relative changes in frequency. 
 
4.4.8 Sitewise Amino Acid Frequencies 
Sitewise amino acid frequencies (Figure 10) provide valuable insight to elucidate 
the evolutionary benefit of the constrained GS design as well as to guide further refinement. 
P, Q, K, and C are consistently depleted at broadly diversified sites in evolved binders. S 
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is depleted at all but site 18. The aforementioned benefit of W is especially observed at 
sites 14 and 17, adjacent sites on the ‘top’ of helix 1, and is also mildly enriched at other 
sites. Two other residues that benefit B* relative to BLC*, F and L (and homolog I), are 
generally enriched in helix 2. 
At site 9, enrichment of W (16% to 31%) and L (12% to 21%), as well as 
maintenance of large hydrophobic M (5%), in evolved binders demonstrates the value in 
constraining diversity to increase the initial frequencies of these residues within the GS 
library. Yet depletion of the remainder of the constrained subset suggest further constraint 
to WLM could be advantageous to both increase the frequency of these beneficial residues 
and decrease the frequency of detrimental options, especially cationic R (17% to 5%) and 
K (7% to 2%). At site 11, which is relatively exposed (51% SASA), the strong hydrophilics 
D and N are enriched whereas the mid-hydrophilics S, Y, T, and A are depleted. Thus, the 
GS design benefits from D and N bias but is hindered by bias to S, Y, T, and A. At site 13, 
aromatics (F and Y) and hydrophobics (F, I, and V from already elevated initial 
frequencies; and L from rare mutagenic PCR (0.1% to 0.7%)) were enriched in evolved 
binders whereas hydrophilics (D, N, S, and T) and the small A were depleted. Further 
hydrophobic constraint of this modestly buried site (27% SASA) to FLIV would likely 
provide additional benefit. Site 24 (88% SASA) generally tolerates its relatively broad 
diversity. The reasonably buried (27% SASA) site 27, benefits from bias to hydrophobic I 
and V, which are strongly enriched in evolved binders, but is hindered by bias to R, K, M, 
and L, which are depleted upon evolution. 
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Figure 4-10. The changes in frequency between the initial and evolved populations are 
shown for the GS (left side of each column) and GSLC (right) design campaigns. Bolded 
sites indicate the nine broadly diversified positions. These nine sites are averaged in 
the BGS column on the right. 
 
Strong wild-type enrichment is observed at several of the newly diversified sites 
(Figure 10 and Figure 11A). At site 15, wild-type E enrichment is countered by depletion 
of S and V while wild-type homolog Q is slightly enriched. At site 31, in addition to wild-
type I, homolog L and similar hydrophobe V are enriched while numerous amino acids are 
depleted. Site 36 reveals a more modest shift in its wild-type, D, along with significant 
depletion of the alternative mutant offering, N. At site 6, the Z-domain wild-type N is 
depleted, as well as T; S is maintained, and Y is enriched. Notably, alanine, conserved in 
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the first generation library because of its benefit in the optimized affibody backbone196 and 
able to appear in second generation via mutagenic PCR and homologous recombination 
with linearized vector encoding for A, is enriched. As a result of these wild-type 
preferences, variants with mutation at three or four of these newly diversified sites are 
depleted (Figure 11B). Interestingly, though wild-type conservation is modestly preferred 
at site 36, mutation is strongly enriched in evolved binders if it is the only mutation within 
this set of newly diversified sites (Figure 11D) or it occurs in tandem with mutation at site 
6 (Figure 11E); but co-mutation of site 36 with site 15 or 31 is depleted in binders. Dual 
mutation of 15 and 31, with or without further mutation at sites 6 or 15, is strongly depleted. 
Overall, in evaluation of the newly created diversity at sites 6, 15, 31, and 36, mild diversity 
is tolerable, but further constraint from the second generation design would benefit 
evolutionary efficiency. The ability of the GS library to outperform NNK despite the 
detrimental over-diversification of these sites indicates significant evolutionary value to 
the other modifications: B* codon biased diversity rather than NNK at broadly diversified 
sites and constrained diversity at sites 9, 11, 13, 24, and 27. Analysis of the traditionally 
diversified 13 sites in functional variants reveals 13-fold enrichment of variants of 
constrained design (Figure 12). 
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Figure 4-11. Among the four newly diversified sites, the tendency for wild type 
conservation or diversification is shown. (A) The frequency of variants having a 
residue other than wild type at each site. (B) The distribution of variants from either 
the initial or evolved populations having exactly 0, 1, 2, 3, or 4 non-wild type amino 
acids. (C) Frequency of clones having WT at all four newly diversified sites. 
Frequency of (D) single, (E) double, and (F) triple mutants exclusively at the 
position(s) listed on the x-axis. The sequences analyzed in panels A, B, D, E, and F all 
meet the requirement of originating from the GS library based on probabilistic 
calculations at all 17 diversified sites. However, the sequences contributing to panel 
C meet the requirement of originating from the GS library based on probabilistic 
calculations at only the thirteen traditionally mutated sites (†GS13-Sites). 
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Figure 4-12. Wild-type (WT) composition at four newly diversified sites. Sequences were 
placed into one of two bins: one where variants were entirely WT at all four newly 
diversified positions (A6, E15, I31, D36); a second bin collected the variants that 
contained a non-WT amino acid at any of the four new sites. Within each bin, 
sequences were analyzed at the 13 classically diversified positions for the likelihood 
of having originated from either the NNK or GS library design. 
 
The NNK library provides a naïve design benchmark, which demonstrated the 
overall evolutionary advantage of the GS library (Figure 7), and can also assess the merit 
of sitewise amino acid preferences. The change in sitewise amino acid frequencies from 
the initial NNK library to binders evolved from the NNK library (i.e. observed 
experimental evolution) were compared to the changes designed into the constrained sites 
of the GS library (i.e predicted to benefit evolution) (Figure 13A). Experimental values 
correlate with predicted design (slope = 0.23 ± 0.05; p < 0.001). For comparison, evaluation 
of evolution away from the GS library indicates negligible correlation (slope = 0.03 ± 0.04; 
p = 0.38; Figure 13B). This further supports the evolutionary merit of the GS design relative 
143 
 
to naïve NNK. Evaluation of experimental vs. design correlation at each site reveals 
comparable correlation at most sites with especially strong correlation at site 17 – driven 
by predicted enrichment of Y and D  as well as depletion of R – and lack of correlation at 
sites 9, 24, and 28 (Figure S4). Overall, the sitewise biases of the GS library design have 
proven superior to the broad, near-uniform NNK library for binder evolution. 
 
 
Figure 4-13. Evaluating predicted diversity. (A) The observed frequency change 
reflects the shift in amino acid frequency that was observed within variants having 
originated from the NNK library design. The predicted frequency change shows the 
absolute difference in amino acid frequencies between the GS and NNK design. 
Observed Change from NNK: fAA i, site j (NNK evolved) – fAA i, site j (NNK initial). Predicted 
Change from NNK: fAA i, site j (GS design) – fAA i, site j (NNK initial). The 95% prediction interval 
is shown. (B) Similar analysis to (A), however, it evaluates the predicted and observed 
mutations away from the GS design. Observed Change from GS: fAA i, site j (GS evolved) – 
fAA i, site j (GS initial). Reverted Change from GS: fAA i, site j (NNK design) – fAA i, site j (GS initial). 
 
4.4.9 Stability 
Constrained diversity is designed, in a sitewise manner, to elevate the frequency of 
evolutionary beneficial amino acids while reducing the frequency of detrimental residues 
to search more fruitful regions of sequence space. One expected mechanism of this 
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hypothesis is that select detrimental residues destabilize the scaffold thereby precluding 
potentially effective binding paratopes because of entropic cost261,262 or enthalpic 
destabilization beyond a foldable limit21,210.  It has been shown that more stable scaffolds 
enable improved evolution21,210,263. A related, but distinct, hypothesis is that reduced 
destabilization upon mutation improves evolvability. That is, a combinatorial library that 
contains variants that are less destabilized will contain a higher fraction of folded variants 
as well as less entropic penalty upon binding (Figure 14A). To partially address this 
hypothesis, thermal stabilities of several evolved binders were measured by thermal 
denaturation and circular dichroism spectroscopy (Figure S5A). Random binding variants 
evolved from the GS library exhibit higher thermal stabilities (Tm = 62 ± 4ºC) than variants 
from NNK libraries either in the current study (Tm = 42 ± 12ºC; p = 0.02) or in the literature 
(49 ± 8ºC, p < 0.001) (Figure 14B). Notably, the NNK-based binders from the current study 
are not more stable than NNK-based binders in the literature. Thus, the eukaryotic 
expression machinery of yeast surface display (compared to phage display selections from 
literature) is not responsible for stability enhancement. Rather, the amino acid constraint 
in the GS library design accounts for this stabilization. 
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Figure 4-14. GS library design yields stable variants. (A) Hypothetical stability 
distributions of mutant populations derived from a single starting point (i.e. parental 
clone). A parental clone (vertical solid line labeled ∆Gf,0) is randomly mutated, 
yielding a population with distributed stability. Properly folding proteins are located 
to the left of the dashed line where the free energy of folding is negative (shaded 
region). A base case is shown in the top panel. The middle panel presents a more stable 
parent (∆Gf,0 = -3) with an equivalent broad distribution of destabilization as the base 
case (∆∆Gf = 3). A third example is shown in the bottom panel where the parental 
clone has equivalent stability to the base case (∆Gf,0 = -3); however, upon mutation, 
destabilization is observed to a much lesser extent throughout the population. This 
illustrates situations where, relative to the base case, an increased fraction in 
functional variants is attainable using either a more stable starting point or reduced 
destabilization upon mutation. (B) Clonal stability of several high-affinity binders 
were analyzed using circular dichroism. Randomly chosen clones having originated 
from either the gradient sitewise (GS) or NNK design are shown alongside stability 
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measurements previously reported in the literature. Average stabilities (green bars) 
were found to be 49 ± 8, 42 ± 12, and 62 ± 4 °C for published, NNK, and GS variants, 
respectively. (C) The relative sequence space afforded by each of the libraries 
discussed in this work: first generation (Gen 1; gray), traditional design (NNK; 
green), and second generation (GS; gold). Sequence diversity coverage shared 
between Gen 1 and GS is highlighted in blue. Sequence space existing within both 
NNK and GS is shown in red between green and blue regions. Relative to NNK (13 
library sites), the theoretical sequence diversity of GS (17 sites) and Gen 1 (15 sites) 
are larger by 10- and 400-fold, respectively. 
 
The improved performance of the GS library was achieved by biasing amino acid 
diversity, including eliminating select amino acid options, within the 13 sites traditionally 
diversified while also expanding diversity by varying four previously conserved sites. The 
constraint reduced possible sequence space 80-fold and also biased the search of the 
possible space by preferential occurrence of select amino acids. This biased diversity was 
13 ± 3 fold more effective than uniformly applied NNK diversity (Figure 12). The 
introduced diversity at sites 6, 15, 31, and 36 increased sequence space 800-fold; variants 
with 0-2 mutations, particularly at sites 6 and 36, were found to be evolutionarily effective 
whereas triple and quadruple mutants were less functional (Figure 11). Thus, while 
diversity at these sites is functional, they would benefit from further bias. Overall, the GS 
library has a 10-fold greater potential sequence space (Figure 14C), but searches this space 
in a more biased manner than the NNK library. The average uniformity of diversity, as 
measured by Shannon entropy, of the NNK library is 0.97 versus 0.74 for the GS library 
(Figure S9). Overall, the result of the sitewise bias in the GS library is a higher frequency 
of binder discovery (Figure 7, Figure S7) and more stable binders (Figure 14B). 
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4.5. Conclusions 
In this study, amino acid frequency distributions for each site in a combinatorial 
affibody library were designed from a multitude of inputs: high-throughput binder 
evolution, computed mutant stabilities, target accessibility, helical propensity, chemical 
complementarity, and frequency in natural homologs. We evaluated the efficiency of the 
gradient sitewise (GS) design by direct competition of multiple libraries in the context of 
binder discovery against a collection of protein targets.  Site-specific amino acid bias, as 
well as introduced diversity at four additional positions, in the GS library enabled more 
efficient evolution than the traditional approach of homogeneous diversity across all 
diversified sites in the NNK library. Analysis indicates that GS’s evolutionary benefit 
resulted from the sitewise constraint and in spite of the broadened diversity at sites 15 and 
31. Amino acid preferences, both overall and at select sites, were revealed. The first 
generation library, designed to explore sitewise amino acid preference from a broad range 
of paratopes, exhibited much broader diversity than optimal, as assessed by sitewise 
frequencies in evolved repertoires. In fact, these ‘overdiversified’ paratopes frequently 
required cysteine pairs to achieve functionality. Conversely, reduction of undesirable 
amino acids at select sites in the second generation library greatly reduced the presence of 
cysteine pairs in evolved clones. Moreover, the sitewise bias yielded variants of higher 
stability (15ºC higher midpoint of thermal destabilization) than NNK-based variants. 
Evolutionary efficiency benefits from increased frequency of not only amino acids that 
drive intermolecular interactions but also intramolecularly tolerated mutants that reduce 
destabilization. Overall, the library design approach favoring constrained amino acid 
diversities that take into account complementarity, amino acid frequencies in previously 
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discovered binders, diversity in natural homologs, and solvent exposed surface area 
produces binding ligands more efficiently than the unconstrained NNK library design in 
the affibody scaffold. 
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Table S4-1. Wild-type affibody sequence and library design summary. The diagram 
compares traditional design (NNK), first generation (Gen 1), and gradient sitewise (GS) library 
designs, as well as framework mutations established by Feldwisch, et al.196 The traditional design 
uniformly diversifies thirteen sites with an NNK degenerate codon. The first generation design 
broadly diversifies ten sites and provides a gradient of diversity at five sites. 
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Figure S4-1. Comparison of broad diversity codon design. (A) Amino acid frequencies for 
broadly diversified sites within the first (20*) and second (B* and BLC*) generation gradient 
sitewise (GS) library designs. The primary second generation GS design (B*) mimics natural 
antibody repertoires (Abysis database) and frequencies forecasted from evolved affibodies (B) 
while also emphasizing reduced levels of glycine, motivated by low the low helix propensity 
observed in previous studies249–254, and potentially non-specific arginine49,54,55. The BLC* codon 
design resembles B* while also reducing the cysteine content. Note that because degenerate 
codons were used to implement 20*, B* and BLC* designs, additional restrictions were imposed 
by the genetic code. (B) Affibody sequences from existing literature and high-throughput 
sequence analysis of binders selected from the first generation affibody library were aggregated. 
The amino acid frequencies associated with both the initial libraries and evolved populations are 
shown. The ‘forecast’ is based on an extrapolation from the trend observed between the initial 
and evolved populations as described by: fforecast = fbinder + 0.25(fbinder – finitial). 
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Figure S4-2. Design vs observed initial libraries. Sitewise comparison between design and 
observed amino acid frequencies (fobserved–fdesign) within the initial populations of the first 
generation library (A) and for each of the three second generation library designs: (B) NNK, (C) GS, 
(D) GSLC .  
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Figure S4-3. First generation evolved binder campaign cysteine content and stability. 
(A) Cysteine content within individual target campaigns using the first generation affibody library 
is shown. The sites contributing to the most enriched cysteine motifs are indicated for each 
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campaign. Aggregate data was calculated by weighting the relative number of family clusters from 
each campaign where rabbit IgG outnumbered lysozyme 479 vs 44. (B) Thermal stability of 
cysteine-rich clones was evaluated using circular dichroism under reducing (2mM DTT, red) or 
non-reducing (0mM DTT, black) conditions. The 220 nm wavelength was monitored over a range 
of temperatures. Cysteine positions are labeled above each denaturation plot and variant names 
are indicated on the lower right (e.g. “AαrIgG-1”). 
A 
 
B 
  
Aα rIgG-1 AαLyso-1 
Aα rIgG -2 Aα rIgG -3 
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Figure S4-4: Predictive analysis of GS vs NNK library designs. Observed and predicted 
changes in sitewise amino acid frequencies were calculated within variants determined, via 
maximum posterior probability, to have originated from the NNK library. The observed frequency 
change reflects the change in amino acid frequency that was observed upon discovery and 
evolution: ∆fobs = fAA i, site j (NNK evolved) – fAA i, site j (NNK initial). The predicted frequency change shows the 
absolute difference in amino acid frequencies between the GS and NNK design: ∆fpred = fAA i, site j (GS 
design) – fAA i, site j (NNK initial). ∆fobs was plotted versus ∆fpred for each site (with each amino acid providing 
a data point for each site). (A) The slope (± standard deviation) of the linear regression of ∆fobs vs. 
∆fpred. (B) The ∆fobs vs. ∆fpred plots for the two sites having the highest (i.e. ‘Best Predictions’) and 
lowest (i.e. ‘Worst Predictions’) slopes and their respective 95% prediction intervals.  
A 
 
B 
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Table S4-2: Sitewise amino acid frequencies from natural homolog sequences of affibody, Pfam family B(PF02216). The 
most 
frequently observed amino acids for each site are listed at the bottom. Values are shown as percentages. 
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Sitewise Design of Second Generation Library  
At site 9, low SASA (19%), constrained homolog sequences (Shannon entropy: 0.12), and poor 
theoretical mutational tolerance (only seven residues tolerated at 1.5 kcal/mol) motivate 
sequence constraint while position near the center of the paratope supports mild diversity. Wild-
type Q appears 93% in homologs, is maintained (3 to 4%) in binders, and is predicted to be stable. 
L, M, and R occur naturally, are predicted to be stabilizing, and increase in binding populations. 
Aggregate data from gradient library evolved binders and previously published binders show an 
increase in W from 2% to 7%. V and K are predicted to be stable and enriched in binders. Note 
that constrained N decreases 37% to 20% in the gradient library. Thus, QLMRRK/VWLG (G part of 
degenerate codon) was chosen for diversity. Site 10 is naturally constrained (87% Q, 12% N, and 
1% W) but is well-exposed (66% SASA) and tolerant of mutations theoretically (13 tolerant amino 
acids) and in evolved binders. B* diversity was used. N11 shows reasonable solvent exposure 
(51%), albeit with only modest proximity to the paratope core. It is naturally diverse (Shannon 
entropy: 0.37) and predicted tolerant of mutation (19 tolerant amino acids). N and A occur 
naturally (60% and 12%), are prevalent in binders (8% and 8% from 10% and 6%), and predicted 
to be stable. S occurs 18% naturally and is predicted to be stable, although it is depleted from 
binders (10% to 6%). D, Y, and T also appear in the NAS degenerate codon. D is maintained in 
binders (3% to 4%). Y is predicted to be stable and is prevalent in antibody CDRH3, although 
slightly depleted at this site in evolved binders. T is predicted to be stable and maintained at 6% 
in binders. NASTDY was used. At F13, binder sequences and FoldX stability calculations (11 
tolerated amino acids) indicate a modest tolerance for mutation, while homology shows 
significant conservation (Shannon entropy: 0.16), and the sidechain is reasonably buried (33%). 
The following amino acids are enriched in binders: A (5% to 15%), T (6% to 10%), Y (7% to 8%), W 
(2% to 5%). Yet W is predicted to be highly destabilizing. F is naturally frequent (86%) and 
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maintained at 4% in binders. Moderate diversity (FYAT, which includes VINDS on the degenerate 
codon) was afforded in the subsequent library. S is tolerated and modifies from 10% in libraries 
to 8% in binders. V is stable and maintained at 5% in binders. I is present naturally, predicted to 
be stable and mildly enriched from 4% to 5% in binders. D and N are mildly destabilizing and 
slightly depleted in binders. Site 14 is exposed (72%), naturally diverse (Shannon entropy: 0.3), 
and tolerant (17 amino acids tolerant). Broad diversity was incorporated. Additionally, the strong 
increase in G (5% to 17%) and W (2% to 8%), both underrepresented in B*, may benefit the 
evolvability. Thus, a mixture of 95% B* and 5% GW was used (to yield 5% G). L17 is near the middle 
of the binding paratope and reasonably naturally diverse (Shannon entropy: 0.30) although only 
40% solvent accessible and poorly tolerant of mutation. Binders have elevated levels of V (5% to 
16%), W (2% to 12%), G (5% to 9%), D (3% to 6%), and Y (7% to 8%). The two dominant naturally 
occurring side chains, L (74%) and K (12%), are depleted (8% to 4% for L; 3% to 2% for K) in binders 
while two other naturally occurring residues, R (9%) and Y (1%), are enriched (8% to 9% for R; 7% 
to 8% for Y). To better match the amino acid observed within binder sequences, this site received 
both 86.5% broad diversity (B*) and 13.5% WGR to yield 5% W, 6% G, and 5% R. Site H18 used B* 
diversity because of broad tolerance (19 stable residues), reasonable diversity in nature (Shannon 
entropy: 0.28), and high exposure (67% SASA).  
Within the second helix, site 24 is well-exposed (88%), naturally diverse (Shannon entropy: 0.32), 
and tolerant (19 tolerant residues). The breadth of diversity suggests B* although Y and S – 
frequent in B* – are depleted in binders (7% to 3% and 10% to 5%) while R and G – rare in B* – 
are enriched (8% to 13% and 5% to 9%). Two amino acids coupled in the genetic code to Y and S 
are not desired: C and F are depleted in binders (4% to 1% and 4% to 3%), although W is enriched 
(2% to 5%) and modestly stable. Thus, a diverse codon encoding 16 amino acids aside from C, F, 
and Y (and also W, unfortunately) was used. Site 25 is well-exposed (90%), naturally diverse 
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(Shannon entropy: 0.42), stable to mutation (all 20 residues tolerant within 1.5 kcal/mol), and 
diverse in binders. B* diversity was used. Site 27, while near the center of the paratope and mildly 
diverse naturally (Shannon entropy: 0.28), is fairly buried (27%) and relatively unstable to 
mutation (only 10 tolerant residues). Wild-type R and fellow cation K are frequent in homologs 
(78% and 12%), stable, and enriched in binders (13% to 20% and 3% to 16%). Small-to-medium 
hydrophobics (A, I, L, M, and V) are also predicted to be stable and reasonably maintained in 
binder development (6% to 5%, 4% to 4%, 8% to 6%, 2% to 4%, and 6% to 9%). RKVMIL was used. 
Site 28 is exposed (71%), near the paratope center, and predicted to be tolerant of mutation (16 
tolerant amino acids) although constrained naturally (95% N; Shannon entropy: 0.09). Only P is 
strongly depleted in binders (6% to 1%) while S (10% to 6%) and Y (7% to 4%) are mildly depleted. 
B* diversity was used. Site 32 is exposed (72%) although pointed slightly away from the paratope 
core. It is naturally diverse (Shannon entropy: 0.3), predicted to be tolerant to mutation (17 amino 
acids), and exhibits broad diversity in binders (with the exception of proline depletion at 6% to 
1%). Enriched amino acids include R (8% to 15%), K (3% to 7%), G (5% to 9%), and A (5% to 9%). 
B* diversity was used. Site 35 is well-exposed (76%) and predicted tolerant (16 residues) although 
naturally conserved (86% K, 11% R, Shannon entropy: 0.19). Binders exhibit reasonable diversity 
although numerous residues are mildly depleted in exchange for enrichment of W (2% to 11%), Y 
(7% to 12%), E (2% to 5%), F (4% to 6%), and L (8% to 10%). B* diversity was used. 
Sites 6, 15, 31, and 36 are not traditionally diversified. Natural diversity at site 6 is high (Shannon 
entropy: 0.49), and mutations to E and A in the context of a HER2 binder were not destabilizing196. 
The site is exposed to solvent and could be expected to interact with target in many cases; in fact 
the HER2 ligand mutants impacted affinity. Mild diversity (NSYT) was tested. Site 15 is naturally 
diverse (Shannon entropy: 0.39) and tolerant of mutation (15 residues), but is pointed away from 
the paratope and only 38% accessible to solvent. Despite 55% E on natural homologs, biased E 
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was strongly depleted in binding populations (38% to 18%) from the gradient library. Wild-type Q 
(30% in homologs) is conserved in published libraries. S is present naturally (1%) and enriched in 
binders (5% to 15%). V (10% naturally and enriched 3% to 5% in binders) will also be considered. 
Thus, QSEV diversity (on three separate oligonucleotides) was allowed. I31 is conserved in 
previous libraries and naturally (96% I; Shannon entropy: 0.07) and is predicted to be poorly 
tolerant of mutation (only eight tolerant residues). Yet it is in the center of the planned paratope 
and tolerated diversity in the gradient library analyses. I was maintained at high levels (33% to 
32%) but most other amino acids were also tolerated with the most significant depletions being 
S (18% to 10%) and Y (11% to 8%). A 30:70 mixture of I and the B* codon was used. D36 is 
conserved in previous libraries and naturally (80% D, 18% E, Shannon entropy: 0.21). Yet it is 
solvent accessible (66%), could be expected to contact target in some cases, and is predicted to 
be tolerant to mutation. Diversity could be beneficial both inter- and intra-molecularly although 
such diversity should be minimal to limit detriment. DN diversity was used. 
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Table S4-3: Second generation library design summary table. Top – Description of amino acids allowed at each site. When 
a residue is listed multiple times, it indicates the relative abundance of the residue at that site.  Bottom – Degenerate codons are 
listed that encode for the amino acids at each site.  
 
 
 
(B) Oligonucleotide sequences used for the construction and assembly of the second generation libraries.  
Name Sequence 
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B_a-a-a-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)SAGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACC
TGACC 
B_a-a-b-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)TCCATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCT
GACC 
B_a-a-c-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)GTGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACC
TGACC 
B_a-a-a-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)SAGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-a-b-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)TCCATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-a-c-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)GTGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-b-a-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGSAGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-b-b-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGTCCATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-b-c-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGGTGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-b-a-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGSAGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-b-b-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGTCCATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-b-c-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGGTGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-a-a-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)SAGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCT
GACC 
B_b-a-b-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)TCCATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCT
GACC 
B_b-a-c-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)GTGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCT
GACC 
B_b-a-a-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)SAGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-a-b-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)TCCATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-a-c-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHC(N1)(N2)(N3)GTGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-b-a-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGSAGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-b-b-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGTCCATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-b-c-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGGTGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-b-a-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGSAGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-b-b-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGTCCATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_b-b-c-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:09153739)(N2:37250830)(N3:00402040)DMCGCGDHCKGGGTGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_a-a-a-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)SAGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACC
TGACC 
Bc_a-a-b-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)TCCATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCT
GACC 
Bc_a-a-c-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)GTGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACC
TGACC 
Bc_a-a-a-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)SAGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_a-a-b-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)TCCATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
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Bc_a-a-c-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)GTGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_a-b-a-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGSAGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_a-b-b-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGTCCATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_a-b-c-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGGTGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_a-b-a-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGSAGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_a-b-b-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGTCCATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_a-b-c-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAMDG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGGTGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-a-a-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)SAGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCT
GACC 
Bc_b-a-b-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)TCCATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCT
GACC 
Bc_b-a-c-a
 GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)GTGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCT
GACC 
Bc_b-a-a-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)SAGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-a-b-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)TCCATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-a-c-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHC(N1)(N2)(N3)GTGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-b-a-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGSAGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-b-b-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGTCCATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-b-c-a GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGGTGATC(N1)(N2)(N3)(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-b-a-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGSAGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-b-b-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGTCCATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
Bc_b-b-c-b GGTTCTGCTAGCGCCGAAGCAAAATACWMCAAAGAAKKG(N1:18223822)(N2:55250317)(N3:00353035)DMCGCGDHCKGGGTGATCBGG(N1)(N2)(N3)CTGCCGAACCTGACC 
B_a-a CTGCCGAACCTGACCSNS(N1:09153739)(N2:37250830)(N3:00402040)CAGARA(N1)(N2)(N3)GCATTCATC(N1)(N2)(N3)GCACTG(N1)(N2)(N3)RACGACCCGTCCCAGAGCTCTG 
B_a-b CTGCCGAACCTGACCSNS(N1:09153739)(N2:37250830)(N3:00402040)CAGARA(N1)(N2)(N3)GCATTC(N1)(N2)(N3)(N1)(N2)(N3)GCACTG(N1)(N2)(N3)RACGACCCGTCCCAGAGCTCTG 
B_b-a CTGCCGAACCTGACCSNS(N1:09153739)(N2:37250830)(N3:00402040)CAGVTR(N1)(N2)(N3)GCATTCATC(N1)(N2)(N3)GCACTG(N1)(N2)(N3)RACGACCCGTCCCAGAGCTCTG 
B_b-b CTGCCGAACCTGACCSNS(N1:09153739)(N2:37250830)(N3:00402040)CAGVTR(N1)(N2)(N3)GCATTC(N1)(N2)(N3)(N1)(N2)(N3)GCACTG(N1)(N2)(N3)RACGACCCGTCCCAGAGCTCTG 
Bc_a-3 CTGCCGAACCTGACCSNS(N1:18223822)(N2:55250317)(N3:00353035)CAGARA(N1)(N2)(N3)GCATTCATC(N1)(N2)(N3)GCACTG(N1)(N2)(N3)RACGACCCGTCCCAGAGCTCTG 
Bc_a-3 CTGCCGAACCTGACCSNS(N1:18223822)(N2:55250317)(N3:00353035)CAGARA(N1)(N2)(N3)GCATTC(N1)(N2)(N3)(N1)(N2)(N3)GCACTG(N1)(N2)(N3)RACGACCCGTCCCAGAGCTCTG 
Bc_b-3 CTGCCGAACCTGACCSNS(N1:18223822)(N2:55250317)(N3:00353035)CAGVTR(N1)(N2)(N3)GCATTCATC(N1)(N2)(N3)GCACTG(N1)(N2)(N3)RACGACCCGTCCCAGAGCTCTG 
Bc_b-3 CTGCCGAACCTGACCSNS(N1:18223822)(N2:55250317)(N3:00353035)CAGVTR(N1)(N2)(N3)GCATTC(N1)(N2)(N3)(N1)(N2)(N3)GCACTG(N1)(N2)(N3)RACGACCCGTCCCAGAGCTCTG 
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Figure S4-5: Biophysical characterization. (A) Circular dichroism was used to assess 
secondary structure and thermal denaturation for several clones. The molar ellipticity of a 
representative affibody clone is shown over a range of temperatures and wavelengths. The 
thermal stability (i.e. midpoint of thermal denaturation) was obtained while monitoring a 
wavelength of 220nm. All clones demonstrated the ability to refold upon cooling, as shown on 
the right. (B) Flow cytometry was used to isolate clones having high-affinity. High stringency 
populations were obtained using 100-150 nM target protein labelling conditions and collecting all 
double positive events (red box). From the high stringency population, an additional sort was 
done under more stringent conditions (5 nM target) to yield the ultra-high stringency populations 
(red triangle). Representative binding populations are shown. 
A 
 
B 
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Figure S4-6: Affinity titration of high (A) and ultra-high (B) stringency variants. 
Randomly selected variants were isolated using either high (100-150 nM) or ultra-high (5 nM) 
stringency sorting conditions. Each variant was incubated at a range of concentrations, then 
analyzed via flow cytometry to measure the fraction of displayed protein bound to the target of 
interest. Panel A indicates the binding affinities (KD; mean ± standard error; n=3) of representative 
clones from each target campaign. Panel B shows binding affinities for two representative unique 
variants from three target binding campaigns. 
A 
 
B 
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Figure S4-7: Library of origin comparison for high and ultra-high stringency 
variants. The posterior probabilities of individual strong binding variants having originated from 
the NNK, GS, or GSLC library were calculated. High-throughput sequencing analyzed the high 
stringency dataset while Sanger sequencing was used for the ultra-high stringency set. The change 
in frequency indicates the difference in likelihood of observing a library member within the 
evolved binding population versus the initial library, fBinders – fInitial. A positive change in frequency 
reflects the preference of a particular library among highly functional variants. Statistical 
significance (*, p < 0.001) is shown between the change in frequency observed for the GS and 
NNK libraries as well as the extent of GS preference between the high and ultra-high stringency 
populations. 
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Figure S4-8: Specificity analysis for high stringency variants. Yeast displaying, 
separately, one representative evolved clone from each target binding campaign, were labeled 
with either the target of interest (50 nM) or non-target protein (100 nM). Binding was detected 
by flow cytometry. Note that the G6PDH binder was screened against only three non-target 
proteins. For calculating the fraction bound, maximum binding signal was established via the 
median fluorescence of strong binding variants under saturating conditions.   
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Figure S4-9: Diversity distributions. The diversity at each site is quantified as Shannon 
entropy for the three library designs. Traditional affibody libraries diversify thirteen sites, each 
with the NNK codon (Shannon entropy = 0.97). The first generation design offered a gradient of 
diversities at fifteen sites where Shannon entropy ranged from 0.68 to 0.87, averaging 0.82. The 
second generation (GS) design included a gradient of diversities at seventeen sites. Shannon 
entropy of sites within the GS design ranged from 0.23 to 0.92, averaging 0.74. 
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Chapter 5 – Concluding Remarks and Future Work 
5.1. Designed constrained libraries are more efficient at protein discovery and yield 
more stable molecules 
In the collection of work described here, the impact of sitewise diversification is 
thoroughly assessed by discovering and evolving high affinity binders in a high-throughput 
manner using combinatorial libraries. The generalizability of this approach is further 
validated by using multiple small protein scaffolds: 10 kDa beta-sandwich fibronectin with 
diversified solvent exposed loops and a 7 kDa three-helix bundle protein with diversified 
helices.  In each case, a gradient of sitewise diversity was observed within the enriched 
binding populations. These results demonstrating constrained diversity are consistent with 
the binding interfaces found within natural ligand libraries (i.e. antibody repertoires), yet 
have been mostly absent from library design schemes of synthetic proteins prior to this 
work. Our results indicate that a constrained library design, compared to broad, uniform 
diversity, generates a larger variety of lead clones able to specifically bind a broad 
collection of targets. Within an under constrained and overly destabilized library setting, 
while the average library member performs suboptimally, rare sequences with stabilizing 
features such as disulfide bonds are dominantly enriched during selection. To overcome 
the need for disulfide-rich variants, several data sets (high-throughput sequences from 
evolved populations, computed stability, phylogenetic analysis, etc.) were collectively 
used to guide amino acid diversity at individual sites. The resulting library, consisting of 
sitewise amino acid bias, yields evolved variants with higher thermal stability. This 
provides evidence in support of the hypothesis that reduced destabilization improves 
evolvability. That is, a higher fraction of folded variants is achievable using a combinatorial 
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library containing variants that are less destabilized. Based on the ability to discover a 
broader collection of lead variants and the tendency of those variants to have superior 
thermal stability, we conclude that a gradient of sitewise diversity is more efficient at 
evolving high-affinity binding ligands. 
Our high-throughput discovery approach was able to demonstrate that a single 
protein target can yield hundreds of diverse families of binders (i.e. subpopulation of 
sequences sharing a common motif with >80% sequence homology among members of the 
cluster). The distinct features between each sequence family suggest that a variety of 
epitopes are being offered by the target. Having several options for lead clones that interact 
with unique target epitopes improves the likelihood of being able to elicit the intended 
effect.264 This presumption of diverse epitopes would benefit from further characterization. 
This could be accomplished using epitope mapping of the target protein to determine where 
binding interactions are occurring. With this method, a library of target variants containing 
point mutations is displayed on the surface of yeast. Analysis of mutations that disrupt 
binding interactions can be used to identify the precise epitope location.265–267 An 
alternative approach could rely on FRET to determine the binding event configuration. 
However, with a typical detection range of 1–10 nm, this method would make it 
challenging to discern closely adjacent epitopes.268–270 
Building on the progress discussed in this thesis, many future directions would 
further benefit protein engineering and improve our ability to discover highly functional 
proteins. Within the diverse sequence data sets, epistatic interactions between multiple sites 
should be explored further and incorporated into the design process. Pair-wise and higher 
order cooperative cohorts can be identified using metrics such as mutual information271, 
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maximum-entropy probability models272,273, and statistical-coupling analysis169. 
Diversification of site clusters can then be designed on the DNA level to ensure that 
correlated amino acids are implemented in tandem. 
This thesis work addresses fundamental concepts involving an efficient search 
through sequence space in pursuit of stable proteins with novel function. It is, therefore, 
reasonable to expect that the conclusions derived from discovering binding ligands can be 
extended to enzyme engineering as well. Combinatorial libraries are widely used for 
increasing stability and improving enzymatic activity274 but examples of engineering truly 
novel function are limited.275 The field would benefit from implementing our approach to 
constrained sitewise library design in the context of discovering new catalytic function.  
The field of protein engineering has brought forth a wealth of knowledge with far 
reaching consequences. Society has gained therapeutic ligands for clinical treatments, 
molecular recognition agents for detecting and monitoring diseases, as well as a much 
deeper understanding of fundamental molecular interactions. Nevertheless, there remains 
a tremendous scope of disease treatments and novel applications that have not yet been 
realized. Inevitably, the efficiency at which the field is able to identify problems and 
discover solutions will determine the pace of future progress. The methodology and 
accomplishments outlined in this thesis make direct contributions to improving the 
efficiency at which we discover proteins with novel function to address these challenges.  
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Appendix  
Quantification of MET expression in pseudo-metastatic tumors 
High expression of hepatocyte growth factor receptor (MET) is associated with certain invasive 
cancer types. Developing small protein ligands that specifically bind to hepatocyte growth factor 
receptor (MET) with high affinity will provide opportunities for detecting cancerous tumors and 
metastasis. We aim to establish a model system for characterizing engineered proteins that bind 
to MET in the context of pseudo-metastatic tumors localized in the lung. Several cell lines were 
analyzed for their potential utility as model systems of high MET expression (Figure 1). For 
future comparative studies, identifying a cell line with low expression of MET was also 
necessary.  
Pseudo-metastatic tumors were generated via mice tail vein injection of each cell type and 
subsequently characterized for MET expression. Cell line characterization consisted of excising 
lungs that contained tumor growth, preparing a single cell suspension of the tumor cells, and 
quantifying the level of MET expression per cell using flow cytometry. Thus far, we have 
determined the expression level for multiple cell lines ranging from 1.6 – 50k MET per cell in 
the context of pseudo-metastatic tumors (Figure 2).  
In addition, MET expression has been assessed in the context of multiple growth environments. 
Comparing the extent that MET is expressed by metastasized cells, xenograft tumors or cells 
having been cultured in petri dishes alone will elucidate the impact of cellular micro-
environment on surface protein content (Figure 1). This work would benefit from further 
investigation of possible relationships between MET expression and the prevalence of tumor 
vasculature, extracellular matrix, lymphocytes, and immune cells.   
 
   
Cell isolation and preparation  
Protocol adapted from Blake Jacobson and Jeremy Drees 
Tumor cell isolation 
1. Remove tumor sample from receptacle and place into dry 60mm petri dish.  
2. Mince tumor using clean razor blade until ~1mm pieces. 
a. Note: only 1g of tumor or less should be homogenized at this point. 
3. Use razor blade to “scoop” minced tissue and add to labeled gentlemacs C tube 
4. Add 2.5mL of tumor digestion enzyme mix to gentlemacs C tube  
Note: Use this 2.5 mL to rinse the razor blade above the C-tube to leave as little sample 
behind as possible Note: FBS inactivates the enzymes in the solution, this is why if possible 
the tissues should be collected in FBS-free medium. 
5. Add Gentlemacs tubes containing sample to a GentleMacs Tissue dissociator, run program 
m_impTumor_02. 
6. Incubate with gentle mixing for 45 minutes at 37oC  
a. If possible, use the GentleMacs rotator mixer; however only 4 C-tubes will fit on in 
this apparatus. If more than 4 samples need incubation, a 50mL conical vial rack 
works just as well: make sure the tissue is not “stuck” in the tube blades, face all of 
the tubes in the same orientation in the rack, tape the tubes in place in the rack, lay 
the rack on its side in an incubator shaker, and shake on a slow rotation for the 
incubation period. 
b. During this incubation time, move on to prepping other tissues in steps 2-4 (if 
applicable). 
7. Following incubation, add gentlemacs tubes again to tissue dissociator and run program 
Mouse m_impTumor_03. Add tubes to ice following this program. 
8. Place nylon strainer onto labeled 50ml conical vial and pour homogenized sample into 
strainer. Add 5mL of ice cold RMPI+10%FBS, to gentlemacs tube, recap the tube and mix 
the medium around to wash remaining tissue homogenate from the C-tube. Pour this wash 
through the strainer as well.   
Note: At this point the homogenate and wash will most likely be close to overflowing in the 
strainer, especially if larger tumors were homogenized. To help the cell homogenate through 
the strainer, slowly lift the strainer out of the tube by the lip. This will usually force the 
homogenate through. Replacing and lifting the strainer multiple times will usually work with 
particularly large or troublesome tumor samples. 
9. (Optional) Transfer the homogenate to a 15ml conical vial.  
Note: Usually enough samples are being processed where it is more practical to do 
subsequent processing in 15mL tubes instead of the 50ml conical vial, at the expense of more 
plasticware. 
10. Spin the samples at 4oC at 300xg for 5 minutes.  
11. Aspirate supernatant. 
a. Be sure to get as much supernatant as possible, FBS will prevent lysis of RBS in the 
next step. 
12. Resuspend in 2mL of room temp (RT) ACK lysis buffer. Incubate at RT for 2 minutes.  
Note: Red blood cells can interfere with flow analysis. See figure below. Lysing the red blood 
cells is sometimes not necessary for more poorly vascularized tumors, but it cleans up the 
sample well. However, it is recommended for every flank or lung tumor sample. 
13. Add 13mL of ice cold RPMI+10% FBS to cells. 
a. This inactivates the lysis buffer and prevents the lysis of leukocytes.  
b. At this point, run the samples through a new cell strainer held above a 15ml conical 
vial to remove any more debris that may be in the cell suspension. If no debris is seen 
floating in the suspension, it is not necessary. To do this, hold the strainer tightly 
against the 15ml conical vial centered below it, slowly pour the liquid into the center 
of the strainer. Sample will be lost if this is done too quickly or if it is not poured 
directly above the 15ml conical vial. 
14. Spin again at 4oC at 300xg for 5 minutes. 
15. Resuspend in 3mL of RPMI+FBS. Cells are now ready to be stained. Keep vials on ice until 
other organs are prepped (if any).  
Note: Cells should only be kept on ice in suspension for a maximum of 4 hours. If cells are 
going to be on ice for a while (i.e. many other organ samples still need to be prepped before 
staining at this point), lay vials horizontally on ice to prevent cell pelleting. Gently swirl 
periodically to keep cells in suspension as much as possible to maintain viability). 
 
Quantification of Cell Expression via Beads 
Primary labeling  
Beads 
1. In new 1.7mL tube, add 2.5 μL of each bead  Bead labels: B, 1, 2, 3, 4 
2. Add 1 μL 9E10 to the beads 
3. Add 36.5 μL PBSA (total V = 50 uL) 
Mammalian Cells 
4. Cells: Add ~100,000 cells to each tube (Count using hemocytometer) 
5. Label cells at 0 μg/mL (negative control) and 10 μg/mL Target Ab 
a. Anti-hHGF R/cMET clone 95106 (~150kDa)  10ug/mL in 50 μL 
6. Incubate Primary mixes for ~20 min, 4 C; wash with PBSA 
Secondary labeling 
7. Label beads and cells with 1:1000 dilution of Goat anti-Mouse-647 
8. Incubate 5-10 min, 4 C; wash with PBSA 
9. Analyze via cytometry (Accuri) – compare histogram peaks of beads and sample. 
